SUPRIYA LIFESCIENCE LTD.

SHAPING A STRONGER TOMORROW

Annual Report
2025-26

INDEX

See the report online at
www.supriyalifescience.com



SHAPING A STRONGER TOMORROW

For Supriya Lifescience, a stronger future is being shaped by the capabilities it builds today. Leveraging nearly four decades of pharmaceutical expertise, the Company is strengthening its core, expanding into higher-value opportunities, and investing in capabilities that will power its next phase of growth.

FY 2025–26 reflected this momentum, with the Company delivering its highest-ever revenue and EBITDA, supported by strong demand across core therapeutic segments, a favourable product mix, deeper backward integration, and disciplined execution.

Supriya continues to reinforce its API franchise through new product development, lifecycle management, and process optimisation, while expanding into new growth avenues. Its enhanced R&D capabilities are enabling the development of niche molecules, opening CMO/CDMO opportunities with global pharmaceutical and innovator companies, and building a differentiated formulations pipeline. Strategic capacity additions and advanced technologies are strengthening the Company's capabilities in finished formulations and specialised dosage forms, while the planned development at Patalganga provides headroom for accelerated expansion.

With enhanced manufacturing capacity, deeper backward integration, world-class R&D, and an unwavering commitment to quality and regulatory excellence, Supriya is transforming into an integrated, future-ready life sciences organisation, poised to capitalise on unprecedented opportunities and deliver sustainable growth.

SUPRIYA LIFESCIENCE AT A GLANCE

Corporate Overview

TRUSTED PARTNER IN GLOBAL REGULATED LIFESCIENCES SPACE

Established in 1987 as a partnership firm and incorporated as a public limited company in 2008, Supriya Lifescience is a leading global life sciences company engaged in the development and manufacturing of niche Active Pharmaceutical Ingredients (APIs), formulations, and CMO/CDMO solutions. Headquartered in Mumbai, the Company serves over 1,500 customers across 120+ countries, reinforcing its position as a trusted global pharmaceutical partner.

Backed by state-of-the-art manufacturing facilities, deep chemistry expertise, and advanced R&D capabilities, the Company delivers high-quality solutions to leading pharmaceutical and innovator companies worldwide. Its collaborative approach, operational excellence, and backward integration have fostered long-standing customer relationships.

VISION

Innovation-driven manufacturing organisation establishing market leadership in the therapeutic segment to supply pharmaceutical products supporting patients globally.

MISSION

- Become a leader in the therapeutic categories in the business
- Deliverables are driven by customers' needs
- Develop commercially sustainable process
- Portfolio expansion with current regulatory requirement

VALUES

Sustainability and consistency

Fulfilling all stakeholders' expectations by adhering to sustainable, consistent and ethical business practices

Integrity and Sincerity

Retain the trust of customers by consistently meeting their quality and delivery timeline expectations

Innovate

- Minimise complexity
- Attract new ideas
- Thrive to change
- Be adaptable

PRODUCT PORTFOLIO

The Company offers a robust portfolio of 40+ specialised APIs, with 15 backward-integrated products, spanning key therapeutic segments including anaesthetics, antihistamines, analgesics, vitamins, anti-asthmatics, and anti-allergics, among others, underscoring its strong focus on therapeutic diversity and specialisation.

BACKWARD INTEGRATED BUSINESS MODEL

The Company's integrated business model strengthens operational efficiency, enhances supply chain reliability, and supports consistent revenue growth while sustaining margins. A significant portion of the performance was supported by backward-integrated products, which contributed meaningfully to scalability and resilience.

Cost-competitive Structure
Increasing margins

Supply Security
Steady supply of essential raw materials



In-House Processes
Less Dependence On External Parties

Low Price Risk
Protection against market fluctuations

KEY HIGHLIGHTS

40+
Years of experience and expertise

40+ APIs
Product portfolio

120+
Country of presence

1,500+
Customers

5
Manufacturing blocks

35,000 SQ. MTS.
Land area

1,050 KL
Reactor capacity

3
R&D centres

15
Backward integrated products

76%
Share of backward integrated products

607
Employees

KEY CERTIFICATIONS

USFDA (United States Food and Drug Administration)
Regulates and approves the safety, efficacy, and quality of drugs and APIs for the U.S. market.

Health Canada
Governs and certifies pharmaceutical products for compliance with Canadian health regulations.

WHO-GMP (World Health Organisation Good Manufacturing Practices):
Ensures that pharmaceutical manufacturing processes meet global safety and quality standards.

ISO 9001:2015
Specifies requirements for a quality management system that consistently delivers products meeting customer and regulatory expectations.

FAMI-QS
A European certification for the safety, quality, and regulatory compliance of feed additives and premixtures.

Halal Certification
Confirms that products and manufacturing processes comply with Islamic dietary and cleanliness laws.

EDQM (European Directorate for the Quality of Medicines)
Grants Certificates of Suitability (CEP) to ensure compliance with European Pharmacopoeia standards.

FSSAI (Food Safety and Standards Authority of India)
Regulates and certifies food safety and hygiene standards in India.

Journey

MILESTONES IN OUR JOURNEY

2008
Incorporation and conversion from a partnership firm to a public limited company

2009
Commenced production of Ketamine hydrochloride

2010
Granted a Certificate of Suitability (CEP) for Chlorphenamine Maleate

2011
Received Import Drug License (IDL) for Chlorphenamine Maleate

2013
Granted COFEPRIS (Mexico) and KFDA (Korea) approvals

2014
Received USFDA approval and Import Drug License (IDL) for Brompheniramine Maleate

2015
Granted EUGMP (AIFA, Italy) and EDQM (European Union) approvals

2017
Received CEP for Pheniramine Maleate and USFDA approval for the second time

2018
Granted Certificate of Suitability (CEP) for Brompheniramine Maleate, Mepyramine Maleate and Ketamine Hydrochloride

2020
Received USFDA approval for the third time

2021
Granted Certificate of Suitability (CEP) for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate. Listed on the BSE and NSE. Received Health Canada and NMPA approvals

2022
Renewed Certificate of Suitability for Pheniramine Maleate, Chlorpheniramine Maleate, and Ketamine Hydrochloride

2023
Started operations at a new R&D lab in Lote Parshuram

2024
Commenced operations at new R&D lab in Ambernath

2025
Commissioned state-of-the-art Module E production block at Lote Parshuram, increasing the installed capacity from 597 KLPD to 932 KLPD

2026
Commercialised CMO facility at Ambernath. Received 4th USFDA approval for Lote facility

Geographic Presence

EXTENSIVE GLOBAL FOOTPRINT

FY 2025-26 HIGHLIGHTS

82%
Revenue from exports

52%
Revenue share of top 10 customers

REGION-WISE REVENUE CONTRIBUTION (%)



Asia
Europe
Latam
North America
Others

Presence in
120+
countries across the globe



Manufacturing facilities:
Lote Parshuram and Ambernath

R&D facilities:
Lote Parshuram and Ambernath

Headquarters:
Mumbai

Map not to scale. For illustrative purposes only.

Product Portfolio and Therapeutic Segments

SUPPORTING HEALTHCARE ACROSS DIVERSE THERAPIES

The Company has built a diversified portfolio across high-value therapeutic segments, addressing evolving healthcare needs. From anaesthetics and antihistamines to cardiovascular, its specialised APIs are backed by advanced manufacturing, scientific expertise, and stringent quality standards. Through continuous innovation, portfolio expansion, and customer-centric development, the Company aims to strengthen its leadership across these therapeutic areas.

SEGMENT-WISE REVENUE CONTRIBUTION (%)



Therapeutic Segments	Segment Overview	Key Highlights FY 2025-26	Outlook
Anaesthetic	- Worlwide consumption 67.5 Mn Kgs valued at US$ 1.1 billion. - The market is expected to grow at a CAGR (Compound Annual Growth Rate) between 4.5% and 7.79% in the coming years. - The market is driven by high demand for rapid induction/recovery agents, particularly in pediatric and outpatient surgical settings. - North America continues to lead the market, supported by advanced healthcare infrastructure, while Asia-Pacific is experiencing rapid growth due to increasing industrialisation and healthcare spending.	- 35 MT sold in the financal year. - Seeding established with new customers. - Tapped a global player for contract manufacturing for their worldwide requirement.	- Expecting market volumes to grow at 10 - 15%.
Anaesthetic	Worlwide consumption 37.5 Mn kgs valued at US$ 1.8 billion. Market is projected to expand at a CAGR of 4.6% to 7.4% through 2030-2033. North America leads in revenue (over 40% share), followed by Europe (over 30%), with Asia-Pacific witnessing the fastest	- Finised Dosage seeding has been established with various customers	- Expecting ROW markets orders for Finished Dosage.
Anaesthetic	The global injectable market was valued at approximately US$ 750 million in 2024 and is expected to grow significantly to around US$ 3.42 billion to US$ 3.87 billion by 2034–2035.	- 175 MT sold in the financial year. - Major markets are Europe, LATAM and US - Pharmacy Compounding opportunities tapped in the US market.	- Products are expected to grow at 10 - 15%.
Anaesthetic	The global injection market is experiencing significant growth, with the market size estimated at US$ 1.08 billion in 2025 and expected to reach US$ 1.16 billion in 2026. The market is projected to reach US$ 1.73 billion by 2032, growing at a CAGR of 6.92% from 2026 to 2032.	- Major mrakets are Europe and LATAM. - New seedings initiated with Key Players for the US market.	- Products are expected to get launched in 2028 in regulated markets.
Analgesic	The current market is valued at approximately US$ 2.47 billion for core applications and reaches up to US$ 5.08 billion when including all combined finished drug formulations. The global market size is forecasted to reach between US$ 3.97 billion (by 2034) and US$ 6.76 billion (by 2030).	- Major markets are Europe, African and Middle East. - New seedings initiated in the US and EU markets.	- Products are expected to grow at 10 - 12% in markets.
Anti-Histamine	The global Chlorpheniramine Maleate market size is valued at approximately US$ 452.2 million to US$ 502.9 million. The market is expanding at a stable (CAGR) of 4.8% to 5.3%. The Active Pharmaceutical Ingredient (API) subsection represents a focused slice of this value, tracking toward US$ 160 million by 2035.	- Global presence across all markets. - 219 MT sold in the last financial year. - Steady increase of quantities across all markets. - Seeding done successfully for new customers in Asia and Far East.	- Product is growing at 3 - 4% across all the markets. - Growing demand for veterinary applications.

Therapeutic Segments	Segment Overview	Key Highlights FY 2025-26	Outlook
Anti-Histamine	The global market size was valued at US$ 850 million in 2023 and is projected to expand significantly. The market is expected to reach approximately US$ 1.25 billion by 2032, at a CAGR of 4.3%. The API market valued at US$ 250 million in 2024 and is forecast to climb to US$ 380 million by 2033, reflecting a 5.3% CAGR.	- Major markets are LATAM and Asia Pacific. - 6.33 MT sold in the last financial year. - Steady demand of the product in both the markets.	- Product is having steady demand in the Asia pacific. - New developments has started in Vietnam and Philippines.
Anti-Histamine	The global market is valued at approximately US$ 1.26 billion and is projected to reach US$ 1.88 billion by 2033. The market is expanding at a CAGR of 5.09%.	- Major markets are USA, LATAM, Far East and Asia Pacific. - 5 MT sold in the last financial year. - Steady demand of the products in all the markets.	- New developments for the US OTC and ANDA Segments. - Steady demand from Far East and Asia Pacific.
Vitamins	The global market, driven by rising demand for vitamin B12 deficiency treatment and neurological health, was valued between US$1.2 billion and US$1.42 billion in 2024–2025. The market is projected to reach over US$2.5 billion by 2032–2034, growing at a CAGR of roughly 4% to 9%.	- Globally the product has being doing good. - 4 MT sold in the last financial year. - Main Markets are domestic, Far East, Asia and USA	- New developments has been initiated in the US and Canada markets. - Quantities from Southeast Asia and Middle East increasing. - Steady demand from Domestic.
Vitamins	The global market was valued at approximately US$1.1 billion in 2024, projected to grow to over US$2.3 billion by 2033.	- Globally the product is growing in various markets. - Approximately, 65 kgs sold in the last financial year. - New developments in the US, Canada, Taiwan, Korea and Australia. - New Commercial business started in the Domestic Market.	- New developments US, Canada and Far East Asian Markets.
Vitamins	The global market, driven by high demand in pharmaceuticals, food, and nutraceuticals, is experiencing significant growth, with 2024 valuations estimated around US$410 million, projected to reach US$730 million by 2033. Another analysis indicates a valuation of US$12.18 billion in 2025, forecasting growth to US$19.97 billion by 2035 at a 6.37% CAGR.	- Commercial requirement for DSM has started and supplied 16 MT. - Overall 102 MT supplied in the last financial year.	- New developments US, Canada, Asian markets and Middle East. - Requiring for Veterinary market picking up in the Middle East.
Anti-Asthmatic	The global market is experiencing significant growth, driven by rising asthma and COPD prevalence. The API market alone was valued at over US$3 billion in 2025 and is projected to reach US$4.14 billion by 2030.	- Product is gaining momentum in multiple markets. - 65 MT sold in the last financial year. - Traction for both ANDA and CEP grade is picking up.	- Market is growing at a rate of 4.5%. - New developments has started in Middle East, Russia, ASIA and US.
Anti-Allergic	The global market, valued at approximately US$6.14 billion to US$6.5 billion in 2023-2025, is projected to reach over US$7.88 billion to US$8.88 billion by 2031-2034	- Active discussion going on for both OTC and ANDA segments. - 45 MT sold in the last financial year. - Business picking up in Southeast Asian, Far East and Middle East.	- Market is growing at a rate of 2.5%. - New developments has started for US and EU markets.
Anti-Allergic	The market is experiencing steady growth, with the market size expected to reach approximately US$ 1.01 billion to US$ 1.58 billion in 2025. Driven by rising allergy cases and over-the-counter (OTC) demand for insomnia treatments	- Strong competition from China. - Strict regulatory scrutiny for the Nitrosamine Drug Substance related Impurities. - 100 MT sold in the last financial year.	- Market is growing at a rate of 2.3%.
Anti-Hypertensive	The global market is valued at approximately US$ 1.5 billion to US$ 3.4 billion in 2026, with projections showing steady growth to over US$ 5 billion by 2035, driven by the high prevalence of cardiovascular diseases and rising demand for generic antihypertensive medications.	- Major compeition is coming from Indian players. - Growing demand in Russia, CIS, Asian and Middle East markets. - 9 MT sold in the last financial year.	- Market is growing at a rate of 5.3%. - New developments ongoing for the ANDA segment. - Alternate qualifications initiated in the Aisan markets.
Anti-Hypertensive	The market is experiencing steady growth, with estimates placing its value around US$ 450–451 million in 2024 and projected to reach over US$ 760 million by 2032.	- Supriya is having a significant position for this product. - Growing demand from Asia, Russia, Middle East and Korean Markets. - 3.5 MT sold in the last financial year.	- Market is growing at a rate of 6.25%. - Development initiated for Korean and Russian market.

Performance Highlights

DELIVERING CONSISTENT GROWTH

REVENUE (₹ in cr.)



EBITDA (₹ in cr.)



EBITDA Margins (%)



PAT (₹ in cr.)



PAT Margins (%)



RETURN ON NET WORTH (%)



ROCE (%)



GEARING (%)



ASSET TURNOVER RATIO (%)



INTEREST COVER (%)



NET WORKING CAPITAL (days)



STRATEGIC AND PERFORMANCE REVIEW

CHAIRMAN & EXECUTIVE DIRECTOR'S MESSAGE

OUR STRATEGY OVER THE PAST FEW YEARS HAS REMAINED CONSISTENT: REDUCE DEPENDENCE ON INDIVIDUAL PRODUCTS AND MARKETS, EXPAND PARTICIPATION IN REGULATED GEOGRAPHIES AND CREATE ADDITIONAL AVENUES FOR VALUE CREATION.

Dear Shareholders,

It is my privilege to present Supriya Lifescience's Annual Report for FY 2025-26. The year under review marked meaningful progress in the Company's evolution. Several strategic priorities advanced, the business demonstrated resilience through periods of disruption and investments made earlier began to translate more visibly into performance. Above all, the year reinforced our confidence in the direction of the Company and in the foundations being laid for the future.

Our strategy over the past few years has remained consistent: reduce dependence on individual products and markets, expand participation in regulated geographies and create additional avenues for value creation. We have supported this through sustained investment in manufacturing, research, quality and organisational depth.

In FY26, those choices became more evident in the shape of the business, contributing to our highest-ever annual revenue and EBITDA. Revenue from operations stood at ₹ 827.9 crore, an increase of 18.9% year-on-year. EBITDA grew by 12.8% to ₹ 294.1 crore, with a margin of 35.5%, while profit after tax increased by 11.2% to ₹ 209.1 crore.

The path to this performance, however, was not uniform. Planned maintenance and debottlenecking at Lote affected production in the early months, while geopolitical events, supply-chain disruptions and volatility in crude and solvent prices added to operating pressures later. Momentum was restored as the year progressed, culminating in our highest-ever quarterly revenue in the fourth quarter and a full-year performance broadly in line with the objective we had set. The response of our teams was particularly encouraging, reflecting an ability to adapt, honour customer commitments and stay focused on longer-term priorities despite a challenging operating environment.

RESILIENCE AND NEW GROWTH ENGINES

The experience of the year reinforced the importance of supply-chain resilience. Backward integration, strategic sourcing, alternate supplier development and long-standing vendor relationships helped maintain continuity despite logistics constraints and fluctuations in raw-material availability. Backward-integrated products accounted for 76% of revenue, supporting cost competitiveness while giving us greater control over critical inputs.

The composition of our portfolio is also evolving. APIs remain central, drawing on decades of chemistry expertise, manufacturing experience and customer relationships. Alongside this core, newer products began contributing more meaningfully, with additions across cardiovascular, ADHD and liquid anaesthetics. Anaesthetics further consolidated their position as our largest therapeutic category. As these molecules mature alongside existing products, the portfolio gains depth and dependence on legacy products reduces over time.

THE YEAR UNDER REVIEW MARKED MEANINGFUL PROGRESS IN THE COMPANY'S EVOLUTION. SEVERAL STRATEGIC PRIORITIES ADVANCED, THE BUSINESS DEMONSTRATED RESILIENCE THROUGH PERIODS OF DISRUPTION AND INVESTMENTS MADE EARLIER BEGAN TO TRANSLATE MORE VISIBLY INTO PERFORMANCE.

Our international business continued to advance, with Europe strengthening its position within our global mix. Additional regulatory approvals supported new customer qualifications and greater penetration of this important regulated market. Newer molecules generally establish an initial presence in markets with shorter approval cycles before progressing towards more regulated geographies. This enables us to commercialise progressively while building the registrations and customer relationships required for sustained participation in mature markets.

Our CMO/CDMO strategy also moved forward, with existing engagements gaining commercial traction and discussions continuing with global pharmaceutical companies across APIs and advanced intermediates. While still an emerging part of Supriya, this business is beginning to complement our own product portfolio and widen our role from product supplier to development and manufacturing partner.

OUR SCIENTIFIC BASE IS ADVANCING IN PARALLEL. R&D HAS MOVED BEYOND A PREDOMINANTLY LIFECYCLE-MANAGEMENT ROLE TO ENCOMPASS NEW PRODUCT DEVELOPMENT, PROCESS IMPROVEMENT AND MORE COMPLEX CUSTOMER REQUIREMENTS.

QUALITY AND REGULATORY DISCIPLINE

One of the year's defining milestones was the USFDA inspection of our Lote facility. The surprise inspection concluded with one minor observation, which was proactively addressed, and the facility subsequently received its Establishment Inspection Report. This outcome reflects the quality culture built across Supriya over many years. Regulatory readiness has to be embedded in everyday behaviour, processes and decision-making. As our engagement with regulated markets and larger global pharmaceutical companies expands, this discipline will remain central to how we operate.

INVESTING WITH A LONG-TERM VIEW

We continued to invest behind our strategic priorities, with capital expenditure of ₹ 152 crore directed largely towards Ambernath, along with maintenance and selected expansion projects. Ambernath extends our manufacturing footprint beyond the traditional API base into formulations and contract manufacturing.

We have also received the necessary clearances for the Patalganga site, where phased development is planned to commence in FY27. This gives us the flexibility to add capacity in line with emerging demand while maintaining a measured approach to capital deployment.

Our scientific base is advancing in parallel. R&D has moved beyond a predominantly lifecycle-management role to encompass new product development, process improvement and more complex customer requirements. Research infrastructure at Lote and Ambernath has expanded the range of chemistries and programmes our teams can undertake and strengthened the link between laboratory development and commercialisation.

The organisation's digital architecture is also being upgraded. Greater automation, enterprise platforms and digitally enabled quality processes are improving visibility, standardisation and control. A more integrated technology backbone will become increasingly valuable in maintaining consistency and supporting informed decision-making as the scale and complexity of our operations increase.

BUILDING A SUSTAINABLE ENTERPRISE

Enduring performance also depends on how responsibly the business is run. Our environmental priorities include cleaner manufacturing, solvent recovery, water conservation, resource efficiency and the progressive replacement of hazardous materials with safer alternatives. These measures help lower environmental impact while improving process efficiency.

Our people remain central to Supriya's long-term competitiveness. We continue to invest in specialised talent, workplace safety, employee development and engagement. Through our CSR programmes, we supported initiatives in education, healthcare, environmental conservation and rural development. Underpinning these efforts is a governance framework centred on accountability, ethical conduct, transparency and regulatory compliance, all of which remain fundamental to sustaining stakeholder trust.

LOOKING AHEAD

As we enter FY27, the ₹ 1,000 crore revenue milestone communicated over previous years is now within sight. We approach this next phase with confidence while recognising that pharmaceutical growth is rarely linear. Regulatory timelines, customer qualifications, manufacturing schedules and external conditions can influence individual periods.

Beyond the milestone itself, the priority is to keep improving the quality of the enterprise behind it: a more differentiated portfolio, stronger customer relevance, disciplined capital allocation and the financial flexibility to support future requirements. Our balance

OUR PEOPLE REMAIN CENTRAL TO SUPRIYA'S LONG-TERM COMPETITIVENESS. WE CONTINUE TO INVEST IN SPECIALISED TALENT, WORKPLACE SAFETY, EMPLOYEE DEVELOPMENT AND ENGAGEMENT.

sheet remains an important enabler of this approach.

Supriya today is better equipped to address a wider range of customer and market requirements. Considerable ground remains to be covered and that is precisely what makes the next phase significant. We will continue to invest thoughtfully, choose our priorities carefully and maintain disciplined execution, with the aim of ensuring that each stage of development leaves the Company more capable and better prepared for what follows.

The achievements of the year were made possible by the commitment of our people, the confidence of our customers and partners and the continued trust of our shareholders. On behalf of the Board, I thank each of you for your association and support. We remain committed to building on this progress and delivering sustained value over the long term.

Dr. Satish Waman Wagh
Chairman & Executive Director

MANAGING DIRECTOR'S MESSAGE

OUR R&D STRATEGY IS FOCUSED ON THREE CLEAR AREAS. FIRST, WE INTEND TO ADD NICHE API's FROM NEWER THERAPEUTIC AREAS THROUGH SUSTAINABLE PROCESSES. SECOND, WE ARE BOLSTERING CAPABILITIES TO SUPPORT LARGER CMO/ CDMO PARTNERSHIPS WITH ESTEEMED GLOBAL PHARMACEUTICAL AND INNOVATOR COMPANIES.

Dear Shareholders,

FY 2025-26 was another year of strong progress for Supriya Lifescience. We delivered our highest-ever annual revenue and EBITDA amid a volatile operating environment, reinforcing the strength of our business model and the disciplined execution of our strategy. This performance was supported by a favourable product mix, growing demand across global markets, deeper backward integration, new product contributions, and cost optimisation.

More notably, we made meaningful advances across our product portfolio, manufacturing infrastructure, R&D capabilities, regulated market presence and CMO/CDMO business. These initiatives are steadily transforming Supriya from a predominantly API-focused company into an integrated, future-ready life sciences organisation.

KEY ACHIEVEMENTS OF THE YEAR

Our core API portfolio performed well during the year, while newer products began contributing significantly. A key cardiovascular product, launched in the third quarter, commenced revenue contribution and is now scaling with a robust order pipeline. Our ADHD product witnessed encouraging demand across Europe and Latin America, while the liquid anaesthetic API was successfully commercialised with regular supplies during the year. In FY 2026-27, we plan to introduce additional products across the anaesthetics and ADHD segments, aligned with our strategy of adding 3-4 products every year.

STRENGTHENING THE INNOVATION ENGINE

Over the past few years, we have strengthened our research infrastructure with new facilities at Lote and Ambernath, while increasing investments in scientific talent and advanced analytical capabilities.

Our R&D strategy is focused on three clear areas. First, we intend to add niche APIs from newer therapeutic areas through sustainable processes. Second, we are bolstering capabilities to support larger CMO/CDMO partnerships with esteemed global pharmaceutical and innovator companies. Third, our formulation R&D platform at Ambernath is developing differentiated finished dosage products across tablets, capsules, injections and inhalation liquids.

The pipeline is gaining depth. Around 30 finished dosage products are currently under development, with multiple exhibits completed. We have also developed a novel Semaglutide tablet formulation and filed intellectual property around the differentiated formulation. These initiatives reflect our intent to progressively move into complex, high-value pharmaceutical opportunities.

SCALING CMO/CDMO OPPORTUNITIES

The progress in our CMO/CDMO business has been particularly encouraging. One CMO project has moved into the commercial phase with committed volumes for the next decade, while additional projects are in advanced stages of discussion.

We are also evaluating exclusive manufacturing opportunities in liquid inhalation products, progressing GLP-1 development and supply for a leading Indian generics company and discussing a novel combination product with an innovator partner. Multiple finished dosage development and supply opportunities are also under active consideration.

FUTURE OUTLOOK

As we look ahead, the building blocks for Supriya's next phase are firmly in place. The opportunities before us are greater than ever, from scaling our established API franchise and launching new niche products to expanding formulations, accelerating CMO/CDMO partnerships, and entering new regulated markets. We remain focused on delivering 3-4 new products annually, expanding capacities in line with demand and strengthening our presence across high-value therapeutic segments. Capacity additions at Lote, the scale-up of Ambernath, and the phased development of the Patalganga site will provide the manufacturing platform to support these ambitions.

What gives us confidence is the diversity of the capabilities we are building. By combining nearly four decades of pharmaceutical expertise with deeper R&D, expanding manufacturing capacity, backward integration, and regulatory excellence, we are shaping a stronger organisation poised to deliver enduring value for all.

I would like to thank our employees for their dedication, our customers and partners for their continued trust, and our shareholders for their confidence in Supriya.

Dr. Saloni Satish Wagh
Managing Director

JOINT MANAGING DIRECTOR'S MESSAGE

> OUR GROWING PRESENCE IN REGULATED MARKETS IS UNDERPINNED BY CONSISTENT QUALITY, SUPPLY RELIABILITY, AND REGULATORY COMPLIANCE, AREAS WHERE SUPRIYA HAS BUILT STRONG CREDENTIALS OVER THE YEARS.

Dear Shareholders,

The fiscal year 2025-26 was one of remarkable progress in our export business. Our focus remained clear: deepen penetration in regulated markets, expand customer relationships, scale newer products, and build a stronger platform for export-led growth. Despite geopolitical uncertainty, supply chain disruptions, currency volatility and elevated input costs, we maintained reliable supplies across markets and enhanced our global presence. Strategic sourcing, alternate vendor development, backward integration and disciplined inventory planning enabled us to navigate these challenges while sustaining market competitiveness.

BUSINESS REVIEW

Exports remain central to our business, contributing 82% of revenues during the year. Europe continued to be our largest market, accounting for 40% of revenues, supported by higher volumes from existing customers and new customer additions. Latin America (LATAM) gained significant prominence, with increasing traction across both established and new products.

Our ADHD portfolio witnessed encouraging demand across Europe and LATAM, while our newer cardiovascular product began contributing to the commercial portfolio. We also expanded our customer base across Europe, Japan and the US, driven by ongoing registrations and higher engagement with existing customers.

Our approach to international growth is centred on long-term partnerships rather than transactional relationships. We are working closely with customers to identify opportunities across multiple products, APIs, formulations and CMO/CDMO engagements, enabling us to participate across the entire pharmaceutical value chain.

Supply chain resilience is equally important to our export-led model. Backward-integrated products accounted for 76% of revenues during the year, giving us greater control over critical inputs while supporting cost competitiveness and supply reliability. Strategic sourcing, alternate supplier development and long-standing vendor relationships further helped us maintain continuity amid raw material and logistical disruptions.

DEEPENING REGULATED MARKET PRESENCE

Our growing presence in regulated markets is underpinned by consistent quality, supply reliability, and regulatory compliance, areas where Supriya has built strong credentials over the years. The successful unannounced USFDA inspection at our Lote facility in February 2026 reinforced the robustness of our quality systems and strengthened our credentials with global customers. At the same time, product registrations across Europe, the US and other geographies continue to progress, supporting future growth.

Customer engagement became more focused during the year. Participation in global pharmaceutical platforms such as CPHI, DCAT, iPHEX and EuroPLX, complemented by increased in-person interactions with key customers, has helped us bolster existing relationships and pursue new opportunities.

WAY AHEAD

We remain committed to achieving the ₹ 1,000 crore revenue milestone in FY 2026-27, while maintaining a healthy EBITDA margin. The fundamentals that have differentiated Supriya remain undeterred—quality, reliability, regulatory excellence and customer trust.

Looking ahead, our international growth strategy remains focused on deeper market penetration, new product registrations and enduring customer partnerships. Europe and Latin America will remain important growth markets, while our presence in the US and Japan will expand as newer products mature and regulatory approvals advance. Our formulations platform at Ambernath will broaden our commercial offering and create opportunities to engage customers beyond APIs, while the growing CMO/CDMO pipeline will extend our relationships with global pharmaceutical and innovator companies.

I thank our customers and partners for their continued trust and our teams for their commitment and agility throughout the year. We look forward to building on this momentum and creating sustainable value for all.

Shivani Satish Wagh
Joint Managing Director

Manufacturing Prowess

DRIVING GROWTH THROUGH MANUFACTURING EXCELLENCE

Manufacturing excellence forms the cornerstone of the Company's ability to deliver high-quality pharmaceutical solutions. Over the years, it has built a robust ecosystem that combines advanced process engineering, backward integration, regulatory compliance, and operational excellence. Continuous investments in infrastructure, automation, and process improvements strengthen the Company's manufacturing capabilities, positioning it for long-term growth.

MANUFACTURING INFRASTRUCTURE

Since commencing operations at its Lote facility in Ratnagiri, Maharashtra, in 1987, Supriya has continuously expanded its manufacturing footprint through capacity augmentation, infrastructure development, and technology investments. Today, the facility has evolved into a globally benchmarked manufacturing complex, serving leading pharmaceutical companies while supporting the Company's leadership in therapeutic segments such as anti-histamines, anti-allergics, anaesthetics, vitamins, anti-asthmatics, and food products.

Spanning approximately 12 acres, this state-of-the-art manufacturing facility comprises five dedicated blocks supported by specialised infrastructure for quality control, quality assurance, engineering maintenance, administration, R&D, and warehouses for raw materials, packaging materials, finished goods, solvents, and hazardous materials. Purpose-built cleanroom environments, modern utilities, and integrated support functions ensure efficient operations while meeting stringent global regulatory standards.

The facility holds accreditations from leading global regulatory bodies, including the US FDA, EDQM, ANVISA, and COFEPRIS, and other authorities.

5 Manufacturing blocks	**35,000** SQ. MTS. Land area	**1,050** KL Reactor capacity	**12** Clean rooms
40+ APIs	**74%** Capacity utilisation	**100** MT Production capacity per month	**1,000** Employees at the site

FY 2025-26 HIGHLIGHTS

- Successful development and commercial scale-up of Midazolam, Pentobarbital, ATS-8, Sevoflurane, and Lisdexamfetamine
- Capacity enhancement for Tramadol Hydrochloride, Riboflavin Sodium Phosphate, Methylcobalamin, and Nicorandil, supporting higher sales volumes
- Installation of a precision distillation facility for a strategic API supporting long-term CMO opportunities
- Commissioning of a dedicated production block for a CMO customer
- Addition of advanced solvent recovery systems to improve operational efficiency and sustainability
- Initiated planning for two additional production blocks at the Lote facility to support future growth

CMO/CDMO CAPABILITIES

Over the past two years, the Company has established a strong foundation in the CMO/CDMO segment, leveraging its advanced manufacturing infrastructure, scientific expertise, and R&D capabilities. The business has gained significant momentum, reflecting Supriya's ability to deliver integrated manufacturing solutions to global pharmaceutical customers.

One CMO project has entered the commercial phase with committed production volumes extending over the next decade, while two additional projects are in advanced stages of finalisation, providing long-term business visibility. The Company's facilities continue to undergo assessments by leading global pharmaceutical companies for future partnerships. The Company is also strengthening its R&D capabilities to capitalise on the growing CMO/CDMO opportunities across markets.

SUSTAINABLE MANUFACTURING

The Company integrates sustainability across its manufacturing operations through continuous process improvements and responsible practices. During the year, it replaced bromine with safer alternative materials in additional product lines, including Diphenhydramine. The adoption of closed manufacturing systems, automated solvent dispensing, and powder transfer systems enhanced process safety, operational efficiency, and environmental performance.

OUTLOOK

Supriya is well positioned to drive the next phase of growth. The Company has accelerated capacity expansion at its newly acquired industrial site in Isambe, Patalganga. The operationalisation of its formulation development and manufacturing facility will enable the Company to forward integrate into dosage-form manufacturing and enhance its CMO/CDMO offerings.

Research and Development (R&D) Edge

ADVANCING R&D AND INNOVATION CAPABILITIES

Innovation is integral to the Company's long-term growth strategy. Through continuous investments in scientific capabilities and technology advancements, Supriya aims to build a robust innovation pipeline, delivering differentiated solutions for evolving global healthcare needs.

R&D ECOSYSTEM

The Company operates three cutting-edge, R&D centres, comprising two API and one formulation development centre. These facilities support the entire product development lifecycle, from molecule selection and process development to formulation design, technology transfer, validation, and commercialisation.

Its API research centres are equipped with advanced laboratory infrastructure and analytical instruments for complex multi-step synthesis, while the formulation development centre focuses on developing oral solids, liquids, injections, nasal sprays, and other specialised dosage forms.

3
Dedicated R&D centres

90
Scientists driving API and formulations process development

4-5
New APIs under development annually

10-15
New formulations under development annually

FY 2025-26 HIGHLIGHTS

- Successfully developed and commercialised four new APIs:
  - Lisdexamfetamine Dimesylate
  - Ibuprofen Picanol
  - Sevoflurane
  - ATS-8 (Atorvastatin Calcium Intermediate)
- Successfully developed 12 new formulations
- Completed technology transfer for all newly developed APIs using a First-Time-Right (FTR) validation approach
- Filed a product patent covering a novel, non-infringing, cost-efficient process for Lisdexamfetamine Dimesylate
- Filed a process patent for Ibuprofen Picanol
- Yield improvement and backward integration of PCBHP intermediate for Cetirizine Dihydrochloride
- Yield enhancement and backward integration of the oxirane intermediate for Bisoprolol Fumarate

LIFECYCLE MANAGEMENT & COST OPTIMISATION

The Company's R&D strategy extends beyond new product development to lifecycle management of existing products through process innovation, backward integration, and manufacturing optimisation.

Key measures include:

- Optimising solvent consumption
- Reducing reagent and key starting material usage
- Improving reaction yields
- Shortening reaction cycles
- Replacing hazardous reagents with sustainable alternatives
- Backward integrating high-cost intermediates
- Enhancing overall manufacturing efficiency

These initiatives significantly improve productivity, reduce API costs, and strengthen Supriya's global competitiveness.

SUPPORTING CDMO GROWTH

R&D plays a pivotal role in expanding the Company's CDMO business. By developing scalable, cost-efficient, and environmentally sustainable manufacturing processes, the Company aims to collaborate with leading multinational pharmaceutical companies while meeting their stringent quality, scalability, and cost expectations.

EXPERTISE IN COMPLEX CHEMISTRIES

Supriya possesses deep expertise in complex chemistries and multi-step synthetic processes across diverse therapeutic segments. Its API teams leverage advanced capabilities to develop scalable and cost-efficient technologies. The Formulation team develops differentiated dosage forms and innovative drug delivery approaches, ensuring successful validation and commercialisation.

OUTLOOK

The Company remains committed to developing novel technologies that improve process efficiencies, accelerate commercialisation, and expand its product pipeline.

Supply Chain Management

BUILDING A RESILIENT SUPPLY CHAIN NETWORK

The Company's integrated supply chain framework ensures seamless procurement of raw materials, inventory optimisation, and timely product deliveries. Backed by proactive planning, strategic supplier partnerships, and disciplined execution, it strengthens supply chain resilience while enhancing cost competitiveness and operational efficiency.

SUPPLY CHAIN MANAGEMENT

Over the past few years, the global supply chain landscape has undergone significant transformation. Geopolitical conflicts, rising energy prices, supply shortages, currency volatility, and logistics disruptions have significantly impacted raw material availability and input costs across the industry.

Despite these challenges, the Company ensured uninterrupted production through timely procurement of quality raw materials at competitive prices. Strategic sourcing, long-term supplier partnerships, alternate vendor development, and disciplined inventory management enabled the Company to maintain procurement efficiency of over 90% during the year.

DRIVING EFFICIENCY THROUGH TECHNOLOGY INTEGRATION

The Company is leveraging advanced technologies such as artificial intelligence, machine learning, robotics, warehouse automation, and smart logistics to optimise inventory management, enhance warehouse operations, and improve supply chain responsiveness.

SUSTAINABLE SUPPLY CHAIN

The Company embeds sustainability into its supply chain by promoting responsible sourcing practices. It actively recovers and recycles solvents used in manufacturing, embraces green chemistry principles, and continuously enhances resource efficiency to reduce environmental impact. As Supriya expands its formulations business, it collaborates with suppliers that uphold sustainable practices while encouraging logistics partners to adopt lower-emission transportation solutions.

OUTLOOK

The external environment is expected to remain dynamic amid geopolitical uncertainties, inflationary pressures, and evolving trade dynamics. Against this backdrop, the Company aims to bolster its supply chain resilience through strategic sourcing, deeper vendor partnerships, technology adoption, and enhanced inventory planning.

Quality Excellence

EMBEDDING QUALITY ACROSS THE VALUE CHAIN

Quality remains an unwavering priority across Supriya's operations. Guided by a robust quality framework and a culture of continuous improvement, the Company upholds the highest standards of quality, safety, and regulatory compliance, ensuring product integrity and reliability. This approach strengthens customer confidence and reinforces its position as a trusted partner to global pharmaceutical companies.

QUALITY MANAGEMENT FRAMEWORK

A comprehensive Quality Management System (QMS) governs all critical operations, including manufacturing, quality assurance, quality control, warehousing, engineering, and support functions. The framework enables effective management of deviations, change controls, risk assessments, corrective and preventive actions (CAPA), and continuous improvement. Regular training programmes, internal audits, and management reviews support effective implementation and ongoing system maturity.

During the year, the Company enhanced its quality governance through the implementation of TrackWise Digital, an electronic Quality Management System (eQMS). The platform enables seamless management of quality documentation, strengthens data integrity, improves process standardisation, and enhances management visibility, aligning Supriya's quality practices with global best-in-class standards.

- Experienced management and technical teams ensuring operational continuity and compliance
- Robust regulatory compliance track record across multiple international jurisdictions
- Digitally enabled QMS supporting transparency, traceability, and governance
- Multi-block manufacturing infrastructure enabling segregation, flexibility, and scalability
- Ability to manage complex chemical and high-pressure reactions
- Well-equipped quality control laboratories supported by trained professionals
- Clear product safety profile, with no manufacture of hormones, steroids, cytotoxins, beta lactams, or allergens
- Structured Environment, Health and Safety (EHS) framework with internal effluent treatment facilities

QUALITY CERTIFICATIONS

Supriya's manufacturing facilities operate in compliance with stringent international regulatory and quality standards, including:

FDA	EU GMP	edqm / Council of Europe	Health Canada
Kosher	FAMI-QS	Australian Government Department of Health and Aged Care Therapeutic Goods Administration	CHINA NMPA
CDSCO	Cofepris	ANVISA	Majelis Ulama Indonesia
Pmda	ISO 9001:2015	KFDA 식품의약품안전청	WHO-GMP
Halal India / HALAL Indonesia	Agenzia Italiana del Farmaco AIFA	FSSC 22000	Certified Kosher

During FY 2025–26, Supriya completed multiple regulatory inspections, certification audits, surveillance audits, customer audits, and a successful USFDA inspection conducted in February 2026, reaffirming the robustness of its quality systems and regulatory compliance framework.

FY 2025-26 HIGHLIGHTS

50+
Registrations across global markets

21
US DMFs

11
CEPs

10
CADIFA (Brazil)

5
KDMF (Korea)

4
NMPA (China)

50+
ROW

500+
Customer audit approvals

OUTLOOK

The Company is focused on strengthening its quality and compliance framework as a key enabler of sustainable growth. Ongoing priorities include enhancement of quality systems, effective use of digital platforms, continued regulatory engagement, and adherence to safe and responsible manufacturing practices. With well-established governance systems, regulatory approvals across key markets, and investments in people and processes, Supriya is poised to meet evolving regulatory expectations while delivering safe, reliable, and high-quality products.

Technology

ACCELERATING DIGITAL TRANSFORMATION

The Company continues to strengthen its digital capabilities by investing in modern enterprise systems, cloud technologies, and process automation that enhance operational efficiency, improve data visibility, and support informed decision-making. These initiatives are helping build a scalable, secure, and future-ready technology ecosystem aligned with evolving business requirements.

KEY TECHNOLOGY INITIATIVES

During FY 2025–26, the Company advanced its digital transformation with a strong focus on enhancing organisational capabilities and operational efficiency:

- Migrated the Microsoft Dynamics 365 ERP platform to the cloud, enhancing system scalability, accessibility, and resilience
- Initiated the migration of domain and file server infrastructure to Amazon Web Services (AWS), modernising the core technology architecture while improving reliability, cybersecurity, and operational agility
- Implemented advanced process control automation in the E Block, improving process robustness and reducing quality deviations. The successful implementation is now being extended to the BC Block

OUTLOOK

The Company aims to accelerate its digital ecosystem through increased investments in cloud infrastructure, enterprise applications, and intelligent automation. The phased migration of its domain and file server environment to AWS will support business continuity, cybersecurity, and operational flexibility. The implementation of SAP as the Company's next-generation ERP platform is progressing as planned, with deployment targeted for completion by the beginning of FY 2027-28. It will establish an integrated, future-ready enterprise platform, driving process standardisation, improved decision-making, and long-term growth.

Sales and Marketing

DEEPENING MARKET REACH AND CUSTOMER ENGAGEMENT

Supriya's commercial strategy is driven by scientific expertise, customer-centric approach, and deep market insights. Through meaningful customer engagement, participation in leading global industry platforms, and targeted business development initiatives, the Company expands its market presence and unlocks new growth opportunities.

MARKETING INITIATIVES

- Participation in leading global pharmaceutical exhibitions and conferences, including CPHI, DCAT, and iPHEX, strengthening brand visibility
- Product- and customer-focused engagements during EuroPLX
- Increased in-person interactions through visits to key customer locations
- Continuous customer engagement to ensure responsiveness and enhance customer

FY 2025-26 HIGHLIGHTS

During the year, Supriya added new customers across key international markets.

Customer Additions

- United States: 7–8 customers
- Europe: 5–6 customers
- Latin America: 5–6 customers
- Asia-Pacific: 10–11 customers
- Middle East & North Africa (MENA): 6–7 customers
- India: 10–11 customers

OUTLOOK

Supriya will continue to strengthen its market presence by expanding volumes across key products, promoting newly developed molecules, and deepening customer engagements through multi-product partnerships. The Company also aims to capitalise on emerging opportunities in the CMO/CDMO segment while expanding its reach across global markets.

ESG OVERVIEW

Environment, Social and Governance (ESG)

COMMITTED TO SUSTAINABLE IMPACT

ESG APPROACH AND POLICY

As a responsible organisation, Supriya is committed to providing a safe workplace and protecting the environment. Our stewardship on sustainability is to provide an overview of our approach to managing Environment, Social & Governance (ESG) risks across our organisation so that we can continue to fulfil our safety, health, and environmental protection commitments, both internally and externally. The scope involves ESG comprehensively, inclusive of environmental sustainability, occupational health and wellbeing, environmental protection and compliance, occupational hygiene and safety of all employees, workers and all other stakeholders.

ESG RATINGS

- Carbon Disclosure Project (CDP) - “B” Rating
- ISO Certification 14000 and 45001
- EcoVadis – Silver

ESG HIGHLIGHTS

Environmental

- Strengthened Environmental Management System
- Operated and maintained the Effluent Treatment Plant to ensure compliant wastewater treatment and disposal. Implemented water conservation initiatives such as rainwater collection and reuse of treated water for utilities
- Undertook energy conservation projects
- Maintained compliance with applicable environmental regulations, permits, and statutory requirements
- 11,000 plantations in Miyawaki Forest

Social

- Continued focus on employee health, safety, and well-being
- Conducted regular safety training, toolbox talks, emergency mock drills, fire-fighting training, and first-aid awareness programs. Promoted a proactive safety culture through employee engagement and safety suggestion initiatives

Governance

- Maintained a strong corporate governance framework
- Reinforced ethical business practices
- Promoted transparency through ESG-related disclosures, including EcoVadis participation (achieving silver rating in Feb-2026) and CDP reporting / submission, having B rating. Continued commitment to integrity, anti-corruption, responsible sourcing and stakeholder engagement

Environment

STRENGTHENING ENVIRONMENTAL STEWARDSHIP

Environmental stewardship is crucial to responsible pharmaceutical manufacturing, given the industry’s reliance on resource-intensive processes and disposal of hazardous substances. The Company continually invests in cleaner technologies, resource-efficient processes, and sustainable practices to enhance operational efficiency and minimise its environmental footprint.

KEY INITIATIVES

EMISSIONS AND ENERGY MANAGEMENT

- Installed multi-stage scrubber systems and bag filters to strengthen air emission control
- Replaced conventional boiler-based heating with oil heating skids in two manufacturing units, improving process efficiency and reducing emissions
- Commissioned an Online Continuous Emission Monitoring System (OCEMS) connected to the SPCB and CPCB
- Developed and implemented liquid bromine-free manufacturing processes, reducing the use of hazardous materials
- Eliminated the use of liquid ammonia and IPA. HCl in selected manufacturing processes
- Optimised manufacturing processes from five stages to three stages, reducing energy consumption and process waste
- Installed Variable Frequency Drives (VFDs) across motors to improve energy efficiency
- Expanded the use of LED lighting across facilities to reduce electricity consumption
- Installed steam condensate recycling pumps to improve thermal energy recovery and resource efficiency

WASTE MANAGEMENT

- Implemented recovery and recycling of N-Diisopropylamine, reducing raw material consumption, hazardous waste generation, and environmental impact
- Established recovery of Lithium as Lithium Carbonate, lowering wastewater TDS and COD while improving overall effluent quality
- Reused recovered materials within manufacturing processes, reducing effluent generation and minimising waste treatment requirements
- Implemented the TrackWise Digital platform, reducing paper consumption

WATER MANAGEMENT

- Initiated a warehouse rooftop rainwater harvesting project to capture and reuse rainwater for utility applications
- Implemented steam condensate recirculation to boilers, improving water conservation

Social

EMPOWERING PEOPLE AND COMMUNITIES

The Company focuses on attracting and nurturing talent, strengthening functional capabilities, recognising performance, and fostering a culture of collaboration and continuous learning. During the year, it strengthened its talent pool through strategic hiring, including experienced senior professionals across key functions. Performance-linked rewards, skill development initiatives, and a strong emphasis on workplace safety support employee growth and organisational effectiveness.

EMPLOYEE ENGAGEMENT

The Company strives to foster an engaged, collaborative, and inclusive workplace where employees feel valued, connected, and motivated to contribute to organisational goals. During the year, employee celebrations, cultural events, team-building activities, interactive sessions, and recognition programmes helped strengthen employee connect, encourage collaboration, and build a greater sense of belonging.

CORPORATE SOCIAL RESPONSIBILITY (CSR)

At Supriya, sustainable impact extends beyond business to making a meaningful difference in the communities. Its CSR initiatives are implemented through the Satish Wagh Foundation, its implementing agency, focusing on measurable outcomes. Through targeted initiatives in education, healthcare, environmental conservation, and community development, the Company strives to empower underprivileged communities and contribute to inclusive growth.

₹5.09 CRORE
Total CSR spend in FY 2025-26

₹1.72 CRORE
Healthcare

₹1.52 CRORE
Rural Development

₹1.11 CRORE
Education

₹0.73 CRORE
Wildlife Protection

KEY CSR INITIATIVES

EDUCATION

Supported the strengthening of educational infrastructure, provision of learning materials and digital resources, scholarship programmes, and establishment of computer labs and chemical labs at Vishnubuva Kendra, S.P.M. School, Marathi Vidnyan Parishad and Thadomal Shahani Engineering College, Institute of Chemical Technology.

₹0.44 CRORE
Investment in computer lab

42
Computers installed

200+
Students benefitted

HEALTHCARE

- Donated dialysis machines to Prabodhan Goregaon and Arnala Health Trust, enhancing access to life-saving renal care for patients suffering from chronic kidney disease
- Established first-of-its-kind healthcare centre at Lote, Ratnagiri, dedicated to providing accessible, affordable, and high-quality medical services
- Organised large-scale blood donation camps in collaboration with ShivShahu Pratishthan
- Treatment sponsorships for needy patients at Tata Memorial Hospital

9
Dialysis machines distributed

216
Patients treated

2,500
Blood donors

7,500
Lives saved

RURAL DEVELOPMENT

- Introduced digital policy applications such as 'RAIDS' and 'Bandobast' for Ratnagiri District Police, spanning duty management, GPS tracking, and criminal intelligence
- Extended funding to Sundar Jessaram Kataria Foundation for elderly care, nutritious meals, safe living, and rehabilitation services
- Organised fitness activities for Ratnagiri Police and a marathon event through Bavdhan Brigade Athletics Foundation, Pune

₹1 CRORE
Provided to Jillaahdhikari for rural development projects

2
RAIDS and Bandobast digital policing applications

1,000
Aspiring athletes at the Bavdhan Marathon event

WILDLIFE PROTECTION

- Supported wildlife conservation at Sanjay Gandhi National Park (SGNP) through diverse initiatives such as animal adoption, animal feed, and providing electric buggies

3
Animals adopted

2
Electric buggies

₹50 LAKHS
Investment in animal feed

BOARD OF DIRECTORS

Dr. Satish Waman Wagh
Chairman & Executive Director

Dr. Saloni Satish Wagh
Managing Director

Ms. Shivani Satish Wagh
Joint Managing Director

Mrs. Smita Satish Wagh
Whole Time Director

Mr. Balasaheb Gulabrao Sawant
Whole Time Director

Mr. Manish Panchal
Non-Executive –
Independent Director

Mr. Hari K
Non-Executive
Independent Director

Dr. Neelam Yashpal Arora
Non-Executive –
Independent Director

Dr. Ganapati Dadasaheb Yadav
Non-Executive –
Independent Director

Dr. Sunil Subhash Bhagwat
Non-Executive –
Independent Director

Awards and Accolades

INDUSTRY RECOGNITION FOR EXCELLENCE

State Export Excellence Award (2018–2022)

Saraswat Chaitanya Gaurav Sohala 2025 (November 15, 2025)

Udyog Mantra – Local Bandhan Award

CPHI India Pharma Awards 2025 (New Delhi)

Ranked A+ with positive outlook by Ind-Ra

CORPORATE INFORMATION

BOARD OF DIRECTORS:

Dr. Satish Waman Wagh
Chairman & Executive Director

Dr. Saloni Satish Wagh
Managing Director

Ms. Shivani Satish Wagh
Joint Managing Director

Mrs. Smita Satish Wagh
Whole Time Director

Mr. Balasaheb Gulabrao Sawant
Whole Time Director

Mr. Manish Panchal
Non-Executive – Independent Director

Mr. Hari K
Non-Executive – Independent Director

Dr. Neelam Yashpal Arora
Non-Executive – Independent Director

Dr. Ganapati Dadasaheb Yadav
Non-Executive – Independent Director

Dr. Sunil Subhash Bhagwat
Non-Executive – Independent Director

BOARD COMMITTEES

Audit Committee

1. Mr. Hari K (Chairman)
2. Dr. Satish Waman Wagh
3. Dr. Ganapati Dadasaheb Yadav
4. Mr. Manish Panchal

Stakeholders Relationship Committee

1. Mr. Manish Panchal (Chairman)
2. Dr. Satish Waman Wagh
3. Dr. Saloni Satish Wagh

Nomination & Remuneration Committee

1. Mr. Hari K (Chairman)
2. Dr. Sunil Subhash Bhagwat
3. Mr. Manish Panchal

Corporate Social Responsibility Committee

1. Dr. Satish Waman Wagh (Chairman)
2. Dr. Saloni Satish Wagh
3. Dr. Sunil Subhash Bhagwat

Risk Management Committee

1. Dr. Satish Waman Wagh (Chairman)
2. Dr. Saloni Satish Wagh
3. Dr. Ganapati Dadasaheb Yadav

CHIEF FINANCIAL OFFICER

Mr. Krishna Raghunathan

COMPANY SECRETARY & COMPLIANCE OFFICER

Ms. Prachi Suhas Sathe

AUDITORS:

Statutory Auditor
M/s. Kakaria & Associates LLP, Chartered Accountants

Cost Auditors
M/s. Rampurawala Mohammed A & Co.,
Cost Accountants

Secretarial Auditor
M/s. DSM & Associates, Practicing Company Secretary

Corporate Identification Number
L51900MH2008PLC180452

REGISTERED OFFICE

207/208, Udyog Bhavan, Sonawala Road,
Goregaon (East), Mumbai – 400063.

BANKERS

Saraswat Co-Op. Bank Ltd.
Axis Bank Ltd.
Kotak Bank Ltd.

REGISTRAR & SHARE TRANSFER AGENTS

MUFG Intime India Private Limited
C-101, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai – 400 083.

Notice

Notice is Hereby given that the 18th Annual General Meeting ("AGM") of Members of Supriya Lifescience Limited '(The Company') will be held on Thursday, September 24, 2026 At 3:00 P.M. (IST) through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM") to Transact the following Business:

ORDINARY BUSINESS:

1. To receive, consider, approve and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026, and the reports of the Board of Directors and Auditors' thereon.

2. To declare a Final Dividend of Re. 1.00/- (50%) per Equity Shares of ₹ 2/- for the Financial Year ended March 31, 2026.

3. To appoint a Director in place of Dr. Saloni Satish Wagh (DIN: 08491410) and Ms. Shivani Satish Wagh (DIN:08491420) who retires by rotation in terms of Section 152 (6) of the Companies Act, 2013, and being eligible, offers themselves for re-appointment.

SPECIAL BUSINESS:

4. To ratify the remuneration of Cost Auditors for FY 2026-27 and, in this regard, to consider and if thought fit, to pass the following resolution as an **Ordinary Resolution:**

   "**RESOLVED THAT** pursuant to provisions of Section 148 of the Companies Act, 2013 read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and other applicable provisions, the remuneration of ₹ 2,50,000/- (Rupees Two Lakhs Fifty Thousand only) plus applicable tax and out-of-pocket expenses payable to M/s. Rampurawala Mohammed A & Co, Cost Accountants, having Firm Registration No. 003011, appointed by Board of Directors of the Company as Cost Auditors to conduct the audit of cost records of the Company for FY 2026-27 amounting to ₹ 2,50,000/- , be and is hereby ratified and confirmed."

Registered Office:
207 /208, Udyog Bhavan, Sonawala Road,
Goregaon (East),
Mumbai – 400063

By Order of the Board of Directors
For Supriya Lifescience Limited

Place: Mumbai
Date: May 27, 2026

Prachi Suhas Sathe
Company Secretary & Compliance Officer

NOTES:

1. Pursuant to the General Circular No. 03/2025 dated September 22, 2025 ('MCA Circulars') and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold EGM/AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, EGM/AGM shall be conducted through VC / OAVM.

2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this EGM/AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the EGM/AGM through VC/OAVM and participate there at and cast their votes through e-voting.

3. The Members can join the EGM/AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the EGM/AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the EGM/AGM without restriction on account of first come first served basis.

4. The attendance of the Members attending the EGM/AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secretarial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the EGM/AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the EGM/AGM will be provided by NSDL.

6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the EGM/AGM has been uploaded on the website of the Company at https://www.supriyalifescience.com/. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and the EGM/AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

7. EGM/AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time.

8. As per the provisions of Clause 3.A.II. of the General Circular No. 20/2020 dated May 5, 2020, the matter of Special Business as appearing at Item Nos. 3 of the accompanying Notice, is considered to be unavoidable by the Board and hence, forming part of this Notice.

9. The Company has fixed Friday, September 4, 2026 as the "Record Date" for determining entitlement of Members to final dividend for the financial year ended March 31, 2026, if approved at the AGM.

10. If the final dividend, as recommended by the Board of Directors, is approved at the AGM, will be paid subject to deduction of tax at source, as applicable on or after Thursday, September 24, 2026.

11. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended) and the Secretarial Standard on General Meetings (SS-2) issued by the ICSI, and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the AGM will be provided by NSDL.

12. In compliance with the aforesaid MCA Circulars and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024, this Notice of AGM along with the Annual Report 2025-26 is being sent only through electronic mode to those Members whose email addresses are registered with the Company, Depositories/ Depository Participants.

The Notice of AGM and the Annual Report 2025-26 will also be available on the Company's website www.supriyalifescience.com websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively and on the website of NSDL https://www.evoting.nsdl.com.

Additionally, as per Regulation 36(1)(b) of the Listing Regulations a letter providing the weblink of the Annual Report for FY 2025-26, will be sent to those shareholder(s) who have not registered their email address with the Company/ Depositories/ Depository Participants.

The Company will also be publishing an advertisement in newspapers containing the details about the AGM i.e., date and time of AGM, details for e-voting, availability of notice of AGM at the Company's website, manner of registering the email IDs of those shareholders who have not registered their email addresses, manner of providing mandate for dividends, and other matters as may be required.

For Members holding shares in Demat form:

(i) The dividend shall be paid to those Members whose names stand registered in the Company's register of Members as Beneficial Owners as at the end of business day on Friday, September 4, 2026 as per the list to be furnished by National Securities Depository Limited ("NSDL") and Central Depository Services (India) Limited ("CDSL").

(ii) Members are requested to intimate immediately any change in their name, postal address, email address, telephone/ mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc., with their Depository Participants ("DP"). While making payment of dividend, Registrar and Share Transfer Agent is obliged to use only the data provided by the Depositories, in case of such demat shares.

(iii) SEBI vide circular nos. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023, and SEBI/HO/OIAE/ OIAE_IAD-1/P/CIR/2023/135 dated 4 August 2023, read with master circular no. SEBI/HO/ OIAE/OIAE_IAD-1/P/CIR/2023/145 dated July 31, 2023 has established a common Online Dispute Resolution Portal ("ODR Portal") for resolution of disputes arising in the Indian Securities Market. Pursuant to abovementioned circulars, post exhausting the option to resolve their grievance with the RTA/Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (https://smartodr.in/login) and the same can also be accessed through the Company's website

13. **Deduction of Tax on Dividend:**
   1. As per the Income Tax Act, 2025 ("the IT Act"), dividends paid or distributed by the Company is taxable in the hands of the shareholders. Accordingly, companies are required to deduct tax at source from dividends paid to shareholders.

      The rate of deduction of tax depends on:

      A. Residential status of the shareholder.

      B. Valid tax registration (PAN or equivalent tax payer identification).

      C. The documents/declarations submitted by the shareholder and accepted by the Company.

   2. For resident individual shareholders:
      A) As per section 393(1) [Table: Sr. No. 7] of the IT Act, any domestic company making payment to a resident shareholder shall deduct tax 10% at the time of payment of dividend to shareholder if it exceeds ₹ 10,000 and who has provided valid PAN. However, on submission of any lower withholding tax certificate under provision of the Act for Tax Year 2026-27, the withholding tax shall be at the rate mentioned in the certificate issued by the Authority.

      B) As per section 393(4) [Table: Sr. No. 10], no tax shall be deducted if the amount or aggregate of amounts of such dividend distributed or paid or likely to be distributed or paid during the tax year does not exceed ₹ 10,000 and the dividend is paid in any mode other than in cash. As per section 393(6) of the IT Act, if shareholder provides duly filed declaration in Form 121 for relevant tax year (T.Y. 2026-27) complete in all respects and all the required eligibility conditions are met then, NIL tax will be deducted at source.

      C) The new taxation regime under Section 202 of the IT Act is the default tax regime as per Income Tax Provisions. Accordingly, we shall consider the forms for exemption only in cases where estimated total income for individual whose age is below 60 years is <= ₹ 4,00,000 and in case of individual exceeding age of 60 years is <= ₹ 12,00,000 as per provisions of Section 393(6) of the IT Act.

      D) In case of invalid or non-availability of PAN, tax will be deducted at the rate of 20%.

   3. For resident shareholders other than individual (HUF/LLP/AOP/Companies/Firm/Trust): At 10% on the entire amount of dividend to be received by the shareholder without any threshold. However, on submission of any lower withholding tax certificate or any exemption status under provision of the IT Act obtained by shareholders for Tax Year 2026-27, the withholding tax shall be at the rate mentioned in the certificate issued by the authority. In case of invalid or non-availability of PAN, the withholding tax shall be at 20%. The User Manual for filling and submission of declarations on the above link is available on the website of the Company at https://www.supriyalifescience.com/ir-dividend.php

   4. For non-resident shareholders including Foreign Portfolio Investor ("FPI")/("FII") Category: At 20% (plus applicable surcharge and cess) on the entire amount of dividend to be received by the shareholder without any threshold. However, as per Section 159 of the IT Act, the non-resident shareholder has the option to be governed by the provisions of the Double Tax Avoidance Agreement (tax treaty) between India and the country of tax residence of the shareholder, if they are more beneficial to them. For this purpose, i.e., to avail a lower rate of deduction of tax at source under an applicable tax treaty read with multilateral instruments, if applicable, such non-resident shareholders must provide the following: Self-attested copy of the PAN allotted by the Indian Income Tax authorities, if any. Self-attested copy of Tax Residency Certificate ("TRC") obtained from the tax authorities of the country of which the shareholder is resident for Tax Year 2026-27 and containing TRC number., if available. Self-attested copy of acknowledgement and copy of Form 41 filed online for Tax Year 2026-27 in https://www.incometax.gov.in/iec/foportal/.

   5. Self-declaration, certifying the following points that no PE declaration should cover points given below:

- Non-Resident is and will continue to remain a tax resident of the country of residence during Tax Year 2026-27.
- Non-Resident is eligible to claim the beneficial DTAA rate for the purposes of tax withholding on dividend declared by the Company.
- Non-Resident has no reason to believe that the claim for the benefits of the DTAA is impaired in any manner.
- Non-Resident is the ultimate beneficial owner of the shareholding in the Company and Dividend receivable from the Company.
- Non-Resident does not have a taxable presence or a permanent establishment in India during Tax Year 2026-27.
- The aforesaid declarations are to be submitted in the relevant forms, declarations and documents through their respective custodians who are registered with NSDL for tax services, on or before the aforesaid timelines.
- Note : As per the IT Act and rules thereto, for generating certificate for foreign remittances to non-resident shareholder (i.e., Form 145 and/ or 146), mentioning Tax Identification No. ("TIN") or equivalent unique identification number is Mandatory irrespective whether DTAA benefit claimed or not. Thus request every non-resident shareholder to provide TIN or equivalent unique identification number.
- Benefit under Rule 203- If dividend income on which tax has been deducted at source is assessable in the hands of a person other than the shareholder, then declaration needs to be provided by shareholder as per Rule 203 of the Income-tax Rules, 2026. The aforesaid declaration is to be e-mailed to rnt.helpdesk@in.mpms.mufg.com or cs@supriyalifescience.com on or before Friday, September 4, 2026.

General Instructions:

1. All the documents submitted by the shareholder will be verified by the Company / its Authorised Representative and the Company will consider the same while deducting appropriate taxes, if they are in accordance with the provisions of the IT Act.
3. For resident shareholders, the rate of TDS would not be increased by surcharge and cess. For non-resident shareholders, the rate of TDS would be increased by applicable surcharge and cess.
4. The Company shall not be obligated to apply the beneficial DTAA rates at the time of withholding tax on the dividend amount. Application of beneficial DTAA rate shall depend upon the completeness and satisfactory review by the Company, of the documents submitted by the non-resident shareholder.
5. If for any reason the tax on dividend is deducted at a higher rate for the shareholder, there would still be an option available with the shareholder to file the return of income and claim an appropriate refund, if eligible.

6. In the event of any income-tax demand (including interest, penalty etc.) arising from any misrepresentation, inaccuracy or omission of information provided / to be provided by the shareholders, such shareholders will be responsible to pay and indemnify such income tax demand (including interest, penalty, etc.) and provide the Company with all information / documents that may be necessary and cooperate in any proceedings before any income tax/ appellate authority.

   The above withholding tax is in summarised form of law and not detailed analysis nor any tax advice. For detailed tax advice related to their tax matters, shareholders are advised to seek professional guidance.

14. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

15. There were no shares lying to claim in the Unclaimed Suspense Account.

16. The Register of Directors' and Key Managerial Personnel and their shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which the Directors are interested under Section 189 of the Companies Act, 2013, will be available electronically for inspection by the Members during the AGM and all other documents referred to in the Notice and Explanatory Statements, will be available for inspection through electronic mode without any fee by the Members from the date of circulation of this Notice up to the date of AGM. Members can inspect the same by sending an email to cs@supriyalifescience.com.

17. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in the securities market. Members holding shares in dematerialized form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their Demat Accounts.

18. Pursuant to the amendments introduced by the Securities and Exchange Board of India ("SEBI") concerning the issuance of securities in dematerialised form for investor service requests, the practice of issuing Letters of Confirmation ("LOC") has been discontinued with effect from April 2026. In line with the revised framework, which aims to facilitate the direct credit of securities in electronic form and enable the processing of service request, the shareholders are required to submit the prescribed documents, duly completed in all respects. These include: (i) Form ISR-4, properly filled in as per the format specified under the relevant SEBI circular; (ii) a Demat Conversion Request Form ("DCRF") in case of NSDL or a Demat Request Form ("DRF") in case of CDSL, as provided by your Depository Participant ("DP"); (iii) a latest Client Master List ("CML") of shareholder's demat account, not older than two months and duly attested by the DP; and (iv) attestation of the signature of the beneficial owner of the demat account by the DP on the DCRF or the CML, as applicable.

19. Shareholders/Members are requested to note that dividends, if not encashed for a consecutive period of 7 years from the date of transfer to the Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). Further, the shares in respect of such unclaimed dividends are also liable to be transferred to the Demat account of the IEPF Authority. In view of this, members/claimants are requested to claim their dividends from the Company within the stipulated timeline.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER:-

The remote e-voting period begins on Monday, September 21, 2026 at 09:00 A.M. and ends on Wednesday, September 23, 2026 at 05:00 P.M. The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. September 4, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being September 17, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner**" icon under "**Login**" which is available under '**IDeAS**' section , this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "**Access to e-Voting**" under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "**Register Online for IDeAS Portal**" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. **NSDL Mobile App is available on** Download on the App Store GET IT ON Google Play
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.

Type of shareholders	Login Method
	3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/ Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.
   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
   c) How to retrieve your 'initial password'?
      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
      (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered**.
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "**Forgot User Details/Password?**"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) **Physical User Reset Password?**" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/ OAVM" link placed under "Join Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to sanam.u@dsmcs.in with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot

User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to (Name of NSDL Official) at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to cs@supriyalifescience.com

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to cs@supriyalifescience.com If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at step **1 (A)** i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**.

3. Alternatively shareholder/members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR E-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under "**Join meeting**" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/ Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at cs@supriyalifescience.com. The same will be replied by the company suitably.

6. Members are encouraged to submit their questions in advance with regard to the financial statements or any other matter to be placed at the 18th AGM from their registered e-mail address, mentioning their name, DP ID and Client ID number/folio number and mobile number to reach the Company's e-mail address at cs@supriyalifescience.com before 05.00 p.m. on Friday, September 18, 2026. Such questions by the Members shall be suitably replied by the Company.

7. Shareholders who would like to express their views/ask questions during the AGM may register themselves as a speaker by sending their request from their registered email address mentioning their name, DP ID and Client ID/folio number, PAN, mobile number at cs@supriyalifescience.com from Wednesday, September 16, 2026, 09.00 a.m. to Friday, September 18, 2026 05.00 p.m. Those members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM. The same will be replied by the company suitably.

Other Instructions:

1. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Friday, September 4, 2026

2. The members who have cast their vote by remote e-voting prior to the Meeting may also attend the AGM through VC / OAVM but shall not be entitled to cast their vote again.

3. A Member can opt for only one mode of voting i.e. either through remote e-voting or voting system during the AGM ("e-voting"). If a Member casts votes by both modes, then voting done through remote e-voting shall prevail.

4. Any person who have acquired shares of the Company and becomes a Member of the Company after the dispatch of the Annual Report and holding shares as on the cut-off date may approach NSDL for issuance of the User ID and Password by sending a request at evoting@nsdl.com However, if he/ she is already registered with NSDL for remote e-voting then he/ she can use his/her existing User ID and password for casting the vote.

5. Mr. Sanam Umbargikar (M.No. 11777, CP No. 9394) of M/s. DSM & Associates, Practicing Company Secretary, has been appointed as the Scrutinizer to scrutinize the e-voting process to be conducted in a fair and transparent manner for the Annual General Meeting.

6. The Scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and make, not later than 48 hours of conclusion of the AGM, a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same.

7. The results declared along with the Scrutinizer's Report shall be placed on the Company's website www.supriyalifescience.com and on the website of NSDL https://www.evoting.nsdl.com within two working days after the AGM. The Company shall simultaneously forward the results to National Stock Exchange of India Limited and BSE Limited, where the shares of the Company are listed.

Explanatory Statement Annexed to the Notice Pursuant to Section 102 of the Companies Act, 2013

Item No. 4

The Company is directed under Section 148 of the Act to have the audit of its cost records conducted by a cost accountant in practice. The Board of your Company has on the recommendation of the Audit Committee, approved the appointment of M/s. Rampurawala Mohammed A & Co, Cost Accountants as the Cost Auditors of the Company to conduct Cost Audits relating cost records of the Company for the year ending March 31, 2027, at a remuneration of ₹ 2.50 lakhs plus applicable tax and out-of-pocket expenses.

The remuneration payable to the Cost Auditors has to be ratified by the shareholders of the Company. Accordingly, consent of the shareholders is sought for passing an Ordinary Resolution as set out at Item No. 4 of the Notice for ratification of the remuneration payable to the Cost Auditors for the financial year ending March 31, 2027.

None of the Directors, Key Managerial Personnel of the Company or their relatives or any of other officials of the Company as contemplated in the provisions of Section 102 of the Companies Act, 2013 is, in any way, financially or otherwise, concerned or interested in the resolution.

The Board recommends the resolution set out at Item no. 4 of the Notice for approval of the members.

Registered Office:
207 /208, Udyog Bhavan, Sonawala Road,
Goregaon (East),
Mumbai – 400063

By Order of the Board of Directors
For Supriya Lifescience Limited

Place: Mumbai
Date: May 27, 2026

Prachi Suhas Sathe
Company Secretary & Compliance Officer

Annexure A

DETAILS OF DIRECTORS SEEKING RE-APPOINTMENT AT THE 18TH AGM TO BE HELD ON THURSDAY, SEPTEMBER 24, 2026 (PURSUANT TO REGULATION 36(3) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND SECRETARIAL STANDARD 2 ON GENERAL MEETINGS):

Sr. No.	Name of the Director	Dr. Saloni Satish Wagh (DIN: 08491410)
1	Date of Birth & Age	22/06/1990 36 years
2	Date of First Appointment on the Board	01/07/2019
3	Qualification	Ph.D. in Chemistry & Master's degree in Science
4	Brief Resume of the Director	Saloni Satish Wagh is a Managing Director of our Company. She holds a bachelor's degree in science from Parle Tilak Vidhyalaya Association's Sathaye College, University of Mumbai, Mumbai, a master's degree in science from Institute of Science, University of Mumbai, Mumbai and a PhD in chemistry from the Faculty of Science, Pacific University, Udaipur. She is associated with our Company since 2014 was appointed as Whole-time Director w.e.f. July 1, 2019. She is looking after export, Marketing & Business Development and also involved in overall management of the Company. She was further appointed as Managing Director of the Company effective from August 01, 2024.
5	Expertise in Specific functional area	She is looking after export, Marketing & Business Development and is also involved in overall management of the Company.
6	Terms and conditions of re-appointment	Dr. Saloni is liable to retire by rotation and offers herself for re-appointment.
7	Member/ Chairperson/Directorship of committees of the Company (excluding Foreign Companies)	Member in following committees of Supriya Lifescience Limited: 1. Stakeholders' Relationship Committee 2. Risk Management Committee 3. Corporate Social Responsibility Committee
8	Number of board meetings attended during FY 2025-26	4
9	Shareholding including shareholding as beneficial owner (Equity Shares)	1,02,375 shares (0.13%)
10	Membership/Chairmanship/Directorship of committees held in other Indian companies	Nil
11	Listed entities from which he has resigned in the past three years	Nil
12	Relationship with other directors and key managerial personnel	Dr. Saloni is daughter of Dr. Satish Waman Wagh and Mrs. Smita Satish Wagh and sister of Ms. Shivani Satish Wagh.

Sr. No.	Name of the Director	Ms. Shivani Satish Wagh (DIN: 08491420)
1	Date of Birth & Age	27/09/1991 34 years
2	Date of First Appointment on the Board	01/07/2019
3	Qualification	Masters in management studies from M.L. Dahanukar College of Commerce, University of Mumbai, Mumbai and master's degree in international business management from Manchester Business School, University of Manchester, Manchester.
4	Brief Resume of the Director	Shivani Satish Wagh is Joint Managing Director of our Company. She is associated with our Company since 2014. She was appointed as Whole-time Director w.e.f. July 1, 2019, and as Joint Managing Director of the Company w.e.f. August 1, 2024. She is looking after exports mainly pertaining to Europe, Marketing & Business Development and is also involved in overall management of the Company.
5	Expertise in Specific functional area	Ms. Shivani is looking after exports mainly pertaining to Europe, Marketing & Business Development and is also involved in overall management of the Company.
6	Terms and conditions of re-appointment	Ms. Shivani is liable to retire by rotation and offers herself for re-appointment.
7	Member/ Chairperson/Directorship of committees of the Company (excluding Foreign Companies)	Nil
8	Number of board meetings attended during FY 2025-26	4
9	Shareholding including shareholding as beneficial owner (Equity Shares)	1,02,375 shares (0.13%)
10	Membership/Chairmanship/Directorship of committees held in other Indian companies	Nil
11	Listed entities from which he has resigned in the past three years	Nil
12	Relationship with other directors and key managerial personnel	Ms. Shivani is daughter of Dr. Satish Waman Wagh and Mrs. Smita Satish Wagh and sister of Dr. Saloni Satish Wagh.

The profile and specific areas of expertise of the directors and other relevant information as required under SEBI Listing Regulations and Secretarial Standards are provided in the Corporate Governance report which forms part of this Annual Report.

Management Discussion and Report

GLOBAL ECONOMIC REVIEW

Overview

The global economy in 2025 evolved within a complex and increasingly uncertain macroeconomic environment, characterised by trade restrictions, policy uncertainty and persistent geopolitical tensions. Ongoing conflicts in Eastern Europe and the Middle East, including the Russia-Ukraine war, continued to disrupt global supply chains, energy markets and investor sentiment, resulting in periodic volatility in commodity prices and financial conditions. In addition, increasing tariffs, evolving trade arrangements, and geoeconomic fragmentation contributed to uncertainty around global trade flows and investments.

Despite these challenges, global economic activity remained resilient during the year, supported by stable labour markets, continued fiscal support and technology-led investments, particularly in artificial intelligence (AI). Economies also adapted through diversified trade routes, stronger energy security measures and supply chain realignment, supporting a relatively stable recovery. Consequently, global growth stood at 3.4% in 2025, compared to 3.3% in 2024.

Advanced economies expanded by 1.9% in CY 2025, supported by relatively stable labour markets, easing financial conditions and recovering demand, while emerging market and developing economies (EMDEs) grew by 4.4%, driven by resilient domestic consumption, improving manufacturing and services activity and continued infrastructure investment across key Asian economies.

Global headline inflation moderated to 4.1% in 2025, reflecting easing supply-side pressures and the impact of prior monetary tightening. However, inflation trends remained uneven across regions, with inflation above target in the United States while remaining relatively subdued in several other major economies.

Performance of the major economies, 2025

United States: Reported GDP declined to 2.1% in 2025, from 2.8% in 2024.

China: GDP growth in 2025 remained unchanged from 5.0% in 2024.

United Kingdom: GDP growth was 1.3% in 2025 from 0.8% in 2024.

Japan: GDP growth was 1.2% in 2025 from 0.1% in 2024.

Germany: GDP grew to 0.2% in 2025 from -0.5% in 2024.

[Source: IMF World Economic Outlook April 2026]

Outlook

As 2026 unfolds, the global economy faces renewed uncertainty driven largely by escalating tensions in West Asia and disruptions across critical energy transit routes. Heightened risks around oil, LNG and fertiliser supplies have increased concerns over energy security, inflationary pressures and supply chain stability. Against this backdrop, global growth is projected to moderate to 3.1% in 2026 before improving marginally to 3.2% in 2027. However, improving diplomatic efforts, strategic energy diversification, and stronger regional cooperation are expected to gradually ease these pressures, supporting supply chain stability, moderating inflation, and fostering a balanced and resilient global economic recovery.

INDIAN ECONOMIC REVIEW

Overview

The Indian economy remained one of the fastest-growing major economies in FY 2025-26, supported by resilient domestic demand, infrastructure-led investment and policy reforms. According to the Second Advance Estimates released by the National Statistical Office (NSO), real GDP is estimated to grow by 7.6% in FY 2025-26, driven by strong private consumption and investment activity. The services sector remained the key growth driver, while manufacturing witnessed continued improvement supported by government-led production initiatives and infrastructure spending. Real GVA is estimated at ₹ 294.40 lakh crore, reflecting growth of 7.7% over FY 2024-25.

India continues to remain among the world's largest economies, currently ranking as the sixth-largest economy globally in nominal GDP terms as per the IMF. Structural reforms such as GST, Production Linked Incentive (PLI) schemes, and "Make in India 2.0" continue to improve formalisation, manufacturing competitiveness and ease of doing business, while strengthening India's position within global supply chains. Manufacturing activity remained strong, with the HSBC India Manufacturing PMI rising to 54.7 in April 2026, supported by domestic demand and higher output levels.

The conflict in West Asia and disruptions across global trade routes have created fresh uncertainty around energy prices, logistics and availability of critical industrial inputs. As an import-dependent economy for crude oil and intermediate goods, India remains exposed to global supply chain disruptions and commodity price volatility. However, diversified sourcing strategies, domestic manufacturing capabilities and integration with emerging markets are helping mitigate external risks and support industrial continuity.

The government's large-scale investments, reforms and flagship initiatives, such as Make in India, Product-Linked Incentive (PLI) Schemes, have been instrumental in fostering industrial growth. The PLI scheme has attracted investments of approximately ₹ 2.16 lakh across 14 key sectors, in line with the national goals like 'Atmanirbhar Bharat' and India's vision of a US$ 5 trillion economy.

India's Index of Industrial Production (IIP) registered a growth of 4.1% in March 2026, supported by 4.3% growth in the Manufacturing sector and 5.5% growth in Mining activity, reflecting continued resilience in industrial and infrastructure-led economic activity.

Inflation moderated significantly during the year, with the RBI lowering its CPI inflation forecast for FY 2025-26 to 2.0%, supported by favourable supply conditions and easing food prices. In response, the RBI reduced the repo rate cumulatively to 5.25%, supporting credit availability and investment activity. India's exports are projected to approach US$ 1 trillion in FY 2026-27, strengthened by trade agreements, manufacturing scale-up and improving export competitiveness.

The Indian Rupee (₹) hit a record low of 97.15 against the U.S. Dollar (US$) on May 19, 2026. This historic depreciation was driven by surging global crude oil prices, rising U.S. Treasury yields, and heavy foreign capital outflows from domestic equity and bond markets.

India's foreign exchange reserves stood at US$ 688.9 billion for the week ended May 15. This marked a decline of US$ 8.1 billion, largely pressured by rising tensions in West Asia, which have weighed on the rupee and overall emerging market sentiment.

India has reached a significant milestone in its economic development, with gross foreign direct investment (FDI) inflows totalling an impressive US$ 1.14 billion. The rise highlights a sharp 22% year-on-year expansion in rupee terms, reflecting continued strength in foreign investment activity and confidence in India's growth trajectory.

Growth of the Indian economy

	FY 23	FY 24	FY 25	FY 26
Real GDP Growth (%)	7.2	9.2	6.5	7.6

Growth of the Indian economy quarter by quarter, 2025-26

	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Real GDP Growth (%)	6.7%	8.4%	7.8%	7.3%

The banking sector continued to strengthen with gross Non-performing Assets (NPAs) of Scheduled Commercial Banks (SCBs) for domestic operations reaching a historic low of 2.15% as of September 2025. The capital-to-risk-weighted-asset ratio (CRAR) of the SCBs remained strong at 17.2 per cent as of September 2025, boosting banks' profitability and credit growth.

India's overall exports, merchandise and services combined, increased by 13.59% year-on-year to US$ 80.80 billion in April 2026, from US$ 71.13 billion in April 2025. Merchandise exports rose from US$ 38.28 billion to US$ 43.56 billion, while services exports increased from US$ 32.85 billion to US$ 37.24 billion. The surge is likely to be bolstered owing to the reduction of the US tariff on Indian products from 50% to 18%.

India's gross GST collection reached ₹ 22.27 lakh crore in FY 2025–26, registering an annual growth of 8.3% over FY 2024–25, reflecting strong economic activity and improved tax compliance.

The share of Private Final Consumption Expenditure (PFCE) in GDP increased to 61.5% in FY 2025–26, reflecting strong and broad-based consumption demand supported by low inflation, stable employment conditions, and rising real purchasing power. Consumption growth was further driven by resilient rural demand backed by strong agricultural performance and improving urban consumption aided by the rationalisation of direct and indirect taxes.

Indian equity markets remained resilient in 2026 despite global volatility. The NIFTY 50 closed at 23,659, while the BSE Sensex closed at 75,318.39, reflecting sustained investor confidence, domestic macroeconomic fundamentals, and optimism regarding India's growth prospects.

The Indian mutual fund industry's Assets Under Management (AUM) rose to a record ₹ 81.92 lakh crore, while monthly SIP contributions stood at ₹ 31,115 crore. Equity mutual funds recorded inflows of ₹ 38,440 crore during the month.

Foreign Portfolio Investors remained cautious amid rising global yields and geopolitical uncertainties, leading to nearly US$ 23 billion in outflows from Indian equities in 2026.

(Source: Reuters, Tradingeconomics, IBEF, PIB, Gst.gov.in, PIB, Tradingeconomics, Tradingeconomics, MOSPI, RBI, PIB, Fortuneindia, AMFI India, Reuters)

Outlook

India's GDP growth for FY26 is estimated at 7.4%, driven by the double engine of consumption and investment. It reaffirms India's status as the fastest-growing major economy for the fourth consecutive year. The nation is expected to reach a US$ 30-35 trillion economy by 2047, entering the league of developed nations. Structural reforms and sustained growth momentum are driving this rapid progress, while digital and physical infrastructure are also expanding significantly.

Union Budget 2026-2027: India's Union Budget FY 2026-27 emphasises public investment by raising the capital expenditure (capex) outlay to a record ₹ 12.2 lakh crore. This nearly 9% increase from the previous year's estimate of ₹ 11.2 lakh crore is intended to sustain economic momentum and fulfil the government's "Viksit Bharat" vision for a developed India. Capital expenditure is prioritised in the budget, with allocations directed towards roads, railways, ports, airports, power transmission and urban infrastructure.

Free-Trade Agreement: The India–European Union (EU) Free Trade Agreement (FTA) improves market access for Indian exports by reducing tariffs and non-tariff barriers in sectors such as goods, chemicals, pharmaceuticals and IT-enabled services. This trade deal is likely to enhance India's trade competitiveness, foreign direct investment (FDI) and export diversification. Similarly, India and the US have announced an interim trade framework, which is expected to provide tariff relief and US market access to India. This agreement may enhance Indian exports through supply chain integration with the US, while safeguarding domestic sectors such as agriculture.

Impact of Pay Commission: The 8th Pay Commission is projected to significantly impact the Indian economy by boosting consumer spending for over 1.1 crore employees and pensioners, driving growth in sectors like retail, automobile, and housing. Beyond individual pay packets, the changes are also expected to have a wider impact on the economy, especially on consumption, savings and government spending.

Monsoon: A favourable, well-distributed monsoon in 2026 is projected to boost agricultural output, stabilise food inflation, and potentially enable the RBI to cut interest rates, benefiting sectors like FMCG, automobiles, and banking.

Rate Cuts: The Reserve Bank of India's Monetary Policy Committee projected CPI inflation at 4.6% for FY27, reflecting a balanced inflation outlook amid evolving domestic and global macroeconomic risks. In the backdrop of evolving macroeconomic and financial developments, the RBI has reduced the policy repo rate by 25 basis points to 5.25% with a neutral stance. It signals a growth inflation balance, owing to a benign inflation outlook on both the headline and core levels, that continues to provide the policy space to support the growth.

Source: (PIB, Moneycontrol)

GLOBAL PHARMACEUTICAL INDUSTRY

The global pharmaceuticals market continues to witness strong growth momentum, driven by rising healthcare expenditure, increasing prevalence of chronic diseases, and accelerated digital transformation in drug development following the COVID-19 pandemic. The global pharmaceuticals market was valued at US$ 1,999.24 billion in 2025 and is projected to grow to US$ 4,035.35 billion by 2034, registering a CAGR of 8.19%, reflecting sustained global demand for innovative therapies, vaccines, and advanced healthcare solutions. North America dominated the pharmaceuticals market with a market share of 44.81% in 2026. Oncology drugs represent the largest and fastest-growing therapeutic market in the pharmaceutical industry, with global sales accounting for 17.62% market share in 2026.

The global pharmaceutical market is witnessing significant growth, driven by increasing demand for innovations and technologies in the healthcare sector, and rising cases of various chronic and life-threatening diseases. The growth during the projected period is reinforced by government policies, improved healthcare access, and higher investment.

Global growth in medical use is population-driven and is projected to increase at a 2.7% CAGR, unadjusted for population. Additionally, global medicine spending is expected to exceed US$ 2.6 trillion by 2030 and increase at a rate of 5–8% per year. Key drivers of growth include contributions from new products and the impact of patent expiries, particularly the growing role of biosimilars.

Source: (Fortunebusinessinsights, Iqvia)

GLOBAL API INDUSTRY

The global active pharmaceutical ingredient (API) market size was US$ 245.26 billion in 2025 and is projected to grow from US$ 261.28 billion in 2026 to US$ 457.75 billion by 2034 at a CAGR of 7.26% over the forecast period.

In pharmaceutical formulations, active pharmaceutical ingredients (API) constitute the fundamental therapeutic effect. Derived through chemical synthesis or natural extractions, API forms the core of the global drug manufacturing ecosystem. As the industry is shifting towards advanced therapeutics, precision medicine and innovative delivery platforms, demand for specialised APIs is expected to rise steadily.

Over the past two decades, the pharmaceutical supply chain has undergone a significant transformation, driven by globalisation and increased dependence on contract manufacturers. API outsourcing is emerging as a common strategy among pharmaceutical companies to optimise cost, scalability and operational efficiency. This approach is relevant for emerging biopharmaceutical and virtual pharma companies, relying on third-party manufacturers.

During Covid-19 pandemic, this globally dispersed framework showed inherent vulnerabilities. Logistical disruptions, restricted mobility, raw material shortages, and regular hurdles impacted supply continuity. Heightened regulations and compliance further caused production and approval delays. Going forward, the industry is increasingly focussed on improving supply chain resilience, regulatory agility and broader manufacturing base.

Source: (Fortunebusinessinsights)

INDIAN PHARMACEUTICAL INDUSTRY

The Indian pharmaceutical industry continues to play an important role in both domestic healthcare and global medicine supply. India ranks third globally by volume and eleventh by value, supported by more than 3,000 pharmaceutical companies and over 10,500 manufacturing units. The sector remains one of the largest suppliers of generic medicines globally, contributing nearly 20% of global generic drug supply and manufacturing around 60,000 generic brands across 60 therapeutic categories.

The Indian pharmaceutical market was valued at US$ 57.61 billion in 2025 and is estimated to reach US$ 60.32 billion in 2026. It is projected to grow to US$ 79.74 billion by 2031 at a CAGR of 5.74% during 2026–2031. Growth is being supported by rising chronic disease burden, patent expiries that expand the generic pipeline, and government initiatives such as the Production Linked Incentive (PLI) scheme for strengthening domestic API manufacturing.

Prescription drugs accounted for 61.26% of total revenue in 2025, while anti-infectives remained the largest therapy segment with a 34.11% share. Oncology is expected to be the fastest-growing segment with a CAGR of 8.22% through 2031. Retail pharmacies continued to dominate distribution with a 64.57% share, while online pharmacies are expected to grow faster with increasing digital healthcare adoption.

Pharmaceutical exports also remained strong, reaching US$ 30.5 billion in FY2024-25, with supplies to 191 countries. Exports in January 2026 increased to US$ 2.66 billion from US$ 2.59 billion in January 2025. With strong manufacturing capacity, export growth and policy support, the industry outlook remains positive for the coming years

India's pharmaceutical exports are projected to grow from approximately US$ 27 billion in 2023 to US$ 65 billion by 2030 and further to nearly US$ 350 billion by 2047. This growth will be driven by stronger global demand, expansion into regulated markets and competitiveness in complex therapies. India currently ranks 11th globally in export value, and the industry aims to move into the top five pharmaceutical exporters by 2047.

Innovation, regulatory compliance, quality standards and supply chain resilience will be critical for long-term growth. Greater investment in research, manufacturing excellence and domestic API capacity will support this transition. Collaboration between government and industry will also remain important in improving market access and strengthening India's position as a global pharmaceutical manufacturing and export hub. Overall, the industry is likely to shift from scale-driven growth to value-led expansion.

(Source: PIB, Mordorintelligence, IPA)

INDIAN API INDUSTRY OVERVIEW

Active Pharmaceutical Ingredients (API) remain a vital segment within the pharmaceutical sector. The API market, currently valued at approximately US$ 15-16 billion, is expected to grow at a CAGR of 5-7% during FY27 and FY28. This growth is expected to be driven by favourable government policies, increasing demand for high-potency and complex APIs, rising domestic consumption, and expanding penetration into regulated and emerging global markets.

The Indian API sector has emerged as an attractive investment destination, supported by domestic demand, chemical manufacturing ecosystem, skilled workforce and adherence to international quality standards. Additionally, setting up and operating a modern manufacturing facility in India is estimated to cost nearly 40% less than in Western markets, improving its competitiveness.

Concurrently, rising geopolitical tensions between Western nations and China have prompted global pharmaceutical companies to diversify their sourcing hubs. Owing to this shift, India is positioned as a credible alternative for bulk drugs and APIs.

(Source: CareEdge)

Union budget allocation

The Department of Pharmaceuticals (DoP) may get an allocation of ₹ 1,100 crore for two new schemes announced in the Union Budget 2026-27. An increased allocation for the production-linked incentive (PLI) schemes of around ₹ 2,499.84 crore during FY26-27 is also announced, which is around 2.2% higher than the ₹ 2,444.93 crore allocated in FY 2025-26. The Union Budget 2026-27 proposes to allocate ₹ 5,931.22 crore for the DoP, around a 12.6% increase compared to the ₹ 5,268.72 crore allocated under the Budget Estimate (BE) for the fiscal 2025-26. Additionally, this budget proposed the Biopharma SHAKTI with an outlay of ₹ 10,000 crore over five years, aimed at strengthening India's ecosystem to produce biologics and biosimilars. PLI scheme for bulk drugs has been allocated ₹ 66.40 crore in the budget to reduce import dependence and promote indigenous production of critical raw materials, including fermentation-based products like Penicillin G. Medical Devices Industry (SMDI) has an allocation of ₹ 124.17 crore during 2026-27, encouraging indigenous production of advanced medical equipment such as MRI systems and cardiac implants. Promotion of Bulk Drug Parks is also implemented, with a budgetary outlay of ₹ 3,000 crore, under which three bulk drug parks are approved and at developing stages in Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective state implementing agencies. These initiatives aim to improve cost efficiency and supply chain resilience.

(Source: Pharmabiz, PIB)

GROWTH DRIVERS FOR THE INDIAN PHARMACEUTICAL MARKET

Cost-efficient Manufacturing and R&D: India remains a global manufacturing hub for the pharmaceutical industry, supported by its lower manufacturing and research and development (R&D) costs. Cost advantages, combined with scale efficiencies and process expertise, enhance its competitiveness across generics, APIs, and specialty products. Additionally, India boasts the highest number of US Food and Drug Administration (USFDA)-approved manufacturing facilities outside the United States, with estimates ranging from over 650 to over 800+ compliant plants.

Government Support: The Make in India campaign, along with PLI schemes for API/KSM (Active Pharmaceutical Ingredients/Key Starting Materials) manufacturing, bulk drug parks and increased investment, reduces import dependency and fosters domestic production. The Union Budget 2026-27 marks a significant milestone in the Government's ongoing efforts to strengthen India's healthcare system, with substantially enhanced allocation for the Ministry of Health & Family Welfare to ₹ 1,06,530.42 crore, reflecting an increase of nearly 10% over the Revised Estimates of FY 2025–26. India's strong economic growth further drives disposable income, which in turn is translated into higher healthcare expenditure and pharmaceutical demand. Owing to improved affordability, increased health awareness, and greater access to medical services, consumption is increasing.

Increasing Chronic Diseases: A prevalence of lifestyle-related diseases (cardiac, diabetes) drives the need for domestic consumption, complemented by a growing demand for affordable generics.

Ageing Population: By 2061, nearly one in four Indians is expected to be over 60 years of age, increasing the chances of chronic and age-related diseases. This demographic shift will elevate demand for long-term healthcare and pharmaceuticals. Balancing rising healthcare demand with cost pressure will be essential to preserve affordability and sustainability.

Outsourcing: Contract manufacturing remains a key growth driver in India's pharmaceutical industry. Global pharmaceutical companies of the advanced markets are increasingly outsourcing production to India to leverage cost efficiencies, skilled manpower, and manufacturing capabilities.

(Source: PIB)

COMPANY OVERVIEW

Since its Inception in 2008, Supriya Lifescience Limited has remained an established API manufacturer with a portfolio spanning multiple therapeutic categories such as antihistamines, anti-allergics, vitamins, anaesthetics, and anti-asthmatics. With its presence in over 120 countries and a diversified portfolio of more than 38 APIs, the Company serves a broad global clientele. It continues to prioritise developing quality APIs and intermediates, catering to both innovator and generic markets.

During FY 2025-26, the Company launched a cardiovascular API, an ADHD product, a liquid anaesthetic. Ambernath FDF facility (tablets, capsules, liquids, sterile forms) ready for commissioning in H2 FY26. Lote Parshuram facility's reactor capacity is increased by 55% with the commissioning of Module E, supporting future utilisation and margin resilience. The Company further reinforced sustainability through a new treatment plant and IGBC Gold-certified labs while expanding R&D capabilities across two centres with a target of 3 to 4 launches every year. It also added a Kilolab for high-value APIs.

Product-wise performance

Analgesic: During the year under review, the company reported 28.14 crore in this segment, by 3.5 y-o-y.

Anti-histamine: During the year under review, the company reported 76.13 crore in this segment, by 9.5% y-o-y.

Vitamins: During the year under review, the company reported 98.52 crore in this segment, by 12.3% y-o-y.

Anti-asthmatic: During the year under review, the company reported 46.15 crore in this segment, by 5.7% y-o-y.

Anti-allergic: During the year under review, the company reported 29.12 crore in this segment, growing by 3.6% y-o-y.

Outlook

Supriya Lifescience's outlook is centred on scaling operations and market presence. The 10-year CMO contract with a European pharma company is projected to contribute ₹ 600 million every year from FY27, improving long-term visibility. With sustained investments in R&D, backward integration, and sustainability initiatives, Supriya is positioning itself for robust expansion across North America, Japan, Australia, and other regulated markets.

FINANCIAL OVERVIEW

Analysis of the profit and loss statement

Revenues: Revenues from operations reported a 18.97% growth from ₹ 696 crore in 2024-25 to ₹ 828 crore in 2025- 26. Other Income of the company reported an increase by 17.04% as compared to FY 2024-25 and accounted for a 1.37% share of the company's revenues, reflecting the company's dependence on its core business operations.

Expenses: Total expenses increased by 22.52% in 2025-26 from ₹ 435.69 crore in 2024-25 to ₹ 533.83 crore due to business growth and inflation. Raw material costs, accounting for a 32.02% share of the company's revenues, increased by 14.06% due to changes in the product and region mix. Employee expenses, accounting for an 11.68% share of the company's revenues, increased by 20.07% from ₹ 80.52 crore in 2024-25 to ₹ 96.68 crore in 2025-26 due to additions and increments.

Analysis of the Balance Sheet

Sources of funds: The capital employed by the company increased 19.99% from ₹ 1,030.12 crore as on March 31, 2025, to ₹ 1,236.06 crore as on March 31, 2026, due to profits. Return on capital employed, a measurement of returns derived from every rupee invested in the business, decreased by 190 basis points from 24.28% in 2024-25 to 22.38% in 2025-26. The Company achieved growth in profitability during the year, although the increase in capital employed was relatively higher, resulting in a moderation of ROCE compared to the previous year. The net worth of the company increased 20.16% from ₹ 996.76 crore as on March 31, 2025, to ₹ 1,197.73 crore as on March 31, 2026, owing to the current year's profit. As of March 31, 2026, the company has no long-term debt, except for lease liability. Finance costs of the company increased by 12.03% from ₹ 1.69 crore in 2024-25 to ₹ 1.89 crore in 2025-26, due to impact of 'Ind AS – 116'.

Applications of funds: Fixed assets (gross) of the company increased by ₹ 50.51% from ₹ 522.79 crore as on March 31, 2025, to ₹ 786.23 crore as on March 31, 2026, due to E Block, Solar project capitalisation and other capitalisation. Depreciation on tangible assets increased by ₹ 40.85 % from ₹ 19.56 crore in 2024-25 to ₹ 27.55 crore in 2025-26 owing to increased capitalisation during the year.

Investments: Non-current investments of the company were ₹ 63.24 crore in 2024-25, which increased to ₹ 98.52 crore in 2025-26 on account of purchase of investments during the year.

Working capital management: Current assets of the company increased by 20.41% from ₹ 442.07 crore as on March 31, 2025, to ₹ 532.30 crore as on March 31, 2026, due to an increase in inventory and trade receivables. The current and quick ratios of the company stood at 4.40 and 2.69, respectively, at the close of 2025-26 compared to 5.32 and 3.88, respectively, at the close of 2024-25. Inventories, including raw materials, work-in-progress and finished goods, among others, increased by 34.85% from ₹ 118.35 crore as on March 31, 2025, to ₹ 159.60 crore as on March 31, 2026. The inventory cycle increased from 176 days of turnover equivalent in 2024-25 to 197 days of turnover equivalent in 2025-26. Trade receivables increased by 63.33% from ₹ 134.36 crore as on March 31, 2025, to ₹ 219.45 crore as on March 31, 2026, due to an increase in revenue during the year. 100% of the receivables were considered good. The company contained its debtor turnover cycle within 78 days of turnover equivalent in 2025-26, compared to 66 days in 2024-25. Loans and advances made by the company decreased by 38.60% from ₹ 0.93 crore as on March 31, 2025, to ₹ 0.57 crore as on March 31, 2026. Cash and bank balances of the company decreased by 0.36% from ₹ 79.15 crore as on March 31, 2025, to ₹ 78.87 crore as on March 31, 2026.

Margins: The EBITDA margin of the company for 2025-26 was 36.85% as against 38.85% in 2024-25, while the net profit for 2025-26 was 25.26% as against 26.61% in 2025-26. Typically, it takes three years for any new manufacturing block to reach peak capacity.

Key ratios

Particulars	2025-26	2024-25
EBITDA/Turnover (%)	36.85	38.85
EBITDA/Net interest ratio (x)	0.00	154.66
Debt-equity ratio (x)	0.00	0.01
Return on equity (%)	19.06	20.74
Book value per share (H)	148.82	123.85
Earnings per share (H)	25.98	23.35
Debtors Turnover (days)	78.00	66.00
Inventory Turnover (days)	197.00	176.00
Interest Coverage Ratio (x)	0.00	148.36
Current Ratio (x)	4.40	5.32
RMC Margin (%)	69.00	70.00
Operating Profit Margin (%)	32.96	35.42
Net Profit Margin (%)	24.91	26.61

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The internal control and risk management system is organised and employed in accordance with the principles and criteria set out in the corporate governance code of the organisation. It is an inherent part of the general organisational structure of Human Resources of the company and group and involves various persons to work and coordinate amongst each other to complete their respective duties. The board of directors provides various guidelines and supervises the strategy to the executive directors and management, monitoring and support committees. The risk management committee and the head of the audit department are supervised by the board-appointed statutory auditors.

HUMAN RESOURCES

The organisation holds the belief that its workforce plays a pivotal role in propelling business expansion. Throughout 2025-26, competitive compensation packages were offered, along with efforts to cultivate a positive work atmosphere and recognise employee achievements through a formal rewards system. The objective is to establish an environment where every employee can discover and maximise their capabilities. Alongside regular duties, participation in voluntary initiatives fostering learning and fostering creative thought is encouraged. The company's employee strength stood at 607 employees as of March 31, 2026.

CAUTIONARY STATEMENT

This statement made in this section describes the company's objectives, projections, expectation and estimations, which may be 'forward-looking statements' within the meaning of applicable securities laws and regulations. Forward–looking statements are based on certain assumptions and expectations of future events. The company cannot guarantee that these assumptions and expectations are accurate or will be realised by the company. Actual results could differ materially from those expressed in the statement or implied due to the influence of external factors that are beyond the control of the company. The company assumes no responsibility to publicly amend, modify or revise any forward-looking statements on the basis of any subsequent development, information or events.

Boards' Report

To
The Members,
SUPRIYA LIFESCIENCE LIMITED
Mumbai

Your Director's have pleasure in submitting their 18th Annual Report of the Company together with the Audited Statements of Accounts for the year ended March 31, 2026.

1. FINANCIAL RESULTS:

The summarized standalone results of your Company are given in the table below:

Particulars	FY Ended	
	31/03/2026	*31/03/2025
Net Sales / Income from Business Operations	8,278.75	6,964.85
Other Income	114.87	98.15
Total Gross Revenue	8,393.62	7,063.00
Provision for Depreciation / Amortization	284.09	204.44
Profit/(loss) after Depreciation and before Provision for Tax	2,747.79	2,484.80
Less: Provision for Income Tax	614.33	566.57
Less: Provision for Deferred Tax	42.26	38.66
Net Profit/(Loss) After Tax	2091.21	1,879.58
Other Comprehensive Income	(1.00)	(1.25)
Total Comprehensive Income	2,090.21	1,878.33
Earnings Per Share (Basic & Diluted)	25.98	23.35
Appropriations:		
Dividend on equity shares	-	80.48

*Previous year's Figures have been regrouped / rearranged wherever necessary.

2. BUSINESS INFORMATION:

Your Company is engaged in Manufacturing of Active Pharmaceuticals Ingredients ("APIs") and are one of the key Indian manufacturers and suppliers of APIs, with a focus on Research and Development. The products are registered with various International Regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA ,Taiwan FDA and CADIFA, Brazil.

The business operations of your Company are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq. mts in 4 Manufacturing blocks segregated therapy wise, having reactor capacity of 597 KL/ day and seven cleanrooms. The API facility located at Lote, Maharashtra, India has received approvals of USFDA, EDQM/EUGMP Health Canada multiple times.

3. PERFORMANCE REVIEW:

Financial statements have been prepared in accordance with the Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time and other relevant provisions of the Act.

Some of the highlights of the operations for the year are:

- Profit before Tax (PBT) for the year has grown by 10.58% to ₹ 2,747.79 million as against a PBT of ₹ 2,484.80 million for the last year.
- Tax Provision for the current year amounted to ₹ 656.59 millions as against a tax provision of ₹ 605.23 million for the last year.
- Profit after Tax (PAT) before other comprehensive income for the year grew by 11.26% to ₹ 2,091.21 million as against a PAT of ₹ 1,879.58 million last year.
- Earnings Per Share of ₹ 2/- each works out to ₹ 25.98 for the year as against ₹ 23.35 last year.

4. DIVIDEND:

Your directors are pleased to recommend a dividend of ₹ 1/- per equity share of ₹ 2/- each, i.e., 50 % for the FY ended March 31, 2026, subject to approval of members at the ensuing Annual General Meeting. The Dividend, if approved by the members at the ensuing Annual General Meeting, will result into an outflow of ₹ 80.48 million.

5. DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, your Company has formulated a Dividend Distribution Policy in accordance with which the dividend is recommended by the Company. The said policy is available on Company's website at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Dividend-Distribution-Policy.pdf

6. TRANSFER OF UNCLAIMED/ UNPAID AMOUNT TO INVESTOR EDUCATION AND PROTECTION FUND:

Your Company does not have any funds as contemplated under Section 125 of the Act lying unpaid or unclaimed which were required to be transferred to Investor Education and Protection Fund (IEPF).

7. TRANSFER TO RESERVE:

Your Company has not transferred any amount to General Reserve for the FY ended March 31, 2026.

8. DEPOSITS:

During the year under review, your Company has neither accepted nor renewed any deposits. Further the Company does not have any outstanding Deposits in terms of Section 73 to 76 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014.

9. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES:

Your Company does not have any Subsidiary, Joint venture or Associate Company.

10. CHANGE IN THE NATURE OF BUSINESS:

During the year under review, there was no change in nature of business of the Company.

11. SHARE CAPITAL:

The equity shares of your Company continue to be listed and traded on BSE Limited and National Stock Exchange of India Limited. The paid-up Equity Share Capital as at March 31, 2026, stood at ₹ 160.97 million, consisting of 8,04,82,800 equity shares of ₹ 2/- each. During the year under review, the Company did not issue any type of shares or convertible securities or shares with differential voting rights.

During the year under review, the Company has not issued shares with differential voting rights or granted any stock options or issued any sweat equity or Bonus Shares. Further, the Company has not bought back any of its securities during the year under review and hence no details / information was invited in this respect.

12. EMPLOYEES STOCK OPTION PLAN

The Company has no employee stock option scheme.

13. MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY.

There have been no material changes and commitments that have affected financial position of the Company between the end of the Financial Year, March 31, 2026, and the date of this Report.

14. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The Loans, Guarantees and Investments made by the Company are within the limits prescribed under the provisions of Section 186 of the Companies Act, 2013 and the details are given in the notes to the Financial Statements.

15. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

There were no contracts or arrangements or transactions entered into by the Company with related parties referred to in sub-section (1) of Section 188 of the Companies Act, 2013 during the course of business which were not at arm's length basis. Suitable disclosure as required by the Indian Accounting Standards (IND AS 24) has been made in the notes to the Financial Statements. The policy on Related Party Transactions as approved by the Board is uploaded on the Company's website.

Accordingly, particulars of contracts or arrangements with related parties referred to in Section 188(1) along with the justification for entering into such contract or arrangement in Form AOC-2 does not form part of this report.

The Policy on Materiality of Related Party Transactions and on dealing with Related Party Transactions as approved by the Board is available on the Company's website at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Policy-on-Related-Party-Transactions.pdf

16. MANAGEMENT DISCUSSION & ANALYSIS REPORT AND CORPORATE GOVERNANCE REPORT BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT:

In compliance with Regulation 34 of the SEBI Listing Regulations, separate section on Management Discussion and Analysis Report, as approved by the Board, which includes details on the state of affairs of the Company, forms part of this Annual Report.

Further, the Corporate Governance Report including General Shareholder Information, as prescribed under Schedule V to the SEBI Listing Regulations, duly approved by the Board of Directors together with the certificate from Secretarial Auditor (Practicing Company Secretaries) confirming compliance with the requirements of SEBI Listing Regulations also forms part of this Annual Report.

In compliance with Regulation 34(2)(f) of the SEBI Listing Regulations read with SEBI circular. The Company has presented the Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 in a separate section of this report.

17. DIRECTORS AND KEY MANAGERIAL PERSONNEL:

As on March 31, 2026, the Board of Directors of your Company comprised of 10 Directors, viz., 5 Executive Directors and 5 Independent Directors including 1 Woman Independent Director.

Dr. Saloni Satish Wagh, Managing Director (DIN: 08491410) and Ms. Shivani Satish Wagh, Joint Managing Director (DIN:08491420) who retires by rotation and being eligible offers themselves for re-appointment at the Annual General Meeting.

The Board, based on recommendation of the Nomination and Remuneration Committee (NRC') appointed Mr. Manish Ishwarlal Panchal (DIN: 08431492), and Mr. Hari Kothandaraman (DIN: 08901674) as Non-Executive Independent Director(s) of the Company w.e.f. February 09, 2026. The said appointments were approved by members of the Company by way of resolutions passed on April 10, 2026 via postal ballot.

Mr. Dinesh Navnitlal Modi (DIN.: 00004556) and Mr. Dileep Kumar Jain (DIN.: 00380311), Non-executive Independent Directors of the Company ceased to be directors upon completion of their term of 5 consecutive years. Subsequently they also ceased to be members of the Board committees w.e.f. the close of business hours on March 24, 2026.

Mr. Balasaheb Sawant (DIN:07743507), Whole Time Director of the Company completed his term on May 25, 2026. The Board upon recommendation of the Nomination and Remuneration Committee have approved his re-appointment as Whole Time Director and Key Managerial Personnel of the Company effective from May 26, 2026 for a further term of 3 years. The said appointment was approved by the Shareholders of the Company via Postal Ballot on August 23, 2026.

As on date of this report, Dr. Saloni Satish Wagh, Managing Director, Ms. Shivani Satish Wagh, Joint Managing Director, Mr. Krishna Raghunathan, Chief Financial Officer and Ms. Prachi Suhas Sathe, Company Secretary & Compliance Officer are the Key Managerial Personnel of the Company within the meaning of Section 203 of the Companies Act, 2013.

18. DECLARATION OF INDEPENDENT DIRECTORS:

As required under Section 149 (7) of the Act, all the Independent Directors on the Board of the Company have given declarations that they meet the criteria of independence as laid down in section 149 (6) of the Act and Regulation 16 (1) (b) and Regulation 25 of SEBI Listing Regulations.

There has been no change in the circumstances affecting their status as Independent Directors of the Company. The Independent Directors have confirmed that they have complied with the Company's Code of Conduct. They have also further confirmed that they have registered their names in the Independent Directors' Databank.

In the opinion of the Board, they fulfil the conditions of independence as specified in the Act and the SEBI Listing Regulations and are independent of the management. Further, the Board is also of the opinion that all the Independent Directors of the Company are persons of integrity and possess relevant expertise and experience to act as Independent Directors of the Company.

19. DIRECTORS' RESPONSIBILITY STATEMENT:

In accordance with the provisions of Section 134(5) of the Companies Act, 2013 the Board hereby states that:

a) In the preparation of annual accounts for Financial Year ended March 31, 2026, the applicable accounting standards have been followed and no material departures have been made from the same.

b) They had selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the Financial Year ended March 31, 2026 and of the profit and loss of the Company for that period.

c) They had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding assets of the Company and for preventing and detecting fraud and other irregularities.

d) They had prepared annual accounts on a going concern basis.

e) They had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively; and

f) They had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

20. NOMINATION AND REMUNERATION POLICY:

The Policy on appointment and remuneration of Directors, Key Managerial Persons and Senior Management Personnel including criteria for determining qualifications, positive attributes and director's independence as required under Section 178(3) of the Companies Act, 2013 and Regulation 19 read with Schedule II Part D of SEBI Listing Regulations has been formulated by the Company. The Policy is available on the website of the Company at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Nomination-and-Remuneration-Policy.pdf

21. PECUNIARY RELATIONSHIP OR TRANSACTIONS OF NED AND DISCLOSURE OF REMUNERATION DETAILS OF DIRECTORS, KMP AND EMPLOYEES:

The non-executive directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees and reimbursement of expenses, if any.

A statement comprising the details required in terms of Section 197(12) of the Act read with Rule 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 has been provided in Annexure I to this report.

22. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

The particulars of employees in compliance with the provisions of Section 134 (3) (q) read with Rule 5 (2) and 5 (3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 will be provided to the shareholder upon request. The said information is open for inspection and any Member interested in obtaining a copy of the same may write to the Company at cs@supriyalifescience.com.

23. MEETINGS OF BOARD OF DIRECTORS:

The details of Board Meetings held during the year are given in the Corporate Governance Report.

24. MEETINGS OF BOARD COMMITTEES:

As required under the Act and the SEBI Listing Regulations, the Company has formed all the statutory committees namely, Audit Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee, Corporate Social Responsibility Committee and Risk Management Committee.

The details pertaining to the composition of the Committees as of March 31, 2026, including its terms of reference and attendance of directors at the Committee Meetings are provided in the Corporate Governance Report.

There have been no instances where the Board did not accept the recommendations of its committees, including the Audit Committee.

25. PERFORMANCE EVALUATION:

The Board of Directors carried out an annual evaluation of its own performance, of the Committees of the Board and of the Chairperson and individual directors pursuant to the provisions of the Companies Act, 2013 and SEBI Listing Regulations.

Performance evaluation was carried out based on the criteria approved by Nomination and Remuneration Committee. Feedback was given by the Directors individually and the committees through a structured questionnaire for performance evaluation of the Board, its committees and individual directors.

In a separate meeting of the Independent Directors held on March 27, 2026, the performance of the Chairman, Non-Independent Directors and the Board was evaluated considering the views of the Non-Independent Directors and the same was discussed in the Board Meeting. Performance evaluation of Independent Directors is done by the entire Board of Directors (excluding the Directors being evaluated).

26. FAMILIARISATION PROGRAMMES FOR INDEPENDENT DIRECTORS:

The Company conducts familiarization program for Independent Directors, and the details are uploaded on the website of the Company on the below mentioned link: https://www.supriyalifescience.com/assets/pdfs/corporate-governance/policies/Familiarization-Programme-for-Independent-Directors.pdf

27. VIGIL MECHANISM/ WHISTLE BLOWER POLICY:

The Company's Audit Committee vide its term of reference has established a vigil mechanism by adopting a Whistle Blower Policy in terms of Section 177(10) of the Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Policy enables the employees concerned to report concerns about illegal or unethical practices, suspected fraud, violation of Code of Conduct if any. The details of the Policy are explained in the Report on Corporate Governance and are also available on the website of the Company at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Whistle-Blower-Policy.pdf

28. RISK MANAGEMENT POLICY:

The Company has constituted a Risk Management Committee in compliance with Regulation 21, of SEBI Listing Regulations in order to identify, evaluate business risks and opportunities. The Company has also formulated a policy viz. Risk Management Policy for identification, evaluation and mitigation of operational, strategic and external risks. This strategy seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company's competitive advantage and helps in identifying risks trends, exposure and potential impact analysis at a Company level as also separately for different business segments.

More details on risks, threats and mitigation plans have been disclosed in the section "Management Discussion and Analysis Report" forming part of this report.

29. INTERNAL FINANCIAL CONTROLS:

Internal financial controls are an integrated part of the risk management process, addressing financial statements and financial reporting risks. The internal financial controls have been documented, digitized, and embedded in the business processes. An assurance of the effectiveness of internal financial controls is obtained through management reviews control, self-assessment, continuous monitoring by functional experts as well as testing of the internal financial control systems by external consultants on behalf of the management at least once a year. We believe that these systems provide reasonable assurance that our internal financial controls are designed effectively and operating as intended. Details in respect of adequacy on internal financial controls concerning the Financial Statements are stated in the Management Discussion and Analysis Section which forms part of this Annual Report.

30. AUDITORS

a) Statutory Auditors:

Pursuant to the provisions of Section 139 of the Act, and rules made thereunder, M/s. Kakaria & Associates LLP, Chartered Accountants, (Firm Registration No. 104558W/W100601) were appointed as Statutory Auditors of the Company for a second term of five consecutive years, to hold office from the conclusion of the 14th AGM held on September 16, 2022 until the conclusion of 19th AGM of the Company to be held in the calendar year 2027.

M/s. Kakaria & Associates LLP, Chartered Accountants, have submitted their Report on the Financial Statements of the Company for the FY 2025-26, which forms part of the Annual Report 2025-2026. There are no observations (including any qualification, reservation, adverse remark or disclaimer) of the Auditors in the Audit Reports issued by them which call for any explanation from the Board of Director. The Auditors have also confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold a valid certificate issued by the Peer Review Board of the ICAI.

b) Secretarial Auditors:

As per Regulation 24A of SEBI LODR Regulations, 2015, M/s. DSM & Associates, Peer Reviewed Firm of Company Secretaries in Practice, were appointed as the Secretarial Auditors of the Company for 1st term of 5 (five) consecutive years to hold office from the conclusion of 17th AGM held on September 24, 2025, until conclusion of 22nd AGM of the Company to be held in the FY 2029-2030.

The Secretarial Audit Report required pursuant to subsection (3) of Section 134 and Section 204 (1) of the Companies Act, 2013, is given in Annexure II to this report.

c) Cost Auditors:

As per Section 148 of the Act read with Companies (Cost Records and Audit) Rules 2014, M/s. Rampurawala Mohammed A & Co, Cost Accountants, Mumbai, Firm Registration No. 003011 have been re-appointed as Cost Auditors for the year ended March 31, 2026, to conduct cost audit of the accounts maintained by the Company in respect of the various products prescribed under the applicable Cost Audit Rules. The remuneration of Cost Auditors has been approved by the Board of Directors on the recommendation of Audit Committee. The requisite resolution for ratification of remuneration of Cost Auditors by members of the Company has been set out in the Notice of ensuing AGM. The Cost Auditors have certified that their appointment is within the limits of Section 141(3)(g) of the Act and that they are not disqualified from appointment within the meaning of the said Act.

d) Internal Auditors:

M/s. Nair & Panickers Audit & Advisory Services were appointed as the internal auditors of the Company. During the year, the Company continued to implement their suggestions and recommendations to improve internal controls. The Company's internal control systems are well established and are commensurate with the nature of its business and the size and complexity of its operations. The recommendations/ suggestions of the internal auditors are reviewed and approved by the Audit Committee at their quarterly meetings. M/s. MP Nair & Associates, Chartered Accountants are appointed by the Board as Internal Auditor of the Company for conducting the Internal Audit and to issue report for the FY 2025-26.

31. REPORTING AND EXPLANATIONS BY AUDITORS:

During the year under review, no instances of fraud committed against the Company by its officers or employees were reported by the Cost Auditors to the Audit committee or Central Government as required under Section 143(12) of the Act.

There are no qualifications, disclaimers, reservations or adverse remarks reported by the Statutory Auditors and Secretarial Auditors in their respective reports during the year under review.

32. CORPORATE SOCIAL RESPONSIBILITY:

The Board of Directors has constituted Corporate Social Responsibility Committee (CSR Committee) consisting of members viz. Dr. Satish Waman Wagh (Chairman), Dr. Saloni Satish Wagh and Dr. Sunil Bhagwat.

Corporate Social Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company was adopted by the Board on the recommendation of the CSR Committee. The policy can be accessed at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/CSR-Policy.pdf

The CSR Committee confirms that the implementation and monitoring of the CSR Policy was done in compliance with the CSR objectives and policy of the Company.

Annual Report on Corporate Social Responsibility as per Rule 8 of Companies (Corporate Social Responsibility Policy) Rules, 2014 is enclosed as Annexure III to this Report. During the year, no revision was made to the CSR Policy of the Company.

33. SECRETARIAL STANDARD:

The Company has devised adequate system to ensure that the applicable Secretarial Standards issued by the Institute of Company Secretaries of India, relating to Meetings of Board of Directors and General Meetings respectively, have been duly complied with.

34. EXTRACT OF ANNUAL RETURN:

The Annual Return as on March 31, 2026 in the prescribed Form No. MGT-7, pursuant to section 92 of the Act is available on the website of the Company at https://supriyalifescience.com/ir-annual-report-return.php

35. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO:

The information pertaining to Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo as required under Section 134 (3)(m) of the Companies Act, 2013 read with Rule 8(3) of the Companies (Accounts) Rules, 2014 is furnished in Annexure IV and is attached to this report.

36. DISCLOSURES AS PER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has adopted a policy on Prevention, Prohibition and Redressal of sexual harassment at workplace in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the year, no complaints or allegations of sexual harassment were filed with the Company.

The Company has complied with the relevant provisions under the Maternity Benefit Act, 1961.

37. CODE FOR PREVENTION OF INSIDER TRADING:

Your Company has adopted a Code of Conduct to regulate, monitor and report trading by insiders as per the requirements under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 which can be accessed at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Code-of-conduct-to-Regulate-monitor-and-report-trading-in-securities-by-insiders.pdf

This Code of Conduct also includes code for practices and procedures for fair disclosure of unpublished price sensitive information which has been made available at https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Code-for-Fair-Discolures-of-UPSI.pdf

38. CREDIT RATING

Details of credit rating ascribed by rating agencies are disclosed in Corporate Governance Report forming part of this Annual Report. The strong credit rating reaffirmed is a reflection of the Company's strong financial position and discipline.

49. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

There are no Material orders passed by the judicial or quasi-Judicial authority which affects the Going Concern Status of the Company during the year under review.

40. APPLICATIONS UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016:

There were no applications made by the Company or upon the Company under the Insolvency and Bankruptcy Code, 2016 during the year under review. There are no proceedings pending under the Insolvency and Bankruptcy Code, 2016 by or against the Company as on March 31, 2026.

41. SAFETY:

The Company conducts regularly Safety audit and Environment audit through competent authorities for its manufacturing facilities located at Lote and Ambernath. The Company also organises various safety awareness programs to impart safety training to its employees.

42. ACKNOWLEDGEMENTS:

The Board of Directors places on record sincere gratitude and appreciation for all the employees of the Company. Our consistent growth has been possible through hard work, solidarity, cooperation, and dedication during the year. The Board conveys its appreciation for its customers, shareholders, suppliers as well as vendors, bankers, business associates, regulatory, and government authorities for their continued support.

For and on Behalf of the Board of Directors
For Supriya Lifescience Limited

Dr. Satish Waman Wagh
Chairman and Executive Director
DIN: 01456982

Place: Mumbai
Date: May 27, 2026

Annexure – I

Particulars of Remuneration

Details pertaining to remuneration as required under section 197(12) read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, as amended

A. Ratio of remuneration paid to each Director to the median remuneration of the employees of the Company and percentage increase in remuneration for the FY 2025-26 is as follows:

Sr. No.	Name of Director / KMP	Designation	Ratio of remuneration of the Director to the median remuneration of the employee	% increase/ decrease in Remuneration
1.	Dr. Satish Waman Wagh	Chairman & Executive Director	274.00:1	-
2.	Mrs. Smita Satish Wagh	Whole Time Director	40.16:1	10%
3.	Dr. Saloni Satish Wagh	Managing Director	77.63:1	28%
4.	Ms. Shivani Satish Wagh	Joint Managing Director	77.63:1	28%
5.	Mr. Balasaheb Gulabrao Sawant	Whole Time Director	17.27:1	-
6.	Mr. Dileep Kumar Jain[4]	Independent Director	1.47:1	-
7.	Mr. Dinesh Navnitlal Modi[4]	Independent Director	1.73:1	-
8.	Dr. Neelam Yashpal Arora	Independent Director	0.80:1	-
9.	Dr. Ganapati Dadasaheb Yadav	Independent Director	0.69:1	-
10.	Dr. Sunil Subhash Bhagwat	Independent Director	1.00:1	-
11.	Mr. Manish Panchal[5]	Independent Director	0.27:1	-
12.	Mr. Hari K[5]	Independent Director	0.27:1	-
13.	Mr. Krishna Raghunathan	Chief Financial Officer	32.10:1	6%
14.	Ms. Prachi Suhas Sathe	Company Secretary & Compliance Officer	2.28:1	NA
15.	Dr. Shekhar Bhaskar Bhirud	President - Business Development, Strategy and R&D	91.33:1	NA
16.	Dr. Prashant Baban Zate	Vice President - QA,QC & RA	22.83:1	35%
17.	Dr. Sushanta Kumar Gouranga Mishra	Chief Scientific Officer	13.70:1	8%

Notes:

1. Remuneration of Independent Directors includes Sitting Fees paid to them during the FY 2025-26.
2. The aforesaid details are calculated on the basis of Cost to Company (CTC) of employees during the FY 2025-26.
3. The remuneration to Directors is within the overall limits approved by the shareholders.
4. Mr. Dileep Kumar Jain and Mr. Dinesh Navnitlal Modi ceased to be Independent Directors of the Company upon completion of their term as Independent Directors w.e.f. March 24, 2026.
5. Mr. Manish Panchal and Mr. Hari K were appointed as Independent Directors of the Company w.e.f. February 09, 2026.

B. Percentage increase in the median remuneration of employee in the financial year:

There was a increase in the median remuneration by 22.56%.

C. The number of permanent employees on the rolls of Company:

There were 607 employees on the rolls of the Company as on March 31, 2026.

D. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last Financial Year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

The average increase in the salary of the employees and the managerial personnel other than the Executive Directors in FY 2025-2026 is 10.21%. There was no change in the remuneration of Managing Director. The Annualise increment percentage is calculated on annual CTC of employees.

The increment given to each individual employee is based on the employees' potential, experience as also their performance and contribution to the Company's progress over a period of time and also as per market trend.

E. Affirmation that the remuneration is as per the remuneration policy of the Company:

It is hereby affirmed that the remuneration paid is as per the Policy for Remuneration of the Directors, Key Managerial Personnel and other Employees.

For and on Behalf of the Board of Directors
For Supriya Lifescience Limited

Dr. Satish Waman Wagh
Chairman and Executive Director
DIN: 01456982

Place: Mumbai
Date: May 27, 2026

Annexure – II

Secretarial Audit Report

For the Financial Year ended 31st March, 2026

(Pursuant to section 204(1) of the Companies Act, 2013 and the Rule No.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To,
The Members of
Supriya Lifescience Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Supriya Lifescience Limited** (CIN: L51900MH2008PLC180452) (hereinafter called "The Company"). We have conducted Secretarial Audit in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2026, complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extend, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2026 according to the provisions of:

(i) The Companies Act, 2013 (the Act) and the rules made there under;

(ii) The Securities Contracts (Regulation) Act, 1956 (SCRA) and the rules made there under;

(iii) The Depositories Act, 1996 and the regulations and bye laws framed there under;

(iv) The Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Director Investment and External Commercial Borrowings;

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act);

a) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

b) SEBI (Prohibition of Insider Trading) Regulations, 2015;

c) SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018;

d) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;

e) The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

(vi) Other specifically applicable laws to the Company during the period under review;

(i) Income Tax Act, 1961;

(ii) Goods and Services Tax Act;

We have also examined compliance with the applicable clause of the following:

(i) Secretarial Standards issued by The Institute of Company Secretaries of India;

(ii) The SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 issued by SEBI and Listing Agreement entered by the Company with National Stock Exchange of India Limited (hereinafter the "NSE") and BSE Limited (hereinafter the "BSE");

Based on the aforesaid information provided by the Company, we report that during the financial year under report, the Company has complied with the provisions of the above mentioned Act/s, Rules, Regulations, Guidelines, Standards, etc. mentioned above to the extent applicable, except for the matters reported in this report.

We further report that

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review, if any, were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors of schedule of the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance except on few occasions where agenda for the Board meeting was circulated to the members of the Board with less than seven days in advance.

As per the minutes of the meetings duly recorded and signed by the Chairman, the decisions at Board Meetings, Committee Meetings and Independent Directors' Meeting were carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committees of the Board or Independent Directors meetings as the case may be.

We further report that, based on the information provided and the representation made by the Company, in our opinion there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the audit period:

1. Dr. Neelam Arora was re-appointed as Non-Executive Independent Director of the Company for second term of five (5) consecutive years from March 25, 2026 to March 24, 2031.
2. Mr. Manish Panchal and Mr. Kothadaraman Hari were appointed as Non-Executive Independent Directors of the Company for a term of five (5) consecutive years, commencing from February 9, 2026 and ending on February 8, 2031, pursuant to the Special Resolution passed through Postal Ballot by remote e-voting on April 10, 2026.
3. Mr. Dileep Kumar Jain and Mr. Dinesh Navnitlal Modi retired from their respective position of Independent Directors of the Company upon completion of their respective terms, which expired on March 24, 2026.

and there were no other specific events/actions in pursuance of the above referred laws, rules, regulations, guidelines, etc. having a major bearing on the Company's affairs.

For DSM & Associates,
Company Secretaries
UCN No. P2015MH038100
Peer Review No.2229/2022.

CS Sanam Umbargikar
Partner
M.No.11777.
CP No.9394.
UDIN: F011777

Date: May 27, 2026
Place: Mumbai.

Annexure – III

Annual Report on Corporate Social Responsibility (CSR) Activities

1. Brief outline on CSR Policy of the Company:

The Corporate Social Responsibility Committee had formulated and recommended to the Board, a Corporate Social Responsibility Policy ("CSR Policy") in compliance with Section 135 of the Companies Act, 2013 (the Act) read with the Companies (Corporate Social Responsibility Policy), Rules 2014 (The CSR Rules). Supriya Lifescience Limited ("SLL") is vigilant in its enforcement towards corporate principles and is committed towards sustainable development. At SLL, we know that we cannot prepare any business, our clients' or our own for the future of work without also considering the future of our planet and our society.

As a socially responsible corporate citizen, the Company is committed to the core values of collective progress and welfare. Corporate Social Responsibility ("CSR") is defined as the integration of business operations and values, whereby the interests of all stakeholders including investors, customers, employees, the community and the environment are reflected in the company's policies and actions.

The Company aims to undertake initiatives that create sustainable growth of the environment and empowers the underprivileged sections of society. The Company's CSR initiatives also address the challenge of capacity building and securing sustainable livelihoods of unprivileged sections of the society around its manufacturing units.

2. Composition of CSR Committee:

Sl. No.	Name of Director	Designation/ Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Dr. Satish Waman Wagh	Chairman, Chairman & Executive Director	1	1
2	Dr. Saloni Satish Wagh	Member, Managing Director	1	1
3	Dr. Sunil Bhagwat	Member, Independent Director	1	1

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company:

Composition of CSR committee	https://supriyalifescience.com/ir-corporate-governance.php
CSR Policy	https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/CSR-Policy.pdf
CSR projects approved by the board of the Company	https://supriyalifescience.com/csr.php

4. **Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable:** The requirement of carrying out the Impact assessment of CSR projects in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, is not applicable to the company.

5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any:

As per the provisions of the Companies Act, 2013, an amount of ₹ 15.08 million that was spent in excess to the eligible CSR amount in the FY 25-26 is available for set off within a span of immediate succeeding three Financial Years

6. **Average net profit of the company as per section 135(5):** ₹ 1,792.17 million

7.

(a)	Two percent of average net profit of the company as per section 135(5):	:	₹ 35.84 million/-
(b)	Surplus arising out of the CSR projects or programs or activities of the previous financial years	:	Nil
(c)	Amount required to be set off for the financial year, if any:	:	Nil
(d)	Total CSR obligation for the financial year (7a+7b-7c).	:	₹ 35.84 million/-

8. (a) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (₹ in million)	Amount Unspent (₹ in million)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5).		
	Amount.	Date of transfer.	Name of the Fund	Amount.	Date of transfer.
₹ 50.92 millions	Nil	NA	NA	Nil	NA

(b) Details of CSR amount spent against ongoing projects for the financial year:

	(2)	(3)	(4)	(5)		(6)		(7)	(10)	(11)	
Sr. No.	Name of the Projec	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No)	Location of the project.		Project duration	Amt allocated for the project (₹ in million)	Amount spent for the project (₹ in million)	Mode of Implementation - Direct (Yes/ No)	Mode of Implementation - Through Implementing Agency	
				State	District					Name	CSR Registration number.
1.	Education activities	(ii)	Yes	Maharashtra	Mumbai & Ratnagiri	2 Years	8.96	11.16	No	Satish Wagh Foundation	CSR00015931
2.	Protection and awareness of Wildlife and Animal Welfare	(iv)	Yes	Maharashtra	Mumbai & Ratnagiri	2 Years	8.94	7.28	No	Satish Wagh Foundation	CSR00015931
3.	Health Care related activities	(i)	Yes	Maharashtra	Mumbai & Ratnagiri	2 Years	8.96	17.22	No	Satish Wagh Foundation	CSR00015931
4.	Rural and Infrastructure Development	(x)	Yes	Maharashtra	Mumbai & Ratnagiri	2 Years	8.94	15.26	No	Satish Wagh Foundation	CSR00015931
	TOTAL						35.84	50.92			

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(7)	(10)	(11)	
Sl. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No)	Location of the project.		Amount spent for the project (₹ in million)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation - Through Implementing Agency	
				State	District			Name	CSR Registration number
NA									

(d) Amount spent in Administrative Overheads : Nil

(e) Amount spent on Impact Assessment, if applicable : Not Applicable

(f) Total amount spent for the Financial Year (8b+8c+8d+8e) : ₹ 50.92 million

(g) Excess amount for set off, if any

Sl. No.	Particulars	Amount (₹ in million)
(i)	Two percent of average net profit of the company as per section 135(5)	₹ 35.84
(ii)	Total amount spent for the Financial Year	₹ 50.92
(iii)	Excess amount spent for the financial year [(ii)-(i)]	₹ 15.07
(iv)	Surplus arising out of the CSR projects or programs or activities of the previous financial years, if any	Nil
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	₹ 15.08

9. a) Details of Unspent CSR amount for the preceding three financial years:

The eligible CSR amount for the financial year was utilized, and consequently, no amount was required to be transferred to the Unspent CSR Account.

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Sl. No.	Project ID	Name of the Project	Financial Year in which the project was commenced.	Project duration	Total amount allocated for the project (in ₹)	Amount spent on the project in the reporting Financial Year (in ₹)	Cumulative amount spent at the end of reporting Financial Year	Status of the project - Completed / Ongoing
1.	FY31.03.2023_1	Health related activities	F.Y. 2022-2023	2 Years	18,98,000	13,23,000	18,98,000	Completed
2.	FY31.03.2023_2	Health related activities	F.Y. 2022-2023	2 Years	29,60,000	29,60,000	29,60,000	Completed

* Company has extended the duration of project.

10. In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year:

a) Date of creation or acquisition of the capital asset(s): NIL

b) Amount of CSR spent for creation or acquisition of capital asset: NIL

c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc: NIL

d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset): NIL

11. **Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per section 135(5).**

The Company has spent the entire eligible CSR amount during the FY 25-26.

For and on Behalf of the Board of Directors
For Supriya Lifescience Limited

Dr. Satish Waman Wagh
Chairman and Executive Director,
Chairman- CSR Committee
DIN: 01456982

Date: May 27, 2026.
Place: Mumbai.

Annexure IV

Conservation of Energy and Technology Absorption

Your Company is not an energy intensive unit. However, possibilities are continuously explored to conserve energy and to reduce energy consumption to the extent possible. During the year under review, considering the nature of activities presently being carried on by the Company, categorical information of the Company in terms of the Rules is provided below:

(A) CONSERVATION OF ENERGY:

(i)	Steps taken or impact on conservation of energy	We started use of power through additional solar grid station thereby reducing consumption of power from conventional energy resources
(ii)	Steps taken by the company for utilizing alternate sources of energy	1. Oil heating skid use implemented in high temperature processes instead of diesel boiler. 2. Gas Boiler installed to replace briquette boiler which will reduce Sulfur dioxide emissions to Nil and minimize particulate emissions
(iii)	Capital Investment on energy conservation equipment;	NIL

(B) TECHNOLOGY ABSORPTION:

(i) the efforts made towards technology absorption:	1. New facility for CMO client commissioned – for supply to the customer over the next 10 years as per supply agreement
(ii) the benefits derived like product improvement, cost reduction, product development or import substitution;	2. Clean chemistry initiatives - Replacement of Bromine with safer reagents continues. Successful implementation in two more major high volume APIs thereby reducing risk and waste generation at the facility 3. Adding more solvent recovery columns to improve recovery and recycle of solvents – 2 new systems installed 4. Batch size increase of key products and implementation of closed systems for material handling 5. Successful development of six products in R&D of which four are scaled up and validated. Two products are import substitutes of which sales have commenced. Capacities for these two import substitute products are now being expanded to meet growing demand 6. Backward integration of two more products taken up and implemented successfully thereby minimizing supply chain uncertainties.
(iii) in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-	Nil
(a) the details of technology imported;	-
(b) the year of import;	-
(c) whether the technology been fully absorbed;	-
(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof;	-

(C) EXPENDITURE INCURRED ON RESEARCH AND DEVELOPMENT:

(₹ in Million)

	March 31, 2026	March 31, 2025
Capital	80.96	63.36
Revenue	87.80	40.46
Total	**168.76**	**103.82**

(D) FOREIGN EXCHANGE EARNINGS AND OUTGO:

The foreign exchange earned in terms of actual inflows during the year and the foreign exchange outgo during the year in terms of actual outflows.

(₹ in Million)

	March 31, 2026	March 31, 2025
Foreign exchange earning	6,591	5,286
Foreign exchanged outgo	1,196	861.6

For and on Behalf of the Board of Directors
For Supriya Lifescience Limited

Dr. Satish Waman Wagh
Chairman and Executive Director,
DIN: 01456982

Date: May 27, 2026
Place: Mumbai.

Report on Corporate Governance

This corporate governance report is prepared in accordance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (herein after referred to as "SEBI Listing Regulations"). The CG Report contains the details of corporate governance systems and processes of the Company.

1. COMPANY'S PHILOSOPHY ON CODE OF CORPORATE GOVERNANCE:

Corporate governance encompasses a set of systems and practices to ensure that the Company's affairs are being managed with accountability, transparency, empowerment, integrity and fairness in all the transactions. We are committed to meet the aspirations of all our stakeholders. The Company's commitment for effective Corporate Governance continues and the Company has always been at the forefront of benchmarking its internal systems and policies within accepted standards so as to facilitate the creation of long-term value for all stakeholders. The Company's overall governance framework, systems, and processes reflect and support our Mission, Vision, Ethics and Values.

The Company firmly believes that good corporate governance is essential to achieve the long-term corporate goals and enhance stakeholder's value. Critical elements of corporate governance are transparency, internal controls, risk management, internal and external communications, high standards of safety, health, environment, accounting fidelity and product and service quality. The Company has established systems and procedures based on the overview and strategic counsel of the Board and it is fully equipped to discharge its responsibilities and to provide management the strategic direction it needs. The Board of Directors of the Company (the "Board") has empowered responsible persons to implement its policies and guidelines and has set up adequate review processes/mechanisms to serve this purpose. The Corporate Governance report is presented below.

2. BOARD OF DIRECTORS:

The Board of Directors (the 'Board') is the primary direct stakeholder influencing corporate governance. The Board of Directors is the highest governance body constituted to oversee the Company's overall functioning. The responsibility of Board is to provide strategic guidance to the Company, to ensure effective monitoring of the management and to be accountable to the Company and the shareholders. The Board of the Company consists of eminent individuals from industry, management, technical, finance and legal field. Information relating to the business, operations and risks affecting the Company is regularly placed before the Board for its consideration apart from information as mentioned in Part A of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations).

2.1. Composition of Directors:

The Board comprises of an optimum combination of Executive, Non-Executive, Independent Directors and Woman Director as required under the Companies Act, 2013 ('the Act') and SEBI Listing Regulations. As on March 31, 2026, the Company's Board consists of Ten (10) directors, five of whom are Executive and remaining are Non-Executive Independent Directors, including One Woman Director who is a Non-Executive Independent Director. The composition of the Board, as on March 31, 2026, is in conformity with the provisions of the Companies Act, 2013 ("the Act") and regulation 17 of the SEBI Listing Regulations.

2.2. Number & Dates of Board Meetings held during the year:

The Board meets at regular intervals to discuss and decide on business strategies, formulation and evaluation of policies and review financial performance of the Company. The notice and detailed agenda along with the relevant notes and other material information are sent well in advance to ensure timely and informed decisions by the Board. The Board reviews the performance of the Company vis-à-vis the budgets/ targets.

During the financial year 2025-26, 4 (Four) meetings of the Board of Directors were held on May 27, 2025, August 13, 2025, November 12, 2025, and February 09, 2026. The Interval between two meetings was well within the maximum period mentioned under Section 173 of the Act and the SEBI Listing Regulations.

2.3. The composition, nature of directorship, number of meetings attended and their directorship in other public companies of the Board of Directors as on March 31, 2026, are as under:

Name of Director	Category / Designation	No. of Board Meetings Attended	Attendance at Last AGM	Directorship in other listed entity	Chairmanship / Membership of Committees in other Public Ltd Cos. $		No. of Shares held by Directors	Directorship details in other Listed Entities
					Chair manship	Membership		
Dr. Satish Waman Wagh	Chairman -Executive Director	4	Yes	-	0	2	5,44,41,205	-
Mrs. Smita Satish Wagh	Executive-Whole Time Director	2	Yes	-	0	0	3,21,750	-
Dr. Saloni Satish Wagh	Executive-Managing Director	4	Yes	-	0	1	1,02,375	-
Ms. Shivani Satish Wagh	Executive-Joint Managing Director	4	Yes	-	0	0	1,02,375	-
Mr. Balasaheb Gulabrao Sawant	Executive-Whole Time Director	4	Yes	-	0	0	0	-
Mr. Dileep Kumar Jain#	Non-Executive-Independent Director	4	Yes	3	2	5	0	1. Lehar Footwears Limited - Non-Executive - Independent Director 2. Uday Jewellery Industries Limited - Non-Executive - Independent Director 3. Narbada Gems And Jewellery Limited - Non-Executive - Independent Director
Mr. Dinesh Navnital Modi#	Non-Executive-Independent Director	4	Yes	-	0	0	0	-
Dr. Neelam Yashpal Arora	Non-Executive-Independent Director	4	Yes	2	2	4	0	1. Shreyas Intermediates Limited – Non-Executive Independent Director 2. Kesar Petroproducts Limited – Non-Executive Independent Director
Dr. Ganapati Dadasaheb Yadav	Non-Executive-Independent Director	4	Yes	4	0	2	0	1. Godrej Industries Limited – Non-Executive Independent Director 2. Clean Science and Technology Limited – Non-Executive Independent Director 3. Meghmani Organics Limited – Non-Executive Independent Director 4. Bhageria Industries Limited – Non-Executive Independent Director 5. Astec Lifesciences Limited – Non-Executive Independent Director
Dr. Sunil Subhash Bhagwat	Non-Executive-Independent Director	3	Yes	-	0	0	0	-
Mr. Manish Panchal*	Non-Executive-Independent Director	1	No	1	0	5	0	1. NESCO Limited
Mr. Hari K*	Non-Executive-Independent Director	1	No	-	0	1	0	1. Century Plyboards (India) Ltd.

Notes:

1. $ Figures includes Committee positions in Audit Committee and Stakeholders Relationship Committee only.
2. * Mr. Manish Panchal and Mr. Hari K were appointed as Independent Directors of the Company w.e.f. February 09, 2026.
3. # Mr. Dinesh Navnitlal Modi and Mr. Dileep Kumar Jain ceased to be Independent Directors of the Company upon completion of their term as Independent Directors w.e.f. March 24, 2026.

2.4. Separate Meeting of Independent Directors:

In compliance with Regulation 25(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a separate meeting of the Independent Directors was held on March 27, 2026 without the presence of Executive Directors or Management representatives, inter alia, to discuss and evaluate the performance of Non-Independent Directors and the Board as a whole, performance of the Chairman of the Company taking into account the views of executive and non-executive directors and the quality, quantity and timeliness of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform its duties. All Independent Directors of the Company attended the meeting.

The Independent Directors provide an annual confirmation that they meet the criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1) (b) of Listing Regulations.

The Board of Directors reviewed the declarations of independence submitted by the Independent Directors at the Board meeting held on May 27, 2026, and confirmed that in their opinion Independent Directors fulfil the conditions specified in SEBI Listing Regulations and are independent of the management.

2.5. Directors Induction and Familiarization Programmes:

Towards familiarization of the Independent Directors with the Company, periodic presentations are made at the Board and Committee meetings on business and performance updates of the Company, global business environment, business strategy and risk involved including their roles, rights, responsibility in the Company, nature of the industry in which the Company operates, business model of the Company and related matters.

The details of such programs for familiarisation of the Independent Directors with the Company are available on the website of the Company viz. www.supriyalifescience.com

2.6. Directors and Officers Insurance (D&O):

In line with the requirements of Regulation 25(10) of the SEBI Listing Regulations, the Company has taken D&O Insurance for all its directors for such quantum and for such risks as determined by the Board of Directors.

2.7. List of Board's skills / expertise / competencies fundamental for the effective functioning of the Company:

The Board has identified the following skills / expertise / competencies fundamental for the effective functioning of the Company which are currently available with the Board:

Skill	Description
General	Finance, Operations, Commercial, Legal, Risk and Human resources related.
Global Business	Understanding, of global business dynamics, across various geographical markets, industry verticals relating to the operations of the Company and regulatory requirements in the geographical markets.
Strategy, Planning & Marketing	Appreciation of long-term trends, strategic choices and experience in guiding and leading management teams to make decisions in uncertain environments.
Corporate Governance	Knowledge of governance processes and compliance to applicable laws and regulations to service best interests of all stakeholders, maintaining Board and Management accountability and corporate ethics and values
Leadership	Extended leadership experience for a significant enterprise, resulting in a practical understanding of organisations, processes, strategic planning, and risk management. Demonstrated strengths in developing talent, planning succession, and driving change and long-term growth
Technology	Knowledge of technology related to Company's current and future products and business opportunities, of evolving trends of usage of its product range and of developing cost-efficient processes

Name of the Director	General	Global Business	Strategy, Planning & Marketing	Corporate Governance	Leadership	Technology
Dr. Satish Waman Wagh	✓	✓	✓	✓	✓	✓
Mrs. Smita Satish Wagh	✓		✓	✓	✓	
Dr. Saloni Satish Wagh	✓	✓	✓	✓	✓	✓
Ms. Shivani Satish Wagh	✓	✓	✓	✓	✓	✓
Mr. Balasaheb Gulabrao Sawant	✓		✓	✓	✓	✓
Dr. Neelam Yashpal Arora	✓		✓	✓	✓	
Dr. Ganapati Dadasaheb Yadav	✓	✓	✓	✓	✓	✓
Dr. Sunil Subhash Bhagwat	✓			✓	✓	✓
Mr. Manish Panchal	✓	✓	✓	✓	✓	✓
Mr. Hari K	✓	✓	✓	✓	✓	

Mr. Manish Pancal and Mr. Hari K were appointed as Independent Directors of the Company w.e.f. February 09, 2026.

Mr. Dileep Kumar Jain & Mr. Dinesh Navnitlal Modi ceased to be Independent Directors of the Company after completion of their terms of 5 consecutive years on March 24, 2026.

3. BOARD COMMITTEES:

The Company has constituted five (5) Committees of the Board which are Audit Committee, Nomination and Remuneration Committee (NRC), Corporate Social Responsibility Committee (CSR), Stakeholders' Relationship Committee (SRC) and Risk Management Committee (RMC). The composition of the committees of the Board (the "Committee/s") is in accordance with the provisions of the Listing Regulations and the Act. Chief Financial Officer is a permanent invitee, and Company Secretary, is the secretary of all the Committees constituted by the Board.

1. Audit Committee:

The Company has a qualified Independent Audit Committee which has been formed pursuant to Regulation 18 of Listing Regulation and Section 177 of the Companies Act. The terms of reference and powers of the Audit Committee are those prescribed under Part C of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as well as Section 177 of the Companies Act, 2013. The primary objective of the Audit Committee of the Company is to monitor and provide effective supervision of the management's financial reporting process with a view to ensure accurate, timely and proper disclosures and transparency, integrity and quality of financial reporting.

The composition of the Audit Committee is given below:

Name of Members	Designation	Category of Directorship
Mr. Hari K *	Chairman	Independent Director
Dr. Ganapati Dadasaheb Yadav	Member	Independent Director
Mr. Manish Panchal*	Member	Independent Director
Dr. Satish Waman Wagh	Member	Chairman & Executive Director

* Appointed as members of the Committee w.e.f. February 09, 2026.

The Chief Financial Officer, Statutory Auditors and Internal Auditors are invitees to the Audit Committee meetings. The Company Secretary acts as Secretary to the Audit Committee.

The Audit Committee met Four (4) times during the financial year 2025-26. Attendance of the Directors at the Audit Committee meetings held during the year is as under:

Members	Audit Committee Meetings during 2025 - 26			
	May 27, 2025	August 13, 2025	November 12, 2025	February 09, 2026
Mr. Dinesh Navnitlal Modi#	Yes	Yes	Yes	Yes
Dr. Satish Waman Wagh	Yes	No	Yes	Yes
Dr. Ganapati Dadasaheb Yadav	Yes	Yes	Yes	Yes
Mr. Hari K*	No	No	No	No
Mr. Manish Panchal*	No	No	No	No

* Appointed as members of the Committee w.e.f. February 09, 2026 .

Ceased to be member of the Committee w.e.f. March 24,2026 upon completion of his term of five consecutive years.

2. Nomination and Remuneration Committee:

The NRC has been entrusted with all the required authority and powers to play an effective role as envisaged under section 178 of the Act and regulation 19 (1) of SEBI Listing Regulations. The purpose of this Committee of the Board is to discharge the Board's responsibility related to Nomination and Remuneration of the Company's Executive/ Non-Executive Directors. The Committee has overall responsibility of approving and evaluating the nomination and remuneration plans, policies and programmes for Directors, Senior Management and Key Management Personnel.

The composition of the Nomination & Remuneration Committee is given below:

Name of Members	Designation	Category of Directorship
Mr. Hari K*	Chairman	Independent Director
Dr. Sunil Subhash Bhagwat	Member	Independent Director
Mr. Manish Panchal*	Member	Independent Director

* Appointed as members of the Committee w.e.f. February 09, 2026.

The powers, role and terms of reference of the Nomination and Remuneration Committee covers the areas as contemplated under Regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 178 of the Companies Act, 2013, besides other terms as may be referred by the Board of Directors. The role includes formulation of criteria for determining qualifications, positive attributes and independence of a director and recommending to the Board a policy, relating to the appointment, removal and payment of remuneration for the Directors, Key Managerial Personnel (KMP), Senior Management Personnel (SMP) and other employees; formulation of criteria for effective evaluation of performance of Boards, its Committees and individual Directors to be carried out either by the Board or by NRC or through an independent external agency and review its implementation and compliance, devising a policy on Board diversity; identification of persons who are qualified to become Directors and who may be appointed as senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal; determining whether to extend or continue the term of appointment of the Independent Director, based on the report of performance evaluation of Independent Directors.

The Nomination & Remuneration Committee met Two (2) times during the financial year 2025-26. Attendance of the Directors at the Nomination and Remuneration Committee meetings held during the year is as under:

Members	Nomination & Remuneration Committee Meetings during 2025-26	
	August 13, 2025	February 09, 2026
Mr. Dinesh Navnitlal Modi#	Yes	Yes
Dr. Sunil Subhash Bhagwat*	Yes	Yes
Mr. Dileep Kumar Jain#	Yes	Yes
Mr. Hari K*	No	No
Mr. Manish Panchal*	No	No

* Appointed as a member of the Committee w.e.f. February 09, 2026.

Ceased to be member of the Committee w.e.f. March 24, 2026 upon completion of their term of five consecutive years.

Performance Evaluation Criteria for Independent Directors:

The performance evaluation criteria for Independent Directors are determined by the Nomination and Remuneration Committee. An indicative list of factors on which evaluation was carried out includes participation and contribution by a director, effective deployment of knowledge and expertise, integrity and maintenance of confidentiality and independence of behaviour and judgment.

Details of remuneration to all Directors:

Remuneration Policy:

The remuneration structure for Directors, Key Managerial Personnel and Senior Management Personnel is performance driven and in considering the remuneration payable to the directors, the Nomination and Remuneration Committee considers the performance of the Company, the current trends in the industry, and the experience of the appointee, their past performance and other relevant factors. Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, Nomination and Remuneration Policy is available on the website of the Company on: https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Nomination-and-Remuneration-Policy.pdf

(i) Non-Executive Directors

The Company does not pay any remuneration to its Non-Executive Independent Directors apart from sitting fees. The sitting fees paid to each Non-Executive Independent Director is ₹ 40,000/- for each Board Meeting, ₹ 20,000/- for each Audit Committee Meeting and ₹ 10,000/- for each Meeting of Stakeholders' Relationship Committee, Risk Management Committee, CSR Committee and NRC Committee.

The Details of sittings fees paid for the financial year 2025-26 are as follows:-

Name of the Directors	Sitting Fees
Mr. Dinesh Navnitlal Modi#	2,60,000
Mr. Dileep Kumar Jain#	2,20,000
Dr. Neelam Yashpal Arora	1,20,000
Dr. Ganapati Dadasaheb Yadav	2,60,000
Dr. Sunil Subhash Bhagwat	1,50,000
Mr. Manish Panchal *	40,000
Mr. Hari K *	40,000

* Appointed as a member of the Board & Committees w.e.f. February 09, 2026.

Ceased to be member of the Board & Committee w.e.f March 24, 2026, upon completion of their term of five consecutive years.

The Non-Executive Directors have no material pecuniary relationships or transactions with the Company in their personal capacity.

(ii) Executive Directors

Remuneration of Managing Director & other Executive Directors are decided by the Board based on the recommendation of the Nomination and Remuneration Committee within the ceiling fixed by the Shareholders as per the Companies Act, 2013.

The elements of remuneration paid to Managing Director & Other Executive Directors during the financial year 2025-26 are as under:

Name of the Directors	Salary, Bonus & Contribution to PF	Commission	Perquisites	Others	Total
Dr. Satish Waman Wagh	12,00,00,000	-	-	-	12,00,00,000
Mrs. Smita Satish Wagh	1,75,90,248	-	-	-	1,75,90,248
Dr. Saloni Satish Wagh	3,40,00,000	-	-	-	3,40,00,000
Ms. Shivani Satish Wagh	3,40,00,000	-	-	-	3,40,00,000
Mr. Balasaheb Gulabrao Sawant	75,62,796	-	-	-	75,62,796

The remuneration structure of the Managing Director comprises of salary, perquisites, allowances, performance bonus, and contribution to provident, superannuation and gratuity funds. Payment of remuneration to the Managing Director is governed as per the Company's policies and subject to the limits approved by the Shareholders from time to time, based on the recommendation of the Nomination and Remuneration Committee and the Board of Directors by the Agreement executed between her and the Company.

3. Stakeholders' Relationship Committee:

The Stakeholders' Relationship Committee is empowered, inter alia, to review all matters connected with the Company's share transfers and transmissions and redressal of shareholders/ investors' complaints like non-transfer of shares, non-receipt of dividend, Annual Report etc. The composition and the terms of reference of Committee are in line with the requirements of provisions of the Companies Act, 2013 and Regulation 20 of SEBI Listing Regulations.

The composition of the Stakeholders' Relationship Committee is given below:

Name of Members	Designation	Category of Directorship
Dr. Satish Waman Wagh	Member	Chairman & Executive Director
Dr. Saloni Satish Wagh	Member	Managing Director
Mr. Manish Panchal*	Chairman	Independent Director

* Appointed as a member of the Committee w.e.f. February 09, 2026.

The functioning and terms of reference of the Committee are as prescribed and in due compliance with the Regulation 20 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as well as Section 178 of the Companies Act, 2013 and include reviewing existing investor redressal system, redressing of Shareholder complaints like non-receipt of declared dividend, resolving the grievances of the security holders of the listed entity including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/ duplicate certificates, general meetings, etc.; review of measures taken for effective exercise of voting rights by shareholders, review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent, review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company.

The Stakeholders Relationship Committee met Four (4) times during the financial year 2025-26. Attendance of the Directors at the Stakeholders Relationship Committee meetings held during the year is as under:

Members	Stakeholders' Relationship Committee Meetings during 2025-26			
	May 27, 2025	August 13, 2025	November 12, 2025	February 09, 2026
Mr. Dileep Kumar Jain#	Yes	Yes	Yes	Yes
Dr. Satish Waman Wagh	Yes	No	Yes	Yes
Dr. Saloni Satish Wagh	Yes	Yes	Yes	Yes
Mr. Manish Panchal*	No	No	No	No

* Appointed as a member of the Committee w.e.f. February 09, 2026.

Ceased to be member of the Committee w.e.f. March 24, 2026, upon completion of his term of five consecutive years.

The details of various complaints received and redressed by the Company during the financial year 2025-26 are as under:

Pending at the Beginning of the Financial year 25-26	Received during the Financial year 25-26	Disposed off during the Financial year 25-26	Pending at the end of the Financial year
Nil	3	3	Nil

Company Secretary is the Compliance Officer in terms of Regulation 6 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as per the details mentioned below:

Name	Designation and Contact Details
Prachi Suhas Sathe	Company Secretary & Compliance Officer Contact No.: +91 22 4033 2727 E-mail: cs@supriyalifescience.com

4. Corporate Social Responsibility Committee:

The Corporate Social Responsibility (CSR) Committee was constituted with the primary responsibility to assist the Board in undertaking CSR activities by way of formulating and monitoring CSR Policy of the Company.

The composition of the Corporate Social Responsibility Committee is given below:

Name of Members	Designation	Category of Directorship
Dr. Satish Waman Wagh	Chairman	Chairman & Executive Director
Dr. Saloni Satish Wagh	Member	Managing Director
Dr. Sunil Bhagwat	Member	Independent Director

The terms of reference of the Corporate Social Responsibility Committee are as follows:

(a) formulate and recommend to the Board, a "Corporate Social Responsibility Policy" which shall indicate the activities to be undertaken by the Company as specified in Schedule VII of the Companies Act, 2013 and the rules made thereunder, as amended, monitor the implementation of the same from time to time, and make any revisions therein as and when decided by the Board;

(b) identify corporate social responsibility policy partners and corporate social responsibility policy programmes;

(c) review and recommend the amount of expenditure to be incurred on the activities referred to in clause (a) and the distribution of the same to various corporate social responsibility programs undertaken by the Company;

(d) delegate responsibilities to the corporate social responsibility team and supervise proper execution of all delegated responsibilities;

(e) review and monitor the implementation of corporate social responsibility programmes and issuing necessary directions as required for proper implementation and timely completion of corporate social responsibility programmes;

(f) any other matter as the Corporate Social Responsibility Committee may deem appropriate after approval of the Board or as may be directed by the Board, from time to time, and

(g) exercise such other powers as may be conferred upon the Corporate Social Responsibility Committee in terms of the provisions of Section 135 of the Companies Act.

The Corporate Social Responsibility Committee met one (1) time during the financial year 2025-26. Attendance of the Directors at the Corporate Social Responsibility Committee meetings held during the year is as under:

Members	Corporate Social Responsibility Committee held on August 13, 2025
Dr. Satish Waman Wagh	No
Dr. Saloni Satish Wagh	Yes
Dr. Sunil Bhagwat	Yes

5. Risk Management Committee:

Risk Management Committee was constituted by the Board, consisting of Executive and Independent Directors, to review the processes and procedures for ensuring that all strategic, operational and regulatory risks are properly identified and that appropriate systems of monitoring and mitigation are in place and to oversee and review the risk management framework, assessment of risks and minimization procedures.

The roles and responsibilities of the Risk Management Committee are as prescribed under Regulation 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and includes monitoring and review of risk management plan and reporting the same to the Board of Directors periodically as it may deem fit, in addition to any other terms as may be referred by the Board of Directors, from time to time.

The Risk Management Committee met two (2) times during the financial year 2025-26. Attendance of the Directors at the Risk Management Committee meetings held during the year is as under:

Members	Risk Management Committee Meetings during 2025-26	
	August 13, 2025	March 09, 2026
Dr. Satish Waman Wagh	No	Yes
Dr. Saloni Satish Wagh	Yes	Yes
Dr. Ganapati Dadasaheb Yadav	Yes	Yes

4. PARTICULARS OF SENIOR MANAGEMENT PERSONNEL AND CHANGES SINCE THE CLOSE OF PREVIOUS FINANCIAL YEAR:

Name of Senior Management Personnel ("SMP")	Designation	Changes, if any	Nature of change and Effective date
Mr. Krishna Raghunathan	Chief Financial Officer	No	-
Dr. Shekhar Bhaskar Bhirud	President - Business Development, Strategy and R&D	No	-
Dr. Prashant Baban Zate	Vice President - QA,QC & RA	No	-
Dr. Sushanta Kumar Gouranga Mishra	Chief Scientific Officer	No	-
Ms. Prachi Suhas Sathe	Company Secretary & Compliance Officer	No	-

5. GENERAL BODY MEETINGS:

1. Location and time, where last three AGMs held:

AGM for the Year ended	Date & Time	Venue	Special Resolution passed
15th AGM March 31, 2023	September 29, 2023 at 03:00 p.m.	Registered Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063, Maharashtra through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")	Nil
16th AGM March 31, 2024	September 27, 2024 at 03:00 p.m.	Through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM")	2*
17th AGM March 31, 2025	September 24, 2025 at 03:00 p.m.	Through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM")	Nil

* The details of Special Resolutions passed at the 16th AGM are as under:

1. Re-appointment of Mrs. Smita Satish Wagh (DIN: 00833912) as Whole Time Director & Key Managerial Personnel of the Company.
2. Continuation of directorship of Mr. Dinesh Navnitlal Modi (DIN: 00004556) as a Non-Executive Independent Director beyond the age of 75 Years

2. Passing of Resolutions by Postal Ballot:

Pursuant to Section 108 and Section 110 of the Act, , as amended read together with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014, read with clarifications issued by Ministry of Corporate Affairs vide General Circular No.14/2020 dated 8th April, 2020, General Circular No.17/2020 dated 13th April, 2020, General Circular No.11/2022 dated 28th December, 2022, General Circular No.9/2023 dated 25th September, 2023, General Circular No. 09/2023 dated September 19, 2024 and General Circular No.03/2025 dated September 22, 2025 , (collectively referred to as the 'MCA Circulars') and other applicable laws and regulations, the Company had sent Postal Ballot Notice by e-mail to all its Members and allowed voting through Remote E-voting system to obtain their approval on the following Special Resolutions passed during the year through Postal Ballot:

Sr. No.	Business/ Resolution proposed	Date of passing of resolutions	Type of Resolution	Votes in favour Percentage	Votes against Percentage
1.	Appointment Of Mr. Manish Panchal (DIN: 08431492) As Non-Executive Independent Director Of The Company For A Term Of Five (5) Consecutive Years From February 09, 2026, To February 08, 2031	April 10, 2026	Special	99.86%	0.14%
2.	Appointment Of Mr. Hari K (DIN: 08901674) As Non-Executive Independent Director Of The Company For A Term Of Five (5) Consecutive Years From February 09, 2026, To February 08, 2031				
3.	Re-Appointment Of Dr. Neelam Arora (DIN: 01603068) As Non-Executive Independent Director Of The Company For Second Term Of Five (5) Consecutive Years From March 25, 2026, To March 24, 2031				
4.	Appointment of Mr. Balasaheb Sawant (DIN: 07743507) as Whole Time Director and Key Managerial Personnel of the Company for a term of three (3) consecutive years from May 26, 2026, to May 25, 2029	August 21, 2026	Special	99.46%	0.54%

In compliance with Regulation 44 of SEBI Listing Regulations and provisions of Sections 108 and 110 of the Act read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, the Company had offered e-voting facility to all its Members to exercise their right to vote. The Company had engaged the services of NSDL for facilitating remote e-Voting to enable the Members to cast their votes electronically.

The Company had appointed CS Sanam Umbargikar (FCS 11777), Partner of M/s. DSM & Associates, Company Secretaries, (hereinafter the "Practicing Company Secretary" or "PCS") as the Scrutinizer for conducting the postal ballot in a fair and transparent manner. All the resolutions were passed with requisite majority on April 10, 2026 and August 21, 2026 respectively, which was also the last day of passing resolutions as per Secretarial Standards – 2 on General Meetings.

6. MEANS OF COMMUNICATION:

1. Quarterly, Half Yearly and Annual Results:

The Quarterly, Half Yearly and Annual Results are published within the timeline stipulated under Listing Regulation. The results are submitted to the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) as well as uploaded on the Company's website at www.supriyalifescience.com.

2. Newspaper Publications:

As per statutory requirement(s) the Quarterly, Half Yearly and Annual Results, various official news releases made to shareholders including notices, record dates for corporate actions, date of general meetings, e-voting information, etc, are published within the statutory timelines in newspapers viz. "Financial Express " and "Loksatta". The Newspaper Publications are available on the Company's website at www.supriyalifescience.com.

3. Press Release and Investor Presentations to Analyst/Investor Meets:

Officials of the Company periodically have conference calls with the Institutional Investors and Analysts. Official Press release and Investor presentations made to Institutional Investor and Analysts are submitted to the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are also uploaded on the Company's website at www.supriyalifescience.com. The audio recording and transcript of call with the analysts/Institutional Investors are also available on the Company's website.

4. Periodic Compliances:

The quarterly, half yearly and annual financial results, shareholding pattern, Corporate Governance Report and other compliances are also posted on the website of the Company.

The Company also discloses all relevant information required to be disclosed under Regulation 30 read with Part 'A' and Part 'B' of Schedule III of the SEBI Listing Regulations including material information having bearing on the performance/operations of the Company and other price sensitive information.

Information to Stock Exchanges are filed electronically on the online portals of BSE Limited i.e. BSE Corporate Compliance & Listing Centre (Listing Centre) and National Stock Exchange of India Ltd. i.e. NSE Electronic Application Processing System (NEAPS).

5. Investor Grievances:

The investors may register their grievance on cs@supriyalifescience.com, an exclusive E-mail ID for registration of complaints by the investors.

7. GENERAL SHAREHOLDER INFORMATION:

Annual General Meeting – date, time and venue	18th Annual General Meeting of the Company will be held on Thursday, September 24, 2026 at 3:00 p.m. through Video Conferencing (VC)/Other Audio-Visual Means (OAVM)
Financial Year	April 1 to March 31
Dividend payment Date	The final dividend for the Financial Year 2025-26, if declared, at the ensuing Annual General Meeting shall be paid /credited within 30 days of declaration, subject to approval of shareholders.
Listing on Stock Exchange	The Equity shares of the Company are listed on BSE Limited having its registered office at P. J. Towers, Dalal Street, Mumbai – 400 001 and National Stock Exchange of India Limited (NSE) having its registered office at Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. The Listing fees for the year 2025-2026 have been paid to both the Stock Exchanges.
ISIN Code.:	INE07RO01027

1. Registrar and Transfer Agent ('RTA'):

MUFG Intime India Private Limited

Unit: Supriya Lifescience Limited

C 101, 247 Park, L B S Marg, Vikhroli West, Mumbai- 400 083.

Tel: +91 22 4918 6000 Fax: +91 22 4918 6060

E-mail: rnt.helpdesk@in.mpms.mufg.com

Website: https://in.mpms.mufg.com/

2. **Share Transfer System:**

Pursuant to SEBI notification dated January 24, 2022, requests for effecting transfer of securities in physical form, shall not be processed by the Company. In case of requests for transmission, transposition, issue of duplicate share certificate, claim from unclaimed suspense account, renewal/ exchange of securities certificate, endorsement, sub-division/splitting of securities certificate, issuances of securities under consolidation of securities certificates/ folios, will be processed only in demat form except for the transfer of securities which were purchased/sold prior to April 1, 2019, whether rejected/returned due to deficiency in documents or not, such transfer can be relodged with requisite documents during the special window provided by SEBI vide their circular no. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, from February 5, 2026 till February 4, 2027. All the Shares of the Company are in Demat form only. Trading in Shares of the Company is permitted only in Demat mode.

The Company's shares are compulsorily traded in dematerialized form on NSE and BSE. Equity shares of the Company representing 100% of the Company's equity share capital are dematerialized as on March 31, 2026. Under the Depository System, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE07RO01027.

As on the date of this report there are no shares lying in the Demat Suspense Account/ Unclaimed Suspense Account.

3. **Distribution of Shareholding as on March 31, 2026:**

Category	No. of Shareholders*	% of Shareholders	No. of Shares	% of total Share Capital
1 to 500	78,098	94.66	48,78,508	6.06
501 to 1000	2,258	2.74	16,87,446	2.10
1001 to 2000	1,120	1.36	16,14,125	2.00
2001 to 3000	344	0.42	8,62,731	1.07
3001 to 4000	158	0.19	5,56,270	0.69
4001 to 5000	108	0.13	5,04,512	0.63
5001 to 10000	209	0.25	15,43,066	1.92
10001 & above	210	0.25	6,88,36,142	85.53
TOTAL	**82,505**	**100**	**8,04,82,800**	**100**

4. **Distribution of Shareholding (Category-wise) as on March 31, 2026:**

Category of Shareholders	No. of Shareholders*	No. of Shares	% of Shareholding
Promoter & Promoter Group	6	5,49,67,815	68.30
Mutual Funds	15	10,72,182	1.33
Alternate Investment Funds	10	16,25,284	2.02
Insurance Companies	2	18,90,566	2.35
Foreign Portfolio Investors (Corporate) – I & II	68	41,51,508	5.16
Trusts			
Body Corporate & LLP	412	21,90,950	2.72
Clearing Members, NBFCs registered with RBI & Hindu Undivided Family	1,324	6,23,785	0.78
Non-Resident Indians	1,991	9,13,396	1.13
Public	78,677	1,30,47,314	16.21
Total	**82,505**	**8,04,82,800**	**100**

5. **Shareholding Profile as on March 31, 2026:**

Mode of Holding	No. of shares	% to Equity
CDSL	6,43,06,808	79.90
NSDL	1,61,75,992	20.10
Total	**8,04,82,800**	**100.00**

6. **Outstanding ADRs/ GDRs/ Warrants or any convertible instruments, conversion date and likely impact on equity:**

The Company does not have any outstanding ADRs/GDRs/ Warrants or any convertible instruments.

7. **Commodity Price Risk or Foreign Exchange Risk and Hedging activities:**

During the year, the Company had managed the foreign exchange risk and hedged to the extent considered necessary. The Company enters into forward contracts for hedging foreign exchange exposures against exports and imports. The details of foreign currency exposure are disclosed in Note No. 28 to the Financial Statements.

8. **Plant Locations:**

A-5/2, Lote Parshuram Industrial Area, MIDC, Village – Lote, Taluka - Khed, District – Ratnagiri.	A-2, MIDC Genekhadpoli, Taluka – Chiplun, District – Ratnagiri	Plot No-60, Additional Ambernath MIDC, Anand Nagar Ambernath (E), District – Thane – 421506, Maharashtra, India

9. **Address for Correspondence:**

Registered Office:

Ms. Prachi Suhas Sathe – Company Secretary & Compliance Officer

Supriya Lifescience Limited

207/208, Udyog Bhavan, Sonawala Road,

Goregaon (East), Mumbai – 400063.

Phone: +91 22 4033 2727

E-mail: cs@supriyalifescience.com

Website: www.supriyalifescience.com

10. **Credit Rating:**

India Ratings and Research (Ind-Ra) has affirmed the credit rating for the Company as Ind - Ra A1 on short-term Fund-based-Post Shipment Credit (PSC), Letter of Credit and Bank Guarantee. And Ind - Ra A (Positive) on Cash Credit (Sub Limit).

8. OTHER DISCLOSURES:

1. **Disclosures on materially significant related party transactions:**

During the year under review, the Company has not entered into any materially significant related party transaction, which could have a potential conflict of interest between the Company and its Promoters or Directors or Management or their relatives other than the transactions carried out in the normal course of business. Other related party transactions have been reported at Note No. 31 of notes to Financial Statements. The policy on Related Party Transactions is available on the website of the Company: www.supriyalifescience.com

2. **Cases of Non-Compliances / Penalties**

The Company has complied with the requirements of the Stock Exchanges, SEBI and other statutory authorities on all matters related to capital markets during the last three years and accordingly no penalties or strictures were imposed on the Company by the Stock Exchanges, SEBI or any other statutory authorities.

3. **Whistle Blower Policy & Vigil Mechanism:**

The Company has adopted a policy on Vigil Mechanism or Whistle Blower as envisaged in the Companies Act and the Rules thereunder and the Listing Regulations The said policy can be accessed on the Company's website at the link

https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/Whistle-Blower-Policy.pdf.

We further confirm that no person was denied access to the Audit Committee.

4. **Code of Conduct:**

A Code of Conduct has been formulated for the Directors and Senior Management Personnel of the Company and the same is available on the Company's website. The Company has received confirmations from all Directors and Senior Management Personnel of the Company regarding compliance with the Code of Conduct for the Financial Year ended March 31, 2026, as applicable to them and also enclosed herewith.

5. **Certificate under Regulation 34(3) of SEBI Listing Regulations:**

A certificate has been received from M/s. DSM & Associates, Practising Company Secretary, that none of the directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as director of companies by the SEBI / Ministry of Corporate Affairs or any such statutory authority is enclosed.

6. The Company is in compliance with all the mandatory requirements of Regulation 17 to 27 and Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The status on adoption of non-mandatory requirement is set out in this report.

7. The Company does not have any subsidiary and hence policy for determining the material subsidiary is not applicable.

8. **Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:**

The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

Number of complaints filed during the financial year	Nil
Number of complaints disposed off during the financial year	Nil
Number of complaints pending as on end of the financial year	Nil

9. Fees paid to Statutory Auditors:

Please refer to the Notes to accounts, for the total fees paid by the Company to the Statutory Auditors for the financial year 2025-26.

10. Details of utilization of funds raised through preferential allotment or qualified institutions placement:

The Company did not raise any funds through preferential allotment or qualified institutions placements specified under Regulation 32 (7A) of the Listing Regulations after the listing of its Equity Shares on the stock exchanges on December 28, 2021.

11. There were no instances where the Board had not accepted any recommendation of any Committees of the Board during the financial year ended March 31, 2026.

12. During the year, the Company has not provided any loans and advances in the nature of loans to firms/ companies in which directors are interested.

13. The Company has not entered into any agreement which are to be disclosed under clause 5A of paragraph A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

14. CEO/ CFO Certification:

The CEO/ CFO of the Company have certified to the Board in relation to reviewing financial statements and other information as required by Regulation 17(8) of the SEBI Listing Regulations and the certificate is appended.

15. Compliance Certificate from Auditors on Corporate Governance:

Certificate from Secretarial auditors M/s. DSM & Associates, Practicing Company Secretary confirming compliance with the conditions of Corporate Governance as stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed as to this Report.

16. Audit Qualification:

The financial statements for the year ended March 31, 2026 are unqualified.

17. Separate Posts of Chairman and CEO/MD:

The Company has separate persons to the post of the Chairman and the Managing Director.

18. Reporting of Internal Auditor:

The Internal Auditors present the Internal Audit Report at the meeting of the Audit Committee every quarter.

19. Investor Presentation and Press Release:

Investor Presentation and Press Release are submitted to Stock Exchanges and are also available on the Website of the Company.

Certificate of Non-Disqualification of Directors

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Supriya Lifescience Limited

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **Supriya Lifescience Limited,** having CIN L51900MH2008PLC180452 and having registered office at 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063, Maharashtra, India, (hereinafter referred to as "the Company") produced before us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in as considered necessary and explanations furnished to us by the Company & its officers, we hereby certify that none of the Directors on the Board of the Company as stated below for the financial year ending on March 31, 2026, have been debarred or disqualified from being appointed or continuing as Directors of Companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority:

Sr. No.	Name of the Directors	DIN	Date of appointment in the Company
1.	Mrs. Smita Satish Wagh	00833912	26th March, 2008
2.	Dr. Satish Waman Wagh	01456982	26th March, 2008
3.	Dr. Saloni Satish Wagh	08491410	1st July, 2019
4.	Ms. Shivani Satish Wagh	08491420	1st July, 2019
5.	Dr. Neelam Yashpal Arora	01603068	25th March, 2021
6.	Mr. Balasaheb Gulabrao Sawant	07743507	26th May, 2023
7.	Mr. Ganapati Dadasaheb Yadav	02235661	24th January, 2025
8.	Dr. Sunil Bhagwat	10178976	24th January, 2025
9.	Mr. Manish Panchal	08431492	9th February, 2026
10.	Mr. Kothandaraman Hari	08901674	9th February, 2026

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these, based on my verification.

This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For DSM & Associates,
Company Secretaries
UCN No. P2015MH038100
Peer Review No.2229/2022.

CS Sanam Umbargikar
Partner
M.No.11777.
CP No.9394.
UDIN: F011777

Date: May 27, 2026
Place: Mumbai.

Declaration on Code of Conduct

I hereby declare that all members of the Board and the Senior Management Personnel of the Company have affirmed compliance with the Code of Conduct laid down by the Board in terms of SEBI (LODR) Regulations, 2015, as applicable to them, for the year ended March 31, 2026.

For Supriya Lifescience Limited

Place : Mumbai
Date: May 27, 2026

Dr. Saloni Satish Wagh
Managing Director

Practicing Company Secretary's Certificate Regarding Compliance of Conditions of Corporate Governance

[Pursuant To Regulation 34(3) and Schedule V Para E of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To the Members of
Supriya Lifescience Limited

We have examined the compliance of conditions of Corporate Governance by **Supriya Lifescience Limited**, for the year ended March 31, 2026, as stipulated in Regulations 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (collectively referred to as "SEBI Listing Regulations, 2015).

The compliance of conditions of Corporate Governance is the responsibility of the Company's management. Our examination was carried out in accordance with the Guidance Note on Certification of Corporate Governance, issued by the Institute of Company Secretaries of India and was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the SEBI Listing Regulations, 2015.

We state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For DSM & Associates,
Company Secretaries
UCN No. P2015MH038100
Peer Review No.2229/2022.

CS Sanam Umbargikar
Partner
M.No.11777.
CP No.9394.
UDIN: F011777

Date: May 27, 2026
Place: Mumbai.

Business Responsibility and Sustainability Report

SECTION A- GENERAL DISCLOSURES

I. Details of the listed entity

1.	**Corporate Identity Number (CIN) of the listed entity**	L51900MH2008PLC180452
2.	**Name of the listed entity**	Supriya Lifescience Limited
3.	**Year of incorporation**	26/03/2008
4.	**Registered office address**	207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063, Maharashtra, India.
5.	**Corporate address**	207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063, Maharashtra, India.
6.	**E-mail**	cs@supriyalifescience.com
7.	**Telephone**	022-40332727
8.	**Website**	www.supriyalifescience.com
9.	**Financial year for which reporting is being done**	April 1, 2025, to March 31, 2026
10.	**Name of the Stock Exchange(s) where shares are listed**	1. BSE Limited ("BSE") 2. The National Stock Exchange of India Limited ("NSE")
11.	**Paid-up Capital**	₹ 160.97 million
12.	**Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report.**	Dr. Saloni Satish Wagh Managing Director Tel. No.: 022 4033 2727 Email id: supriya@supriyalifescience.com
13.	**Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together).**	Standalone Basis
14.	**Name of assurance provider**	NA
15.	**Type of assurance obtained**	Not applicable

II. Products/services

16. Details of business activities (accounting for 90% of the turnover):

S. No.	Description of Main Activity	Description of Business Activity	% of Turnover of the entity
1	Manufacturing of Active Pharmaceutical Ingredients	Manufacturing of Active Pharmaceutical Ingredients	98.17

17. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

S. No.	Product/Service	NIC Code	% of total Turnover contributed
1	Manufacturing & Sale of Active Pharmaceutical Ingredients	21001	98.17

III. Operations

18. Number of locations where plants and/or operations/offices of the entity are situated:

Location	Number of Plants	Number of Offices	Total
National	3	1	4
International	0	0	0

19. Markets served by the entity:

a. Number of locations

Location	Number
National (No. of States)	28
International (No. of Countries)	128

b. What is the contribution of exports as a percentage of the total turnover of the entity?

82%

c. A brief on types of customers

Our diversified customer base comprises innovator companies, generic formulation manufacturers, and traders across a wide range of geographies.

IV. Employees

20. Details as at the end of Financial Year

a. Employees and workers (including differently abled):

No	Particulars	Total(A)	Male		Female	
			No(B)	%(B/A)	No(C)	%(C/A)
	Employees					
1	Permanent (D)	607	546	89.95%	61	10.05%
2	Other than Permanent (E)	703	697	99.15%	6	0.85%
3	Total employees (D + E)	1310	1243	94.89%	67	5.11%
	Workers					
1	Permanent (F)	0	0	NA	0	NA
2	Other than Permanent (G)	0	0	NA	0	NA
3	Total Workers (F + G)	0	0	NA	0	NA

b. Differently abled Employees and workers:

No	Particulars	Total(A)	Male		Female	
			No(B)	%(B/A)	No(C)	%(C/A)
	Differently Abled Employees					
1	Permanent (D)	0	0	NA	0	NA
2	Other than Permanent (E)	0	0	NA	0	NA
3	Total differently abled employees (D + E)	0	0	NA	0	NA
	Differently Abled Workers					
1	Permanent (F)	0	0	NA	0	NA
2	Other than Permanent (G)	0	0	NA	0	NA
3	Total Workers (F + G)	0	0	NA	0	NA

21. Participation/Inclusion/Representation of women

	Total(A)	No. and percentage of Females	
		No(B)	%(B/A)
Board of Directors	10	4	40.00%
Key Management Personnel	2	1	50.00%

22. Turnover rate for permanent employees and workers. (Disclose trends for the past 3 years)

	FY 2025-2026 (Turnover rate in current FY)			FY 2024-2025 (Turnover rate in previous FY)			FY 2023-2024 (Turnover rate in the year prior to the previous FY)		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
Permanent Employees	13.78%	9.60%	13.37%	19.1%	14.9%	18.67%	23.99%	14.46%	21.00%
Permanent Workers	-	-	-	-	-	-	-	-	-

Holding, Subsidiary and Associate Companies (including joint ventures)

23. (a) Names of holding / subsidiary / associate companies / joint ventures.

S. No.	Name of the holding / subsidiary / associate companies / joint ventures (A)	Indicate whether holding/ subsidiary/ associate/ joint venture	% of shares held by listed entity	Does the entity indicated at column A, participate in the Business Responsibility initiatives of the listed entity? (Yes/No)
1	Nil	Nil	Nil	Nil

VI. CSR Details

24. Provide the following CSR details

i) Whether CSR is applicable as per section 135 of Companies Act, 2013 - Yes

ii) Turnover (in Rs.) – 8278.75 million

iii) Net worth (in Rs.) – 11977.33 million

VII. Transparency and Disclosures Compliances

25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Stakeholder group from whom complaint is received	Grievance Redressal Mechanism in Place (Yes/No) (If Yes, then provide web-link for grievance redress policy)	FY 2025-2026			FY 2024-2025		
		Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks	Number of complaints filed during the year	Number of complaints pending resolution at close of the year	Remarks
Communities	Yes, weblink for policy can be accessed at: https://supriyalifescience. com/ assets/pdfs/ corporategovernance/ policies/Grievance%20 policy.pdf	0	0	NA	0	0	NA
Investors (other than shareholders)	Yes, weblink for policy can be accessed at: https://supriyalifescience. com/ assets/pdfs/ corporategovernance/ policies/Grievance%20 policy.pdf	0	0	NA	0	0	NA
Shareholders	Yes, weblink for policy can be accessed at: https://supriyalifescience. com/ assets/pdfs/ corporategovernance/ policies/Grievance%20 policy.pdf	3	0	NA	0	0	NA
Employees and workers	Yes, weblink for policy can be accessed at: https://supriyalifescience.com/ assets/pdfs/corporategovernance/ policies/Grievance%20policy.pdf	0	0	NA	0	0	NA
Customers	Yes, weblink for policy can be accessed at: https://supriyalifescience.com/ assets/pdfs/corporategovernance/ policies/Grievance%20policy.pdf	0	0	NA	0	0	NA
Value Chain partners	Yes, weblink for policy can be accessed at: https://supriyalifescience.com/ assets/pdfs/corporategovernance/ policies/Grievance%20policy.pdf	0	0	NA	0	0	NA

26. Overview of the entity's material responsible business conduct issues. Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or mitigate the risk along-with its financial implications:

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
1	Product Quality and Safety	Risk	Product quality and safety is most important for retaining customers. Any gap with respect to customer expectations impacts revenue	We have stringent quality control and quality assurance processes which ensures that product manufactured by the Company meets quality standards set by itself and regulators	Negative
2	Product quality and safety	Opportunity	Enhancing product quality and safety and meeting the customer expectations will get more customers and revenue.	-	Positive
3	Research and Development	Opportunity	Investment in research and development will lead to building a robust product portfolio. We build, safeguard, and strengthen our research skills and stimulate innovative thinking across our organisation. This allows us to pursue operational excellence and create value for our stakeholders around the world, in accordance with our purpose of 'Caring for Life'.	-	Positive
4	Water Management	Risk	Water is becoming increasingly a scarce resource especially in India where the seasonal rainfalls are the primary source of water. Poor water management will lead to stress for the operations and employee well-being.	Adhering to the existing water management regulations and establishing goals for reducing water. Furthermore, continuously discovering and implementing better ways to measure and reduce water usage through various technologies and behaviour change within the workforce	Negative
5	Waste Management	Risk	The waste generated from our facilities has to be disposed in the most appropriate manner	The waste generated from our facilities is segregated and disposed through pollution control board approved vendors and in compliance with regulations.	Negative

S. No.	Material issue identified	Indicate whether risk or opportunity (R/O)	Rationale for identifying the risk / opportunity	In case of risk, approach to adapt or mitigate	Financial implications of the risk or opportunity (Indicate positive or negative implications)
6	Community Engagement	Opportunity	Community Engagement enables us to create shared value for our local communities, foster meaningful relationships, support social development, and contribute to the well-being of the areas in which we operate.	-	Positive
7	Data Privacy and Digitization	Risk	As a part of the pharmaceutical industry, it is mandatory that data with respect to drugs and drugs products as well as customers remains confidential.	We have a dedicated IT team to assess security risks that may arise at any time.	Negative

SECTION B- MANAGEMENT AND PROCESS DISCLOSURES

Policy and management processes

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
1. a. Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
b. Has the policy been approved by the Board? (Yes/No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
c. Web Link of the Policies, if available	https:// supriyal-ifescience. com/ assets/ pdfs/ corporategovern-ance/ policies/ Code-of-Con-ductfor- Direc-torsand- Senior-Management.pdf	https:// supriyal-ifescience. com/ assets/ pdfs/ corporategovern-ance/ policies/ Sustainable%20 procurement%20 policy.pdf	https:// supri-yalifescience. com/assets/ pdfs/corporat-egovernance/ policies/ SLL_ Equal%20 Op-portunity%20 Policy.pdf	https:// supri-yalifescience. com/assets/ pdfs/corporat-egovernance/ policies/Busi-ness- Responsi-bility- Policy.pdf	https:// supri-yalifescience. com/assets/ pdfs/corpo-rategovern-ance/ policies/ Preventionof-Sexual- Harass-ment-Policy. pdf	https:// supriyal-ifescience. com/ assets/ pdfs/ corporategov-ernance/ pol-icies/EHS%20 Policy.pdf	https:// supriyal-ifescience. com/ assets/ pdfs/ corporategovern-ance/ policies/ Code%20 of%20 Business%20 Conduct.pdf	https:// supri-yalifescience. com/assets/ pdfs/corporat-egovernance/ policies/CSRPol-icy. pdf	https:// supri-yalifescience. com/assets/ pdfs/corpo-rategovern-ance/ policies/ Information%20 Security%20 Policy. pdf
2. Whether the entity has translated the policy into procedures. (Yes / No)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
3. Do the enlisted policies extend to your value chain partners? (Yes/No)	No	No	No	No	No	No	No	No	No
4. Name of the national and international codes/ certifications/labels/ standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted by your entity and mapped to each principle.	CDSCO, USFDA, EDQM, NMPA	-	-	-	-	-	-	-	ISO 9001:2015, CDSCO, USFDA, EDQM, NMPA
5. Specific commitments, goals and targets set by the entity with defined timelines, if any.	We are currently in the process of assessing our ESG performance, and accordingly we will be developing commitments, goals and targets with defined timelines								
6. Performance of the entity against the specific commitments, goals and targets along-with reasons in case the same are not met.	The performance will be periodically monitored once the goals and targets are created								

Governance, leadership and oversight

7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements (listed entity has flexibility regarding the placement of this disclosure)	Dear Stakeholders, I am pleased to present Supriya Lifescience Ltd.'s fourth Business Responsibility and Sustainability Report. With a global presence spanning 128 countries, our mission of "Caring for Life" guides our operations and underpins the value we create for all stakeholders. Over the past year, we have embedded ESG principles into our business practices, enabling us to enhance operational efficiency while remaining mindful of our impact on society, the environment, our partners, and our employees. Environment: Within our operations, a solar project has been implemented, helping reduce our carbon footprint. We remain committed to adopting sustainable fuels, including renewable sources such as solar, biofuel, and bagasse briquettes. On the value chain front, we have further expanded our coverage of sustainable practices. Social: Our strong health and safety systems ensured zero incidents of injuries this year. A majority of our workforce has been trained on health and safety measures, with 100% of our operations assessed for safety practices, extending to 60% of our value chain. We are also working continuously to improve access to and affordability of the products we manufacture. Governance: Ethics, integrity, and robust corporate governance remain the foundation of our ESG journey. We continue to maintain stringent IT protocols and are proud to report zero incidents of data breaches during the year.

8.	Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy (ies).	Dr. Saloni Satish Wagh, Managing Director DIN: 08491410
9.	Does the entity have a specified Committee of the Board/ Director responsible for decision making on sustainability related issues? (Yes / No). If yes, provide details.	Yes, Dr. Saloni Satish Wagh, Managing Director, oversees the Business Responsibility and Sustainability initiatives of the Company

10. Details of Review of NGRBCs by the Company: Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee

Subject for Review	Indicate whether review was undertaken by Director / Committee of the Board/ Any other Committee									Frequency (Annually/ Half yearly/ Quarterly/ Any other – please specify)								
	P1	P2	P3	P4	P5	P6	P7	P8	P9	P1	P2	P3	P4	P5	P6	P7	P8	P9
Performance against above policies and follow up action					Director													
Compliance with statutory requirements of relevance to the principles, and, rectification of any non-compliances					Annually						Annually		Quarterly			Annually		Quarterly

11. Has the entity carried out independent assessment/ evaluation of the working of its policies by an external agency? (Yes/No). If yes, provide name of the agency.

S. no	P1	P2	P3	P4	P5	P6	P7	P8	P9
1	No	No	No	No	No	No	No	No	No

12. If answer to question (1) above is No i.e. not all Principles are covered by a policy, reasons to be stated

Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
The entity does not consider the Principles material to its business (Yes/No)									
The entity is not at a stage where it is in a position to formulate and implement the policies on specified principles (Yes/No)									
The entity does not have the financial or/ human and technical resources available for the task (Yes/No)					Not Applicable				
It is planned to be done in the next financial year (Yes/No)									
Any other reason (please specify)									

SECTION C - PRINCIPLE WISE PERFORMANCE DISCLOSURE

PRINCIPLE 1 Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable

Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the Principles during the financial year

Segment	Total number of training and awareness programmes held	Topics/principles covered under the training and its impact	Percentage of persons in respective category covered by the awareness programmes
Board of directors	4	Code of Conduct, Prevention of Sexual Harassment (POSH). This enables our Board to ensure that responsible, ethical and fair conduct is being adhered to throughout the company.	100.00%
Key Managerial personnel	4	Code of Conduct, Unpublished Price Sensitive Information (UPSI), Prevention of Sexual Harassment (POSH) to ensure that responsible, ethical and fair conduct is being adhered to throughout the company.	100.00%
Employees other than BoD and KMPs	3	Code of Conduct, Prevention of Sexual Harassment (POSH), Health & Safety. These trainings guide our employees with respect to their conduct in the workplace. In addition, Health and Safety trainings are held to ensure that the team is aware of the proper safety norms and protocols and ensure safety at all times. to ensure that responsible, ethical and fair conduct is being adhered to throughout the company.	100.00%
Workers	-	-	-

2. Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on the entity's website):

Monetary					
Category	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Amount (In INR)	Brief of the Case	Has an appeal been preferred? (Yes/No)
Penalty/ Fine	-	-	0	-	-
Settlement	-	-	0	-	-
Compounding fee	-	-	0	-	-

Monetary				
Category	NGRBC Principle	Name of the regulatory/ enforcement agencies/ judicial institutions	Brief of the Case	Has an appeal been preferred? (Yes/No)
Imprisonment	-	-	-	-
Punishment	-	-	-	-

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.

S. No.	Case Details	Name of the regulatory/ enforcement agencies/ judicial institutions
1	-	-

4. **Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web-link to the policy.**

Yes. It is our policy to conduct all of our business in an honest and ethical manner. We take a zero-tolerance approach to bribery and corruption and are committed to acting professionally, fairly and with integrity in all our relationships and business dealings wherever we operate and to implementing and enforcing systems to counter bribery. We will uphold all laws relevant to countering bribery and corruption. We remain bound by the applicable Indian and international laws in respect of our conduct both at home and abroad. The policy is a part of our Code of Conduct Policy and can be accessed here: https:// supriyalifescience.com/assets/pdfs/corporate-overnance/policies/Code%20of%20Business%20Conduct.pdf

5. **Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption:**

Category	Current Financial Year	Previous Financial Year
Directors	0	0
KMPs	0	0
Employees	0	0
Workers	0	0

6. **Details of complaints with regard to conflict of interest:**

Category	Current Financial Year		Previous Financial Year	
	Number - 2025-2026	Remarks - 2025-2026	Number - 2024-2025	Remarks - 2024-2025
Number of complaints received in relation to issues of Conflict of Interest of the Directors	0	-	0	-
Number of complaints received in relation to issues of Conflict of Interest of the KMPs	0	-	0	-

7. **Provide details of any corrective action taken or underway on issues related to fines/ penalties/ action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.**

Nil

8. **Number of days of accounts payables ((Accounts payable × 365) / Cost of goods/services procured) in the following format:**

Particulars	Current Financial Year	Previous Financial Year
Number of days of accounts payables	139	111

9. **Open-ness of business - Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format:**

Parameter	Metrics	FY2025-2026	FY2024-2025
Concentration of Purchases	a. Purchases from trading houses as % of total purchases	0	0
	b. Number of trading houses where purchases are made from	0	0
	c. Purchases from top 10 trading houses as % of total purchases from trading houses	0	0
Concentration of Sales	a. Sales to dealers / distributors as % of total sales	0	0
	b. Number of dealers / distributors to whom sales are made	0	0
	c. Sales to top 10 dealers / distributors as % of total sales to dealers / distributors	0	0
Share of RPTs in	a. Purchases (Purchases with related parties / Total Purchases)	0	0
	b. Sales (Sales to related parties / Total Sales)	0	0
	c. Loans & advances (to related parties / total loans & advances)	0	0
	d. Investments (in related parties / total investments)	0	0

In FY 24-25, there have not been any transactions with trading houses or any related party transactions

Leadership Indicators

1. **Awareness programmes conducted for value chain partners on any of the Principles during the financial year:**

S. No.	Total number of awareness programmes held	Topics / principles covered under the training	% of value chain partners covered (by value of business done with such partners) under the awareness programmes
1	NA	NA	NA

2. **Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) If Yes, provide details of the same.**

Yes, the Company has in place a 'Code of Conduct for Board Members and Senior Management' and a 'Related Party Transaction Policy', which are applicable to our board members. Transactions with the board members or any entity in which such board members are concerned or interested are required to be approved by the Audit Committee and the Board of Directors. In such cases, the interested directors abstain themselves from the discussions at the meeting. The weblink of the abovementioned policies are mentioned below: Code of Conduct for Board Members and Senior Management: https://supriyalifescience.com/assets/pdfs/corporategovernance/policies/Code-of-Conduct-for-Directors-and-Senior-Management.pdf

Related Party Transaction Policy: https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/ Policy-on-Related-Party-Transactions.pdf

PRINCIPLE 2 Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. **Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total R&D and capex investments made by the entity, respectively.**

Particulars	Current Financial Year	Previous Financial Year	Details of improvements in environmental and social impacts
R&D	-	-	NA
Capex	-	9.08%	Solar power plants installed at Nanded in the previous reporting period (FY 24-25)

2. a. **Does the entity have procedures in place for sustainable sourcing? (Yes/No)**

Yes

b. **If yes, what percentage of inputs were sourced sustainably?**

60%

3. **Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life for the following:**

Category	Description
(a) Plastics (including packaging)	The recycling and disposal of the plastics (including packaging) is carried out as per the Central Government rules and the provisions of the Plastic Waste Management Rules.
(b) E-waste	E-waste is disposed of through a registered recycler.
(c) Hazardous waste	Hazardous waste is disposed of to Treatment, storage, and disposal facility (TSDF) or authorized cement industries for further treatment and disposal or compressing.
(d) Other waste	Bio-medical waste is disposed of through authorized common bio-medical waste facilities.

4. **Whether Extended Producer Responsibility (EPR) is applicable to the entity's activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same.**

Not Applicable

Leadership Indicators

1. **Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products (for manufacturing industry) or for its services (for service industry)? If yes, provide details in the following format?**

S. No.	NIC Code	Name of Product / Service	% of total Turnover contributed	Boundary for which the Life Cycle Perspective / Assessment was conducted	Whether conducted by independent external agency (Yes/No)	Results communicated in public domain (Yes/No) If yes, provide the web-link.
1			NA			

2. **If there are any significant social or environmental concerns and/or risks arising from production or disposal of your products / services, as identified in the Life Cycle Perspective / Assessments (LCA) or through any other means, briefly describe the same along-with action taken to mitigate the same.**

S. No.	Name of Product / Service	Description of the risk / concern	Action Taken
1	NA	NA	NA

3. **Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) or providing services (for service industry).**

S. No.	Indicate input material	Recycled or re-used input material to total material	
		FY2025-2026	FY2024-2025
1	NA	NA	NA

4. **Of the products and packaging reclaimed at end of life of products, disclose the amount (in metric tonnes) reused, recycled, and safely disposed, as per the following format:**

	FY2025-2026			FY2024-2025		
	Re-Used	Recycled	Safely Disposed	Re-Used	Recycled	Safely Disposed
Plastics (including packaging)	0	0	0	0	0	0
E-waste	0	0	0	0	0	0
Hazardous waste	0	0	0	0	0	0
Other waste	0	0	0	0	0	0

5. **Reclaimed products and their packaging materials (as percentage of products sold) for each product category.**

S. No.	Indicate product category	Reclaimed products and their packaging materials as % of total products sold in respective category
	NA	

PRINCIPLE 3 Businesses should respect and promote the well-being of all employees, including those in their value chains

Essential Indicators

1. a. **Details of measures for the well-being of employees:**

Category	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent Employees											
Male	546	0	0.00%	546	100.00%	0	0.00%	0	0.00%	0	0.00%
Female	61	0	0.00%	61	100.00%	61	100.00%	0	0.00%	0	0.00%
Total	607	0	0.00%	607	100.00%	61	100.00%	0	0.00%	0	0.00%
Other than permanent Employees											
Male	697	697	100.00%	697	100.00%	0	0.00%	0	0.00%	0	0.00%
Female	6	6	100.00%	6	100.00%	6	100%	0	0.00%	0	0.00%
Total	703	703	100.00%	703	100.00%	6	100%	0	0.00%	0	0.00%

(% of employees covered by)

b. **Details of measures for the well-being of workers:**

Category	Total (A)	Health insurance		Accident insurance		Maternity benefits		Paternity benefits		Day Care facilities	
		Number (B)	% (B / A)	Number (C)	% (C / A)	Number (D)	% (D / A)	Number (E)	% (E / A)	Number (F)	% (F / A)
Permanent Workers											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0	0
Other than permanent Workers											
Male	0	0	0	0	0	0	0	0	0	0	0
Female	0	0	0	0	0	0	0	0	0	0	0
Total	0	0	0	0	0	0	0	0	0	0	0

(% of workers covered by)

c. **Spending on measures towards well-being of employees and workers (including permanent and other than permanent) in the following format:**

Particulars	Current Financial Year	Previous Financial Year
Cost incurred on wellbeing measures as a % of total revenue of the company	0.25%	0.29%

2. **Details of retirement benefits, for Current FY and Previous Financial Year.**

Benefits	No. of employees covered as a % of total employees. (CY)	No. of workers covered as a % of total workers. (CY)	Deducted and deposited with the authority (Y/N/N.A.). (CY)	No. of employees covered as a % of total employees. (PY)	No. of workers covered as a % of total workers. (PY)	Deducted and deposited with the authority (Y/N/N.A.). (PY)
PF	9.6%	0	Y	8.96%	0	Y
Gratuity	9.34%	0	Y	9.34%	0	Y
ESI	4.01%	0	Y	4.01%	0	Y
Others – please specify	0.00%	0	NA	0.00%	0	NA

3. **Are the premises / offices of the entity accessible to differently-abled employees and workers, as per the requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the entity in this regard.**

No, our premises are currently not accessible to differently abled employees and workers. We have facilities available at our office for easy access through Lifts for differently abled employees.

4. **Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, provide a web-link to the policy.**

Yes. https://supriyalifescience.com/assets/pdfs/corporate-governance/policies/SLL_Equal%20Opportunity%20Policy.pdf

5. **Return to work and Retention rates of permanent employees and workers that took parental leave.**

Gender	Permanent employees		Permanent workers	
	Return to work rate	Retention rate	Return to work rate	Retention rate
Male	-	-	-	-
Female	-	-	-	-
Total	-	-	-	-

Note: None of the Employees took parental leave in the year of reporting.

6. **Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If yes, give details of the mechanism in brief.**

Category	Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Employees	All employees are covered under the Grievance Redressal Policy, in which the HR department assists the employees to fill out a grievance form, post which mediation processes are organized. The services of an investigator may be called upon when necessary. Employees are kept informed throughout the process, and once a resolution is reached, they have the ability to appeal the decision if required.
Permanent Workers	All employees are covered under the Grievance Redressal Policy, in which the HR department assists the employees to fill out a grievance form, post which mediation processes are organized. The services of an investigator may be called upon when necessary. Employees are kept informed throughout the process, and once a resolution is reached, they have the ability to appeal the decision if required.
Other than Permanent Employees	All employees are covered under the Grievance Redressal Policy, in which the HR department assists the employees to fill out a grievance form, post which mediation processes are organized. The services of an investigator may be called upon when necessary. Employees are kept informed throughout the process, and once a resolution is reached, they have the ability to appeal the decision if required.
Other than Permanent Workers	All employees are covered under the Grievance Redressal Policy, in which the HR department assists the employees to fill out a grievance form, post which mediation processes are organized. The services of an investigator may be called upon when necessary. Employees are kept informed throughout the process, and once a resolution is reached, they have the ability to appeal the decision if required.

7. **Membership of employees and worker in association(s) or Unions recognised by the listed entity:**

Category	FY2025-2026			FY2024-2025		
	Total employees / workers in respective category (A)	No. of employees / workers in respective category, who are part of association(s) or Union (B)	% (B / A)	Total employees / workers in respective category (C)	No.of employees / workers in respective category, who are part of association(s) or Union (D)	% (D / C)
Total Permanent Employees	607	0	0.00%	515	0	0.00%
Male	546	0	0.00%	460	0	0.00%
Female	61	0	0.00%	55	0	0.00%
Total Permanent Workers	0	0	0.00%	0	0	0.00%
Male	0	0	0.00%	0	0	0.00%
Female	0	0	0.00%	0	0	0.00%

8. **Details of training given to employees and workers:**

Category	FY2025-2026					FY2024-2025				
	Total (A)	On Health and safety measures		On Skill upgradation		Total (D)	On Health and safety measures		On Skill upgradation	
		No. (B)	% (B / A)	No. (C)	% (C / A)		No. (E)	% (E / D)	No. (F)	% (F / D)
Employees										
Male	1243	1243	100.00%	1243	100.00%	1014	1014	100.00%	1014	100.00%
Female	67	67	100.00%	67	100.00%	57	57	100.00%	57	100.00%
Total	1310	1310	100.00%	1310	100.00%	1071	1071	100.00%	1071	100.00%
Workers										
Male	0	0	NA	0	NA	0	0	NA	0	NA
Female	0	0	NA	0	NA	0	0	NA	0	NA
Total	0	0	NA	0	NA	0	0	NA	0	NA

9. **Details of performance and career development reviews of employees and workers:**

Category	FY2025-2026			FY2024-2025		
	Total (A)	No. (B)	% (B / A)	Total (C)	No. (D)	%(D / C)
Employees						
Male	1243	546	43.93%	1014	460	45.36%
Female	67	61	91.04%	57	55	96.49%
Total	1310	607	46.34%	1071	515	48.09%
Workers						
Male	0	0	NA	0	0	NA
Female	0	0	NA	0	0	NA
Total	0	0	NA	0	0	NA

10. a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, the coverage such system?

Yes. Workplace hazards and sources of potential harm or damage in any work environment are identified, investigated, removed and incidents taking place in the workplace are stopped. The policy is designed and implemented to prevent workplace-related injuries and ill-health for workers and to provide a safe and healthy workplace. Our health and safety management system covers all locations, and all staff.

b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

We are using Hazard Identification and Risk Assessment (HIRA) process which is systematic process used to identify potential hazards in the workplace, assess the associated risks, and implement controls to mitigate or eliminate those risks.

c. Whether you have processes for workers to report the work related hazards and to remove themselves from such risks. (Y/N)

Yes, Risk assessment and HAZOP conducting and identifying hazards and evaluating any associated risks within a workplace, then implementing reasonable control measures to remove or reduce them.

d. Do the employees/ worker of the entity have access to non-occupational medical and healthcare services? (Yes/ No)

Yes, the employees and workers have access to non-occupational medical and healthcare services. They are provided with a Group Medical Insurance in case of accidents, premedical checkup, preventive medical, OHC etc.

11. Details of safety related incidents, in the following format:

Safety Incident/Number	Category	FY2025-2026	FY2024-2025
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)	Employees	0	0
	Workers	0	0
Total recordable work-related injuries	Employees	0	0
	Workers	0	0
No. of fatalities	Employees	0	0
	Workers	0	0
High consequence work-related injury or ill-health (excluding fatalities)	Employees	0	0
	Workers	0	0
Number of Permanent Disabilities	Employees	0	0
	Workers	0	0

12. **Describe the measures taken by the entity to ensure a safe and healthy work place.**

We make every effort to integrate safety into all business processes. Our safety and health management system is based on the principle of plan, do, check and act. Credible risks are evaluated, and adequate actions are taken to mitigate this risk. Safety incidents are reported, investigated and lessons learnt are communicated widely within the organization. This is underpinned by continuous improvement objectives and periodic reviews through the Safety and Health Committees, each headed by a Management Committee Member to ensure that we achieve our targets. A robust audit mechanism is in place to verify compliance to internal standards as well as statutory requirements. A safety culture is promoted by undertaking behavioral interventions at all levels and disseminating the importance of safety as a personal value. Positive safety behaviors are promoted, while unsafe behaviors are corrected through established procedures. A comprehensive emergency response plan and related facilities are maintained at all sites and employees are trained to respond accordingly.

13. Number of Complaints on the following made by employees and workers:

	FY2025-2026			FY2024-2025		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Working Conditions	0	0	NA	2	0	NA
Health & Safety	0	0	NA	0	0	NA

14. Assessments for the year:

Category	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Health and safety practices	100.00%
Working Conditions	100.00%

15. **Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.**

We are investigating all recordable incidents to identify the root causes and implement actions to avoid repeat incidents. We ensure closure of all gaps identified during internal and external audits/assessments in a timely manner.

Leadership Indicators

1. **Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees (Y/N) (B) Workers (Y/N).**

Yes

2. **Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the value chain partners.**

The PF, ESIC, PT, & MLWF statutory dues are deducted and deposited governing authority on monthly basis.

3. **Provide the number of employees or workers having suffered high consequence work-related injury / ill-health / fatalities (as reported in EI-11 above), who have been are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment.**

	Total no. of affected employees/ workers		No. of employees/workers that are rehabilitated and placed in suitable employment or whose family members have been placed in suitable employment	
	FY2025-2026	FY2024-2025	FY2025-2026	FY2024-2025
Employees	0	0	0	0
Workers	0	0	0	0

4. **Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)**

Yes

5. **Details on assessment of value chain partners:**

Category	% of value chain partners (by value of business done with such partners) that were assessed
Health and safety practices	NA
Working Conditions	NA

6. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.**

No corrective actions were required to be undertaken.

PRINCIPLE 4 Businesses should provide goods and services in a manner that is sustainable and safe

Essential Indicators

1. **Describe the processes for identifying key stakeholder groups of the entity.**

The stakeholder groups are identified as part of the stakeholder engagement mechanism, built on the principles of inclusivity, accountability, and responsibility. Presently, the given stakeholders group have the immediate impact on the operations and working of the Company. The primary stakeholders in Company include investors, board members, workers, clients, suppliers, the community, and regulators.

2. **List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.**

S. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication ((Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement
1	Investors/ Shareholders	No	Investor and analyst meetings, Annual General Meeting, Stock Exchange Intimations, Annual Report, Email, Company Website, In-person Meeting	Annually/ Half yearly/ Quarterly/ Need-based	Keeping communication channels open with analysts and investor community helps to connect them with the Company

S. No.	Stakeholder Group	Whether identified as Vulnerable & Marginalized Group (Yes/No)	Channels of communication ((Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of engagement (Annually/ Half yearly/ Quarterly / others – please specify)	Purpose and scope of engagement
2	Employees	No	Email & Website, In person meetings	Regular and need-based	Innovation, Operational efficiency, improvement area, Long-term strategy plans, training and awareness, responsible marketing, brand communication, health, safety and engagement initiatives.
3	Customers	No	Emails, brochures, website and meetings (physical and virtual).	Based on business needs	To keep the customers informed about our products and services and to understand the business needs
4	Value chain Partner	No	Email & Website, In person meetings, con-call meetings, Vendor meets	Based on business needs	To ensure timely supply of goods and services in order to maintain business continuity sustainably
5	Government and Regulators	No	E-mails and letters, Conferences, Industry forums, Regulatory filings, Meetings with officials, and Representations	Need Based	To maintain regular engagement, communications and advocacy with Regulatory Authorities, to understand and brief on matters pertaining to regulatory changes from time to time
6	Communities	Yes	Through CSR projects initiatives and meetings and through e-mail communications	Need Based	Livelihood support, disaster relief, CSR activities with a focus on health, education, sanitation and infrastructure development.

Leadership Indicators

1. **Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.**

   The Company management regularly interacts with key stakeholders i.e. investors, customers, suppliers, employees, etc. and has constantly prioritized the engagement with stakeholders as demonstrated by its corporate philosophy in conducting business with morality and responsibility towards society as a good citizen, implementing the code of conduct as a basis of work for all employees, employing the good corporate governance as a principle of management and exercising the sustainable development.

2. **Whether stakeholder consultation is used to support the identification and management of environmental, and social topics (Yes / No). If so, provide details of instances as to how the inputs received from stakeholders on these topics were incorporated into policies and activities of the entity.**

   No

3. **Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.**

   Not Applicable

PRINCIPLE 5 Businesses should respect and promote human rights

Essential Indicators

1. **Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the following format:**

Category	FY2025-2026			FY2024-2025		
	Total (A)	No. of employees / workers covered (B)	%(B / A)	Total(C)	No. of employees / workers covered (D)	%(D / C)
Employees						
Permanent	607	607	100.00%	515	515	100.00%
Other than permanent	703	703	100.00%	556	556	100.00%
Total Employees	1310	1310	100.00%	1071	1071	100.00%
Workers						
Permanent	0	0	NA	0	0	NA
Other than permanent	0	0	NA	0	0	NA
Total Workers	0	0	NA	0	0	NA

2. **Details of minimum wages paid to employees, in the following format:**

Category	FY25-26					FY24-25				
	Total (A)	Equal to Minimum Wage		More than Minimum Wage		Total(D)	Equal to Minimum Wage		More than Minimum Wage	
		No. (B)	% (B /A)	No. (C)	%(C / A)		No.(E)	% (E /D)	No.(F)	%(F / D)
Employees										
Permanent	607	0	0.00%	607	100.00%	515	0	0.00%	515	100.00%
Male	546	0	0.00%	546	100.00%	460	0	0.00%	460	100.00%
Female	61	0	0.00%	61	100.00%	55	0	0.00%	55	100.00%
Other than Permanent	703	703	100.00%	0	0.00%	556	556	100.00%	0	0.00%
Male	697	697	100.00%	0	0.00%	554	554	100.00%	0	0.00%
Female	6	6	100.00%	0	0.00%	2	2	100.00%	0	0.00%
Workers										
Permanent	0	0	NA	0	NA	0	0	NA	0	NA
Male	0	0	NA	0	NA	0	0	NA	0	NA
Female	0	0	NA	0	NA	0	0	NA	0	NA
Other than Permanent	0	0	NA	0	NA	0	0	NA	0	NA
Male	0	0	NA	0	NA	0	0	NA	0	NA
Female	0	0	NA	0	NA	0	0	NA	0	NA

3. a. **Details of remuneration/salary/wages, in the following format: Median remuneration/wages:**

	Male		Female	
	Number	Median remuneration/ salary/ wages of respective category	Number	Median remuneration/ salary/ wages of respective category
Board of Directors (BoD)	2	63.57	3	30
Key Managerial Personnel	2	63.69	1	0.98
Employees other than BoD and KMP	544	0.38	57	4
Workers	0	0	0	0

   b. Provide information on Gross wages paid to females by the entity, in the following format:

Particulars	Current Financial Year	Previous Financial Year
Gross wages paid to females as % of total wages	4.15%	0.14%

4. **Do you have a focal point (Individual/ Committee) responsible for addressing human rights impacts or issues caused or contributed to by the business? (Yes/No)**

No

5. **Describe the internal mechanisms in place to redress grievances related to human rights issues.**

At Supriya Lifescience Ltd., periodic visits are done by the Management to all of the facilities to ensure that all policies and procedures are being adhered to. We provide human rights training to our staff, and in addition, the premises are constantly monitored using CCTV cameras to ensure that there are no human rights violations occurring. Lastly, in case of any grievance, the staff approaches the management with respect to any grievances, and the management is responsible for redressal of the same.

6. **Number of Complaints on the following made by employees and workers:**

	FY2025-2026			FY2024-2025		
	Filed during the year	Pending resolution at the end of year	Remarks	Filed during the year	Pending resolution at the end of year	Remarks
Sexual Harassment	0	0	NA	0	0	0
Discrimination at workplace	0	0	NA	0	0	NA
Child Labour	0	0	NA	0	0	NA
Forced Labour/ Involuntary Labour	0	0	NA	0	0	NA
Wages	0	0	NA	0	0	NA
Other human rights related issues	0	0	NA	0	0	NA

7. **Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:**

Particulars	Current Financial Year	Previous Financial Year
Total Complaints reported under Sexual Harassment on of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	0	0
Complaints on POSH as a % of female employees / workers	0	0
Complaints on POSH upheld	0	0

8. **Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.**

We are committed to ensuring a workplace that is safe for all of our staff and free from discrimination. Should there be any complaint filed with respect to discrimination or harassment, an Internal Complaints Committee oversees the process, in a way that ensures that the confidentiality of the Complainant is maintained throughout. Stringent protocols are followed to ensure that the complainant does not face any adverse consequences during the process or after.

9. **Do human rights requirements form part of your business agreements and contracts? (Yes/No)**

Yes

10. **Assessments for the year:**

Category	% of your plants and offices that were assessed (by entity or statutory authorities or third parties)
Child labour	100.00%
Forced/involuntary labour	100.00%
Sexual harassment	100.00%
Discrimination at workplace	100.00%
Wages	100.00%

11. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 10 above.**

No corrective actions were required to be undertaken as no significant risks/concerns arose from the assessments

Leadership Indicators

1. **Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.**

Not Applicable

2. **Details of the scope and coverage of any human rights due-diligence conducted.**

Not Applicable

3. **Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?**

No

4. **Details on assessment of value chain partners:**

Category	% of value chain partners (by value of business done with such partners) that were assessed
Sexual harassment	NA
Discrimination at workplace	
Child labour	
Forced/involuntary labour	
Wages	
Others – please specify	

5. **Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at LI-4 above.**

Not applicable

PRINCIPLE 6 Businesses should respect and make efforts to protect and restore the environment

Essential Indicators

1. **Details of total energy consumption in GigaJoules (GJ), in the following format:**

Parameter	FY 2025-2026	FY 2024-2025
From renewable sources		
Total electricity consumption (A)	40952.75	22516.12
Total fuel consumption (B)	101146.29	92034.21
Energy consumption through other sources (C)	0.00	0.00
Total energy consumed from renewable sources (A+B+C)	142099.04	114550.33
From non-renewable sources		
Total electricity consumption (D)	77918.5	67678.92
Total fuel consumption (E)	3772.4	3775.00
Energy consumption through other sources (F)	0.00	0.00
Total energy consumed from non-renewable sources (D+E+F)	81690.90	71453.92
Total energy consumed (A+B+C+D+E+F)	223789.94	186004.25
Energy intensity per rupee of turnover (Total energy consumption/ turnover in rupees)	27.03 GJ / Million	26.71 GJ / Million
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total energy consumed / Revenue from operations adjusted for PPP)	557.94 GJ / Million	551.74 GJ / Million
Energy intensity in terms of physical output	0.24 GJ / Production in Kgs	0.16 GJ / Production in Kgs

Indicate if any independent assessment/evaluation/assurance for energy has been conducted by an external agency. If Yes, provide the name of the agency:

No.

2. **Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.**

No

3. **Provide details of the following disclosures related to water, in the following format:**

Parameter	FY 2025-2026	FY 2024-2025
Water withdrawal by source (in kilolitres)		
(i) Surface water	0.00	0.00
(ii)Groundwater	0.00	0.00
(iii)Third party water	138739.00	124289.00
(iv)Seawater / desalinated water	0.00	0.00
(v) Others	0.00	0.00
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)	138739.00	124289.00
Total volume of water consumption (in kilolitres)	70712.00	42842.00
Water intensity per rupee of turnover (Water consumed / turnover)	8.54 KL / Million	6.15 KL / Million
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total water consumption / Revenue from operations adjusted for PPP)	176.30 KL / Million	127.08 KL / Million
Water intensity in terms of physical output	0.08 KL / Production in Kgs	0.04 KL / Production in Kgs

Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency. -

No.

4. **Provide the following details related to water discharged: Water discharge by destination and level of treatment (in kilolitres)**

Parameter	FY2025-2026	FY2024-2025
Water discharge by destination and level of treatment (in kilolitres)		
(i) To Surface water		
- No treatment	0.00	0.00
With treatment – please specify level of treatment	0.00 0	0.00 0
(ii) To Groundwater		
- No treatment	0.00	0.00
With treatment – please specify level of treatment	0.00 0	0.00 0
(iii) To Seawater		
- No treatment	0.00	0.00
With treatment – please specify level of treatment	0.00 0	0.00 0
(iv) Sent to third-parties		
- No treatment	0.00	0.00
With treatment – please specify level of treatment	68027.00 In house effluent treatment facility	81447.00 In house effluent treatment facility
(v) Others		
- No treatment	0.00	0.00
With treatment – please specify level of treatment	0.00 0	0.00 0
Total water discharged (in kilolitres)	**68027.00**	**81447.00**

Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency. -

No.

5. **Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.**

No.

6. **Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:**

Parameter	Please specify unit	Current Financial Year	Previous Financial Year
NOx	mg/Nm^3	52.9	42.5
SOx	mg/Nm^3	19.24	19.13
Particulate matter (PM)	mg/Nm^3	65.15	65.6
Persistent organic pollutants (POP)	-	0	0
Volatile organic compounds (VOC)	-	0	0
Hazardous air pollutants (HAP)	-	0	0

Indicate if any independent assessment/evaluation/assurance for Air emissions has been conducted by an external agency. If Yes, provide the name of the agency:

Y. Padmaja Aero Biological pvt. ltd

7. **Provide details of greenhouse gas emissions (Scope 1 and Scope 2) in MTCO2e, in the following format:**

Parameter	Unit	FY 2025-2026	FY 2024-2025
Total Scope 1 emissions (Break-up of the GHG into CO_2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	TCO_2e	242.2543	243.0794
Total Scope 2 emissions (Break-up of the GHG into CO_2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	TCO_2e	15367.2585	13667.3811
Total Scope 1 and Scope 2 emission intensity per rupee of turnover	TCO_2e / rupee of turnover	1.89 TCO_2e / Million	2.00 TCO_2e / Million
Total Scope 1 and Scope 2 emission intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)	TCO_2e / Million USD	38.92 TCO_2e / Million USD	41.26 TCO_2e / Million USD
Total Scope 1 and Scope 2 emission intensity in terms of physical output	TCO_2e / Production in Kgs	0.02 TCO_2e / Production in Kgs	0.02 TCO_2e / Production in Kgs

Indicate if any independent assessment/evaluation/assurance for GHG Emissions (Scope 1 and 2) has been conducted by an external agency. If Yes, provide the name of the agency: -

No

8. **Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.**

Optimized the process

1. Optimized the process from five stages to three stages, resulting in reduced energy consumption and waste.
2. Installation of VFDs for motors
3. LED lights installation

9. **Provide details related to waste management by the entity for the Current Financial Year:**

Parameter	FY2025-2026	FY2024-2025
Total Waste generated (in metric tonnes)		
Plastic waste (A)	35.0000	12.0000
E-waste(B)	-	0.1060
Bio-medical waste (C)	0.0004	0.0008
Construction and demolition waste (D)	300.0000	-
Battery waste (E)	-	-
Radioactive waste (F)	-	-
Other Hazardous waste.Please specify, if any. (G)	524.6866	75.6000
Other Non-hazardous waste generated (H). Please specify, if any. (Break-up by composition i.e. by materials relevant to the sector)	25.0000	-
Total (A + B + C + D + E + F + G + H)	**884.6870**	**87.7068**
Waste intensity per rupee of turnover (Total Waste Generated / Revenue from operations)	**0.1069 MT / Million**	**0.0125 MT / Million**
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP) (Total Waste Generated / Revenue from operations adjusted for PPP)	**2.2057 MT / Million**	**0.260 MT / Million**
Waste intensity in terms of physical output (Total Waste Generated / Physical Output)	**0.0010 MT / Production in Kgs**	**0.0001 MT / Production in Kgs**
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Category of waste - Plastic		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	35	-
Total Plastic Waste Recycled, Re-used and other recovery operations	**35.0000**	**0.0000**
Category of waste - E-Waste		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total E-Waste Recycled, Re-used and other recovery operations	**0.0000**	**0.0000**
Category of waste - Bio-medical waste		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total Bio-medical Waste Recycled, Re-used and other recovery operations	**0.0000**	**0.0000**
Category of waste - Construction and demolition waste		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	350.0000	-
Total Construction Waste Recycled, Re-used and other recovery operations	**350.0000**	**0.0000**
Category of waste - Battery waste		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total Battery Waste Recycled, Re-used and other recovery operations	**0.0000**	**0.0000**
Category of waste - Radioactive waste		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	-	-
Total Radioactive Waste Recycled, Re-used and other recovery operations	**0.0000**	**0.0000**
Category of waste - Other Hazardous waste		
(i) Recycled	101.6000	-
(ii) Re-used	-	-
(iii) Other recovery operations	-	38.2000
Total Other Hazardous Waste Recycled, Re-used and other recovery operations	**101.6000**	**38.2000**
Category of waste - Other Non-Hazardous waste		
(i) Recycled	-	-
(ii) Re-used	-	-
(iii) Other recovery operations	25	-
Total Other Non-hazardous Waste Recycled, Re-used and other recovery operations	**25.0000**	**0.0000**
Total	**461.6000**	**38.2000**
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Category of waste - Plastic		
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations	-	-
Total Plastic Waste Incineration, Landfilling and other disposal operations	**0.0000**	**0.0000**
Category of waste - E-Waste		
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations	-	0.1060
Total E-waste Waste Incineration, Landfilling and other disposal operations	**0.0000**	**0.1060**
Category of waste - Bio-medical Waste		
(i) Incineration	-	0.8408
(ii) Landfilling	-	-
(iii) Other disposal operations	0.0004	-
Total Bio-medical Waste Incineration, Landfilling and other disposal operations	**0.0004**	**0.8408**
Category of waste - Construction and demolition waste		
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations	-	-
Total Construction Waste Incineration, Landfilling and other disposal operations	**-**	**0.0000**
Category of waste - Battery		
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations	-	-
Total Battery Waste Incineration, Landfilling and Other disposal operations	**0.0000**	**0.0000**

Parameter	FY2025-2026	FY2024-2025
Category of waste - Radioactive		
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations	-	-
Total Radioactive Waste Incineration, Landfilling and Other disposal operations	0.0000	0.0000
Category of waste - Other Hazardous waste. Please specify, if any		
(i) Incineration	2.5014	7.8300
(ii) Landfilling	126.1536	29.5700
(iii) Other disposal operations	294.4316	
Total Other Hazardous Waste Incineration, Landfilling and Other disposal operations	423.0866	37.4000
Category of waste - Other Non-hazardous waste generated		
(i) Incineration	-	-
(ii) Landfilling	-	-
(iii) Other disposal operations	-	-
Total Other Non-hazardous Waste Incineration, Landfilling and Other disposal operations	0.0000	0.0000
Total	423.0870	38.3468

9. Indicate if any independent assessment/evaluation/assurance for Waste has been conducted by an external agency. If Yes, provide the name of the agency:

Yes. Maharashtra Pollution control board

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

Our establishment holds a valid authorization under the Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016, and full compliance with the stipulated conditions is consistently maintained.

We have adopted comprehensive waste management practices at our facility, including the operation of an Effluent Treatment Plant (ETP) for the treatment of wastewater generated from our processes. All wastes generated are properly identified, labeled, and stored in secured designated areas to prevent any environmental or health risks. Disposal of hazardous and other wastes is carried out safely through authorized agencies approved by the Pollution Control Board, in accordance with applicable regulations.

Our Research and Development team is continuously engaged in process improvement initiatives aimed at enhancing product quality while reducing environmental, health, and safety (EHS) risks. These initiatives include the substitution of hazardous chemicals with less toxic alternatives, optimization of processes to minimize waste generation, and recovery and recycling of solvents back into the production process wherever feasible.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals / clearances are required, please specify details in the following format:

S. No.	Location of operations/offices	Type of operations	Whether the conditions of environmental approval / clearance are being complied with? (Y/N) If no, the reasons thereof and corrective action taken, if any.
1	Our facility is located under Maharashtra industrial development corporation, Maharashtra	Manufacturing	Yes

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

S. No.	Name and brief details of project	EIA Notification No.	Date	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
1	-	-	-	-	-	-

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:

S. No.	Specify the law / regulation / guidelines which was not complied with	Provide details of the non-compliance	Any fines / penalties / action taken by regulatory agencies such as pollution control boards or by courts	Corrective action taken, if any
1	Water (Prevention and Control of Pollution) Act 1974, Air (Prevention and Control of Pollution) Act- 1981, Environment protection act and rules thereunder	Nil	No	-

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):

(i) Name of the area

Not in water stress area

(ii) Nature of operations

Manufacturing

1. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency.

NA

2. Please provide details of total Scope 3 emissions (MTCO2E) & its intensity, in the following format:

Parameter	FY 2025-2026	FY 2024-2025
Total Scope 3 emissions (Break-up of the GHG into CO_2, CH4, N2O, HFCs, PFCs, SF6, NF3, if available)	0.00 TCO_2e / Million	0.00 TCO_2e / Million
Total Scope 3 emissions per rupee of turnover	0.00 TCO_2e / Million	0.00 TCO_2e / Million
Total Scope 3 emission intensity (optional) – the relevant metric may be selected by the entity	0.00 TCO_2e / Million	0.00 TCO_2e /

2. Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, name of the external agency. -

3. With respect to the ecologically sensitive areas reported at EI-11 above, provide details of the significant direct & indirect impact of the entity on biodiversity in such areas along with prevention and remediation activities.

No any impact on biodiversity as we are located under MIDC area.

4. **If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives, as per the following format:**

Sr. No.	Initiative undertaken	Details of the initiative (Web-link, if any, may be provided along-with summary)	Outcome of the initiative
1	1) We have provided closed operation system, like Powder transfer system. 2) We have solar power generation system 3) We have initiated collection of rain water and reused for utility.	NA	NA

5. **Does the entity have a business continuity and disaster management plan? If yes, please give details in 100 words or input web link.**

Yes, we have a Business Continuity and Disaster Management Plan in place which outlines the strategies and procedures adopted by the organization to ensure the continuity of critical business operations during and after unforeseen disruptions such as natural disasters, system failures, cyberattacks, pandemics, or other emergencies.

The plan focuses on minimizing operational downtime, protecting employees and assets, safeguarding data, and ensuring timely recovery of essential functions. It includes risk assessment, emergency response protocols, backup and recovery systems, communication mechanisms, and periodic testing and review to enhance preparedness and resilience..

6. **Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard.**

NA

7. **Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.**

NA

8. **How many Green Credits have been generated or procured?**

a. **Generated by the listed entity** - Nil

b. **Procured by the top ten (in terms of value of purchases and sales, respectively) value chain partners** - Nil

PRINCIPLE 7 Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

Essential Indicators

1. a. **Number of affiliations with trade and industry chambers/ associations.**

5

b. **List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity is a member of/ affiliated to.**

S. No.	Name of the trade and industry chambers/associations	Reach of trade and industry chambers/ associations (State/National/International)
1	Chemicals Export Promotion Council (CHEMEXCIL)	National
2	Pharmaceutical Export Promotion Council of India (PHARMEXCIL)	National
3	Federation of Indian Export Organisations (FIEO)	National
4	Maharashtra Chamber of Commerce, Industry & Agriculture (MACCIA)	State
5	IMC Chamber of Commerce and Industry	National

2. **Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities.**

S. No.	Name of authority	Brief of the case	Corrective action taken
1	NA	NA	NA

Leadership Indicators

1. **Details of public policy positions advocated by the entity:**

S. No.	Public policy advocated	Method resorted for such advocacy	Whether information available in public domain? (Yes/No)	Frequency of Review by Board	Web Link, if available
1	NA	NA	NA	NA	NA

PRINCIPLE 8 Businesses should promote inclusive growth and equitable development

Essential Indicators

1. **Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.**

S. No.	Name and brief details of project	SIA Notification No.	Date of notification	Whether conducted by independent external agency (Yes / No)	Results communicated in public domain (Yes / No)	Relevant Web link
1	NA	NA	NA	NA	NA	NA

2. **Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity, in the following format:**

S. No.	Name of Project for which R&R is ongoing	State	District	No. of Project Affected Families (PAFs)	% of PAFs covered by R&R	Amounts paid to PAFs in the Financial Year (In INR)
1	NA	NA	NA	NA	NA	NA

3. **Describe the mechanisms to receive and redress grievances of the community.**

There is a Point of Contact (POC) from the CSR team whom the community can go to report any grievances. The POC visits the community on a regular basis for monitoring of CSR projects and also conducts stakeholder engagement with the community members.

4. **Input material sourced from suppliers (by value):**

Category	Current Financial Year	Previous Financial Year
Directly sourced from MSMEs/ small producers	38%	40%
Sourced directly from within India	79%	80%

5. **Job creation in smaller towns- Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent/on contract basis) in the following locations, as % of total wage cost. (Place to be categorized as per RBI Classification System - rural / semi-urban / urban / metropolitan)**

Location	Current Financial Year	Previous Financial Year
Rural	26.79%	27.78%
Semi-Urban	10.02%	7.49%
Urban	0.00%	0.00%
Metropolitan	63.19%	64.73%

Leadership Indicators

1. **If any Social Impact Assessments have been reported in EI-1, please provide details of actions taken to mitigate any negative social impacts identified:**

S. No.	Details of negative social impact identified	Corrective action taken
1	NA	NA

2. **Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies:**

S. No.	State	Aspirational District	Amount spent (In INR)
1	NA	NA	NA

3. a. **Do you have a preferential procurement policy where you give preference to purchase from suppliers comprising marginalized /vulnerable groups? (Yes/No) - No**

   b. **From which marginalized /vulnerable groups do you procure?** - No

   c. **What percentage of total procurement (by value) does it constitute?** - No

4. **Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current financial year), based on traditional knowledge:**

S. No.	Intellectual Property based on traditional knowledge	Owned/ Acquired (Yes/No)	Benefit shared (Yes / No)	Basis of calculating benefit share
1	NA	NA	NA	NA

5. **Details of corrective actions taken or underway, based on any adverse order in intellectual property-related disputes wherein usage of traditional knowledge is involved.**

S. No.	Name of authority	Brief of the Case	Corrective action taken
1	NA	NA	NA

6. **Details of beneficiaries of CSR Projects:**

S. No.	CSR Project	No. of persons benefitted from CSR Projects	% of beneficiaries from vulnerable and marginalized groups
1	Promoting Education	1300	80
2	Rural Development	2000	90
3	Environmental Sustainability & Animal Welfare	10000	NA
4	Preventive health care and sanitation	1200	90

PRINCIPLE 9 Businesses should engage with and provide value to their consumers in a responsible manner

Essential Indicators

1. **Describe the mechanisms in place to receive and respond to consumer complaints and feedback.**

   All customer complaints are processed by a cross-functional team comprising QA, R&D, and Marketing departments, in compliance with internal protocols. Complaints are received by the Marketing team and forwarded to QA, which acknowledges receipt and initiates a formal investigation. QA requests all pertinent information, including invoice and batch details, from Marketing and other concerned departments. After a complete investigation, QA prepares a CAPA report, which is relayed to the customer through the Marketing team. Ongoing customer feedback is solicited to assess and improve compliance with quality standards and service performance.

2. **Turnover of products and/ services as a percentage of turnover from all products/service that carry information about:**

Category	As a percentage to total turnover
Environmental and social parameters relevant to the product	70
Safe and responsible usage	20
Recycling and/or safe disposal	10

3. **Number of consumer complaints in respect of the following:**

	FY 2025-2026			FY 2024-2025		
	Received during the year	Pending resolution at end of year	Remarks	Received during the year	Pending resolution at end of year	Remarks
Data privacy	0	0	NA	0	0	NA
Advertising	0	0	NA	0	0	NA
Cyber-security	0	0	NA	0	0	NA
Delivery of essential services	0	0	NA	0	0	NA
Restrictive Trade Practices	0	0	NA	0	0	NA
Unfair Trade Practices	0	0	NA	0	0	NA
Other	0	0	NA	0	0	NA

4. **Details of instances of product recalls on account of safety issues:**

Category	Number	Reasons for recall
Voluntary recalls	0	NA
Forced recalls	0	NA

5. **Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.**

   Yes. https://www.supriyalifescience.com/assets/pdfs/corporate-governance/policies/Information%20Security%20Policy.pdf

6. **Provide details of any corrective actions taken or underway on issues relating to any of the following: i. Advertising; ii. Delivery of essential services; iii. Cyber security and data privacy of customers; iv. Re-occurrence of instances of product recalls V. penalty / action taken by regulatory authorities on safety of products / services.**

   No corrective actions have been taken or underway since no such incidents have been reported in any of the above mentioned criterias

7. **Provide the following information relating to data breaches:**
   a. **Number of instances of data breaches**
      0
   b. **Percentage of data breaches involving personally identifiable information of customers**
      0
   c. **Impact, if any, of the data breaches**
      0

Leadership Indicators

1. **Channels/platforms where information on products and services of the entity can be accessed (provide web link, if available).**
   Information of various products can be accessed on Company's website www.supriyalifescience.com
2. **Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.**
   Material safety data sheets are shared with the customer for each product.
3. **Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services**
   Any product disruptions or change in plan are informed to the customers in advance.
4. **Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to consumer satisfaction relating to the major products / services of the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)**
   The Company ensures customer satisfaction by issuing a checklist of key compliance parameters in accordance with the Drugs and Cosmetics Act. The Quality Department is tasked with maintaining and updating the Customer Satisfaction Index in line with applicable laws and client-specific requirements. However, this is not applicable for APIs.

Independent Auditor's Report

To the Members of M/S. SUPRIYA LIFESCIENCE LIMITED

REPORT ON THE FINANCIAL STATEMENTS

OPINION

We have audited the financial statements of SUPRIYA LIFESCIENCE LIMITED ("the Company"), which comprise the balance sheet as at March 31, 2026, and the statement of Profit and Loss, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (herein after referred to as "financial statement").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by The Companies Act,2013("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its Profit and other Comprehensive Income, changes in equity and its cash flows for the year ended on that date.

BASIS FOR OPINION

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on Financial Statements.

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report

Key Audit Matter	Auditor's Response
Revenue recognition (Refer note 2.1 (d) and 21 of the Financial Statements)	
Revenue is one of the key profit drivers and is therefore susceptible to misstatement. Cut-off is the key assertion insofar as revenue recognition is concerned, since an inappropriate cutoff can result in material misstatement of results for the year	Our audit procedures with regard to revenue recognition included testing controls, automated and manual, around dispatches / deliveries, inventory reconciliations and circularization of receivable balances, testing of cut-offs and performing analytical review procedures.

INFORMATION OTHER THAN FINANCIAL STATEMENTS AND AUDITORS REPORT THEREON

The Company management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company annual report, but does not include the financial statement and our auditor's report thereon.

- Our opinion on the financial statement does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statement, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appear to be materially misstated.
- If, based on the work we have performed, we concluded that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

MANAGEMENT'S RESPONSIBILITY FOR THE STANDALONE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with other accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

That Board of Directors are also responsible for overseeing the Company's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatements of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of Internal control.

- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made my management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that the material uncertainty exists, we are required to draw attention in our Auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in

(i) Planning the scope of our audit work and in evaluating the results of our work; and

(ii) To evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books

c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), the Statement of Changes in Equity and the Statement of Cash Flows dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of pending litigations as at 31 March 2026 on its financial position in its Financial Statements.

ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.

iii. The requirement to transfer amounts to the Investor Education and Protection Fund is not presently applicable to the company.

iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

(d) The dividend declared or paid during the year by the Company is in compliance with Section 123 of the Act.

v. Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the financial year ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2026.

For, Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601

CA. Ujwal Kakaria
Partner
Membership No. – 035416
UDIN: - 26035416PHJBQM6305

Place: - Mumbai
Date: - 27th May 2026

Annexure "A" to the Independent Auditor's Report

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of SUPRIYA LIFESCIENCE LIMITED of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

OPINION

We have audited the internal financial controls over financial reporting of SUPRIYA LIFESCIENCE LIMITED ("the Company") as of March 31, 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

MANAGEMENT'S AND BOARD OF DIRECTORS' RESPONSIBILITIES FOR INTERNAL FINANCIAL CONTROLS

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

AUDITOR'S RESPONSIBILITY

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

MEANING OF INTERNAL FINANCIAL CONTROLS WITH REFERENCE TO FINANCIAL STATEMENTS

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

INHERENT LIMITATIONS OF INTERNAL FINANCIAL CONTROLS OVER FINANCIAL REPORTING WITH REFERENCE TO STANDALONE FINANCIAL STATEMENTS

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For, Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601

CA. Ujwal Kakaria
Partner
Membership No. – 035416
UDIN: - 26035416PHJBQM6305

Place: - Mumbai
Date: - 27th May 2026

Annexure 'B' to the Independent Auditor's Report

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of SUPRIYA LIFESCIENCE LIMITED of even date)

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

i. In respect of the Company's Property, Plant and Equipment and Intangible Assets:

a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment and relevant details of right-of-use assets.

(B) The Company has maintained proper records showing full particulars of intangible assets.

b) The Company has a regular program of physical verification of Property, Plant and Equipment and right-of-use assets so to cover all the assets once every three years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were verified during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

c) Based on our examination of the property tax receipts and lease agreement for land on which building is constructed, registered sale deed / transfer deed / conveyance deed provided to us, we report that, the title in respect of self-constructed buildings and title deeds of all other immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee), disclosed in the financial statements included under Property, Plant and Equipment are held in the name of the Company as at the balance sheet date.

d) The Company has not revalued any of its Property, Plant and Equipment (including right-of-use assets) and intangible assets during the year.

e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2026 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

ii. (a) The Management has conducted physical verification in respects of finished goods, stores, spare parts and raw materials at reasonable intervals. The discrepancies which have been noticed on physical verification of stocks as compared to book records did not exceed 10 % or more in the aggregate for any class of the inventory

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks are in agreement with the books of account of the Company.

iii. The Company has not made investments in, companies, firms, Limited Liability Partnerships, and granted unsecured loans to other parties, during the year, in respect of which:

(a) The Company has not provided any loans or advances in the nature of loans or stood guarantee, or provided security to any other entity during the year, and hence reporting under clause 3(iii)(a) of the Order is not applicable.

(b) In our opinion, the investments made and the terms and conditions of the grant of loans, during the year are, prima facie, not prejudicial to the Company's interest.

(c) In respect of loans granted by the Company, the schedule of repayment of principal and payment of interest has been stipulated and the repayments of principal amounts and receipts of interest are generally been regular as per stipulation.

(d) In respect of loans granted by the Company, there is no overdue amount remaining outstanding as at the balance sheet date.

(e) No loan granted by the Company which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to the same parties.

(f) The Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment during the year. Hence, reporting under clause 3(iii)(f) is not applicable.

iv. The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.

v. The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence, reporting under clause 3(v) of the Order is not applicable.

vi. We have broadly reviewed the books of accounts maintained by the company pursuant to the rules made by the central government for the maintenance of cost records under section 148(1) of the companies act 2013, and are of the opinion that prima facie the specified accounts and records have been made and maintained. We have not, however, made a details examination of the same.

vii. In respect of statutory dues:

(a) In our opinion, the Company has generally been regular in depositing undisputed statutory dues, including Goods and Services tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues applicable to it with the appropriate authorities.

There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, Cess and other material statutory dues in arrears as at March 31, 2026 for a period of more than six months from the date they became payable.

(b) Details of statutory dues referred to in sub-clause (a) above which have not been deposited as on March 31, 2026 on account of disputes are given below:

Nature of the statute	Nature of dues	Amount (₹ In Millions)	Period to which the amount relates	Forum where dispute is pending
The Service Tax Act, 1994	Service Tax	₹ 6.55	F.Y 2017-18	Tribunal
Commisioner of Customs	MEIS	₹ 1.67	F.Y 2024-25	JC

viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961).

ix. a. The Company did not have any loans or borrowings from any lender during the year. Accordingly, clause 3(ix) (a) of the Order is not applicable.

b. The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

c. The Company has not taken any term loan during the year and there are no outstanding term loans at the beginning of the year and hence, reporting under clause 3(ix) (c) of the Order is not applicable.

d. On an overall examination of the financial statements of the Company, funds raised on short-term basis have, prima facie, not been used during the year for long-term purposes by the Company.

e. On an overall examination of the financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries.

f. The Company has not raised any loans during the year and hence reporting on clause 3(ix) (f) of the Order is not applicable.

x. a. In our opinion and according to information and explanations given by the management and audit procedures performed by us, monies raised by the company by way of initial public offer were applied for the purpose for which they were raised, though idle/surplus funds which were not required for immediate utilization have been gainfully invested in fixed deposits payable on demand. The maximum amount of idle/surplus funds invested during the year was NIL. Because company used all the funds.

b. During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause 3(x) (b) of the Order is not applicable.

xi. a. No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

b. No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and up to the date of this report.

c. We have taken into consideration the whistle blower complaints received by the Company during the year (and up to the date of this report), while determining the nature, timing and extent of our audit procedures.

xii. The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.

xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.

(b) We have considered, the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.

xv. In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors. And hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

xvi. (a) In our opinion, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause 3(xvi) (a), (b) and (c) of the Order is not applicable.

(b) In our opinion, there is no core investment company within the Group (as defined in the Core Investment Companies (Reserve Bank) Directions, 2016) and accordingly reporting under clause 3(xvi) (d) of the Order is not applicable.

xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.

xviii. There has been no resignation of the statutory auditors of the Company during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

xix. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. (a) There is no amount remaining unspent in compliance with second proviso to sub-section (5) of Section 135 of the said Act in respect of "other than ongoing projects" which required transfer to a Fund specified in Schedule VII to the Companies Act within a period of 6 months of the end of the financial year in compliance with second proviso to sub-section (5) of Section 135 of the said Act. Accordingly, reporting under clause 3(xx)(a) of the Order is not applicable for the year.

(b) The Company has transferred the amount of Corporate Social Responsibility (CSR) remaining unspent amounts towards ongoing projects requiring transfer to unspent Corporate Social Responsibility (CSR) account within a period of 30 days from the end of the said financial year in compliance with the provision of section 135(6) of the Act.

For, Kakaria and Associates LLP
Chartered Accountants.
FRN: 104558W/ W100601

CA. Ujwal Kakaria
Partner
Membership No. – 035416
UDIN: - 26035416PHJBQM6305

Place: - Mumbai
Date: - 27th May 2026

Standalone Balance Sheet as at March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	Notes	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	6,833.17	4,468.32
(b) Right to Use Asset	3	45.23	46.45
(c) Capital Work in progress	5	355.48	1,480.15
(d) Intangible Assets	4	13.12	13.89
(e) Financial Assets			
(i) Investments	6	985.23	632.41
(ii) Loans and Advances	7	-	-
(f) Other Non- Current Assets	8	15.81	111.54
Total Non-current assets		**8,248.04**	**6,752.76**
Current assets			
(a) Inventories	9	1,595.97	1,183.49
(b) Financial Assets			-
(i) Loans and Advances	7	5.69	9.27
(ii) Trade receivables	10	2,194.48	1,343.62
(iii) Cash and cash equivalents	11(a)	375.46	760.57
(iv) Bank balances other than (iii) above	11(a)	413.21	30.97
(v) Other Financial Assets	11(b)	-	7.11
(c) Other current assets	12	738.22	1,085.68
Total Current Assets		**5,323.03**	**4,420.71**
TOTAL ASSETS		**13,571.07**	**11,173.47**
EQUITY AND LIABILITIES			
EQUITY			
(a) Equity share capital	13	160.97	160.97
(b) Other equity	14	11,816.36	9,806.63
Total Equity		**11,977.33**	**9,967.60**
LIABILITIES			
Non-current liabilities			
(a) Financial Liabilities			
(i) Borrowings		-	-
(ii) Lease Liabilities	15	51.89	50.57
(iii) Other financial liabilities	16	-	-
(b) Provisions	17	18.97	13.18
(c) Deferred tax Liabilities	19	312.44	270.18
Total Non-Current Liabilities		**383.30**	**333.93**
Current liabilities			
(a) Financial liabilities			
(i) Borrowings		-	-
(ii) Lease liabilities	15	2.46	3.23
(iii) Trade payables	18		
- Micro Enterprises and Small Enterprises		170.01	-
- Other than Micro Enterprises and Small Enterprises		938.46	745.46
(iii) Other financial liabilities	16	20.40	17.59
(b) Provisions	17	16.71	11.93
(c) Other current liabilities	20	62.40	93.73
Total Current Liabilities		**1,210.44**	**871.94**
TOTAL EQUITY AND LIABILITIES		**13,571.07**	**11,173.47**
Summary of significant accounting policies	2		

The accompanying notes are an integral part of the Standalone Ind AS financial statements. As per our report of even date

For Kakaria And Associates LLP
Chartered Accountants
Firm Regn No 104558W/W100601

For and on behalf of the Board of Directors of
SUPRIYA LIFESCIENCE LIMITED

Ujwal K. Kakaria
Partner
Membership no.: 035416
UDIN NO - 26035416PHJBQM6305

Dr. Satish Waman Wagh
Chairman and Executive Director
DIN : 01456982

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Mr. Krishna Raghunathan
Chief Financial Officer

Ms. Prachi Sathe
Company Secretary
M. No. A70252

Place: Mumbai
Date: May 27, 2026

Place : Mumbai
Date: May 27, 2026

Statement of Profit & Loss for the period ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	Notes	March 31, 2026	March 31, 2025
Income			
Revenue from operations	21	8,278.75	6,964.85
Other income	22	114.87	98.15
Total Income		**8,393.62**	**7,063.00**
Expenses			
Cost of raw materials, components and stores consumed	23	2,651.18	2,324.36
(Increase)/ decrease in inventories	24	(110.89)	(212.59)
Employee benefits expense	25	966.80	805.19
Finance costs	28	18.89	16.86
Depreciation and amortization expense	27	284.09	204.44
Other expenses	26	1,831.18	1,439.93
Total Expenses		**5,641.25**	**4,578.19**
Earnings before Tax and exceptional items		**2,752.37**	**2,484.80**
Exceptional Items			
(One time impact of New LabourCodes (Refer Note 38))		(4.58)	-
Profit before tax		**2,747.79**	**2,484.80**
Tax expense			
Current tax		614.33	566.57
Deferred tax		42.26	38.66
Total tax expense		**656.59**	**605.23**
Profit for the year		**2,091.20**	**1,879.57**
Other comprehensive income			
(A) Items that will not to be reclassified to profit or loss in subsequent periods:			
(a) (i) Re-measurement gains/ (losses) on defined benefit plans (Refer Note 33)		(1.33)	(1.67)
(ii) Income tax relating to above		0.34	0.42
Other comprehensive income ('OCI')		(0.99)	(1.25)
Total comprehensive income for the year (comprising profit and OCI for the year)		**2,090.21**	**1,878.33**
Earnings per equity share			
Basic (₹)		25.98	23.35
Diluted (₹)		25.98	23.35
Summary of significant accounting policies			

The accompanying notes are an integral part of the Standalone Ind AS financial statements. As per our report of even date

For Kakaria And Associates LLP
Chartered Accountants
Firm Regn No 104558W/W100601

For and on behalf of the Board of Directors of
SUPRIYA LIFESCIENCE LIMITED

Ujwal K. Kakaria
Partner
Membership no.: 035416
UDIN NO - 26035416PHJBQM6305

Dr. Satish Waman Wagh
Chairman and Executive Director
DIN : 01456982

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Mr. Krishna Raghunathan
Chief Financial Officer

Ms. Prachi Sathe
Company Secretary
M. No. A70252

Place: Mumbai
Date: May 27, 2026

Place : Mumbai
Date: May 27, 2026

Cash Flow Statement for the period ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

	Particulars	March 31, 2026	March 31, 2025
A	CASH FLOW FROM OPERATING ACTIVITIES		
	Profit before tax	2,747.79	2,484.80
	Adjustments for		
	Depreciation and Amortization	284.09	204.44
	Interest Income (Net of Expenses)	(94.54)	(78.85)
	Dividend Received	(0.00)	(0.05)
	Employee Benefit	9.24	11.75
	Loss on Sale of fixed Assets	0.09	0.06
	Operating profit before working capital changes	2,946.67	2,622.15
	Adjustments for movement in working capital		
	Adjustments for (increase)/ decrease in operating assets		
	Trade Receivables	(850.85)	(226.79)
	Inventories	(412.48)	(331.00)
	Other Non Current & Current Assets	443.18	67.15
	Other Non Current & Current Financial Assets	7.11	37.97
	Loans and Advances	3.58	(0.30)
		(809.46)	(452.97)
	Adjustments for increase/ (decrease) in operating liabilities		
	Trade payables	363.01	149.76
	Other Non Current & Current Financial Liabilities	2.80	1.85
	Other Non Current & Current liabilities	(31.34)	(82.25)
		334.47	69.36
	(Income tax paid)/net of refund	(613.99)	(591.79)
	Net Cash generated from Operating Activities (A)	1,857.69	1,646.75
B	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets	(1,522.35)	(1,623.76)
	(Purchase)/ Sale of Investments	(352.82)	5.56
	Interest Income	113.43	95.71
	Dividend Received	0.00	0.05
	Net Cash generated/(outflow) from Investing Activities (B)	(1,761.74)	(1,522.44)
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Increase/(Decrease) in Long term borrowings	-	-
	Increase/(Decrease) in Short term borrowing	-	-
	Finance Cost	(18.89)	(16.86)
	Dividend Paid	(80.48)	(64.39)
	Repayment of Lease liability	0.55	(1.08)
	Net Cash generated from Financing Activities (C)	(98.82)	(82.33)
	Net Increase/(Decrease) in Cash and Cash equivalents (A+B+C)	(2.87)	41.98
	Cash and Cash Equivalents at the end of previous period	791.54	749.56
	Cash and Cash Equivalents as at the end of the reporting period	788.67	791.54

The accompanying notes are an integral part of the Standalone Ind AS financial statements. As per our report of even date

For Kakaria And Associates LLP
Chartered Accountants
Firm Regn No 104558W/W100601

For and on behalf of the Board of Directors of
SUPRIYA LIFESCIENCE LIMITED

Ujwal K. Kakaria
Partner
Membership no.: 035416
UDIN NO - 26035416PHJBQM6305

Dr. Satish Waman Wagh
Chairman and Executive Director
DIN : 01456982

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Mr. Krishna Raghunathan
Chief Financial Officer

Ms. Prachi Sathe
Company Secretary
M. No. A70252

Place: Mumbai
Date: May 27, 2026

Place : Mumbai
Date: May 27, 2026

Statement of Changes in equity as at March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

I EQUITY SHARE CAPITAL

Particular	No. of Shares	Amount
As at March 2024	80482800	160.97
Addition During the year	-	
As at March 2025	80482800	160.97
Addition During the year	-	
As at March 2026	80482800	160.97

Rights and preferences attached to Equity Shares:

i The Company has one class of equity shares having a par value of Rs.2/- each. Each shareholder is eligible for one vote per share held.

ii In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

II OTHER EQUITY

Particulars	Reserves and Surplus		Items of Other Comprehensive Income	Total
	Securities Premium Reserve	Retained Earnings		
Balance as at 31.03.2024	1,985.40	6,004.47	2.82	7,992.69
Profit for the year	-	1879.58	-	1,879.58
Addition during the year				
Other Appropriations	-	-	-	-
Items of OCI, net of Tax				
Remeasurement of Defined Benefit	-	-	(1.25)	(1.25)
Dividends	-	(64.39)	-	(64.39)
Dividend Distribution Tax	-	-	-	-
Balance as at 31.03.2025	1,985.40	7,819.66	1.57	9,806.63
Profit for the year	-	2,091.20	-	2,091.20
Addition during the year				
Other Appropriations				
Items of OCI, net of Tax				
Remeasurement of Defined Benefit	-	-	(0.99)	(0.99)
Dividends	-	(80.48)	-	(80.48)
Dividend Distribution Tax	-	-	-	-
Balance as at 31.03.2026	1,985.40	9,830.38	0.58	11,816.36

For Kakaria And Associates LLP
Chartered Accountants
Firm Regn No 104558W/W100601

For and on behalf of the Board of Directors of
SUPRIYA LIFESCIENCE LIMITED

Ujwal K. Kakaria
Partner
Membership no.: 035416
UDIN NO - 26035416PHJBQM6305

Dr. Satish Waman Wagh
Chairman and Executive Director
DIN : 01456982

Dr. Saloni Wagh
Managing Director
DIN: 08491410

Mr. Krishna Raghunathan
Chief Financial Officer

Ms. Prachi Sathe
Company Secretary
M. No. A70252

Place: Mumbai
Date: May 27, 2026

Place : Mumbai
Date: May 27, 2026

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

1. CORPORATE INFORMATION

Supriya Lifescience Limited ('the Company') was incorporated in India on March 26, 2008 as a Public Limited Company, under The Companies Act 1956 is primarily engaged in manufacturing of Bulk Drugs and Pharmaceutical Chemicals. The registered office is located at 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai- 400063.

The equity shares of the Company are listed on December 28, 2021 on recognized stock exchanges in India- The Bombay Stock Exchange and the National Stock Exchange.

These standalone financial statements for the year ended March 31, 2026 were approved by the Board of Directors on May 27, 2026.

2. STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES

The Company has prepared financial statements for the year ended March 31, 2026 in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended) read with Section 133 of the Companies Act, 2013, (the 'Act') and other relevant provision of the act together with the comparative data as at and for the year ended March 31, 2026.

The accounting policies are applied consistently to all the periods presented in the standalone financial statements. These financial statements have been prepared on a going concern basis.

The financial statements are presented in Indian Rupees which is the functional currency of the company. All the financials information is presented in Indian rupees and are rounded to the nearest rupees in million except when otherwise indicated.

2.1 Basis of preparation

The financial statements have been prepared on the historical cost basis, except for:

(i) certain financial instruments that are measured at fair values at the end of each reporting period;

(ii) defined benefit plans – plan assets that are measured at fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

The Company has consistently applied the following accounting policies to all periods presented in these financial statements.

a) Use of estimates and judgements

The preparation of Company's financial statements in conformity with the recognition and measurement principles of Ind AS requires management of the Company to make estimates and judgements that affect the reported balances of assets and liabilities, disclosures of contingent liabilities as at the date of company financial statements and the reported amounts of income and expenses for the periods presented. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and future periods are affected. The Company uses the following critical accounting estimates in preparation of its standalone financial statements:

b) Current versus non-current classification

Assets and Liabilities are classified as current or non – current, inter-alia considering the normal operating cycle of the company's operations and the expected realization/settlement thereof within 12 months after the Balance Sheet date.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

c) Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

d) Revenue recognition

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

The Company has generally concluded that it is the principal in its revenue arrangements, since it is the primary obligor in all of its revenue arrangement, as it has pricing latitude and is exposed to inventory and credit risks.

Revenue is stated net of goods and service tax and net of returns, chargebacks, rebates and other similar allowances. These are calculated on the basis of historical experience and the specific terms in the individual contracts.

In determining the transaction price, the Company considers the effects of variable consideration, the existence of significant financing components, noncash consideration, and consideration payable to the customer (if any).

The Company estimates variable consideration at contract inception until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

Royalties: Royalty revenue is recognised on an accrual basis in accordance with the substance of the relevant agreement (provided that it is probable that economic benefits will flow to the Company and the amount of revenue can be measured reliably). Royalty arrangements that are based on production, sales and other measures are recognised by reference to the underlying arrangement.

Interest: Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest applicable. Interest income is included under the head "Other income" in the statement of profit & loss account.

Dividends: Dividend income is recognised when the Company's right to receive dividend is established by the balance sheet date.

e) Cash flow statement

Cash flows are reported using the indirect method, whereby profit for the period is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

f) Income Tax.

Income tax expense consists of current and deferred tax. Income tax expense is recognised in profit or loss except to the extent that it relates to items recognised in OCI or directly in equity, in which case it is recognised in OCI or directly in equity respectively

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

i. **Current income tax**

Current tax is the expected tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of the reporting period, and any adjustment to tax payable in respect of previous years. Current tax assets and tax liabilities are offset where the Company has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities.

Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

The Govt. of India had issued the Taxation Laws (Amendment) Act 2019 which provides Domestic Companies an option to pay corporate tax at reduced rates from April 1, 2019 subject to certain conditions. The company intends to opt for lower tax regime. No tax provision has been made for the year in view of losses. The company has recognised consequential impact by reversing deferred tax assets.

ii. **Deferred tax**

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- When the deferred tax liability arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of taxable temporary differences associated with investments in subsidiaries and interests in joint ventures when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future

Deferred tax assets are recognised for all deductible temporary differences and the carry forward of any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax losses can be utilised, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries and interests in joint ventures deferred tax assets are recognised only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

g) Defined benefit plans (gratuity benefits)

The Company's obligation on account of gratuity is determined based on actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, these liabilities are highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate, the management considers the interest rates of government bonds in currencies consistent with the currencies of the post-employment benefit obligation.

The mortality rate is based on publicly available mortality tables for the specific countries. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates for the respective countries. Further details about gratuity obligations are given in Refer Note 38.

h) Property, plant and equipment

Plant and equipment is stated at cost of acquisition or constructions including attributable borrowing cost till such assets are ready for their intended use, less of accumulated depreciation and accumulated impairment losses, if any. Cost of acquisition for the aforesaid purpose comprises its purchase price, including import duties and other non-refundable taxes or levies and any directly attributable cost of bringing the asset to its working condition for its intended use, net of trade discounts, rebates and credits received if any.

Such cost includes the cost of replacing part of the plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in profit or loss as incurred.

Property Plant and equipment are eliminated from financial statements, either on disposal or when retired from active use. Losses arising in case of retirement of Property, Plant and equipment and gains or losses arising from disposal of property, plant and equipment are recognised in statement of profit and loss in the year of occurrence.

The assets' residual values, useful lives and methods of depreciation are reviewed at each financial year and adjusted prospectively, if appropriate,

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. Useful lives used by the Company are same as prescribed rates prescribed under Schedule II of the Companies Act 2013. The range of useful lives of the property, plant and equipment are as follows:

Particulars	Useful Lives
Buildings	30 years
Plants and Equipment	15 years
Office Equipment	05 years
Computer System	03 years
Motor Cars	08 years
Furniture & Fixture	10 years
Office Equipment	05 years

i) Intangible Assets

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. Intangible assets are amortised as follows:

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

➢ **Software – 5 years**

Software for internal use, which is primarily acquired from third-party vendors and which is an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalised as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognised as expense as incurred. The capitalised costs are amortised over the lower of the estimated useful life of the software and the remaining useful life of the tangible fixed asset.

j) Investments in the nature of equity in subsidiaries.

The Company has elected to recognise its investments in equity instruments in subsidiaries and associates at cost in the separate financial statements in accordance with the option available in Ind AS 27, 'Separate Financial Statements'.

k) Investment properties

Investment properties comprise portions of office buildings and residential premises that are held for long-term rental yields and/or for capital appreciation. Investment properties are initially recognised at cost. Subsequently investment property comprising of building is carried at cost less accumulated depreciation and accumulated impairment losses.

The cost includes the cost of replacing parts and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of the investment property are required to be replaced at intervals, the Group depreciates them separately based on their specific useful lives. All other repair and maintenance costs are recognised in profit and loss as incurred.

Depreciation on building is provided over the estimated useful lives as specified in Schedule II to the Companies Act, 2013. The residual values, useful lives and depreciation method of investment properties are reviewed, and adjusted on prospective basis as appropriate, at each financial year end. The effects of any revision are included in the statement of profit and loss when the changes arise.

Though the group measures investment property using cost-based measurement, the fair value of investment property is disclosed in the notes.

Investment properties are derecognised when either they have been disposed of or when the investment property is permanently withdrawn from use and no future economic benefit is expected from its disposal.

The difference between the net disposal proceeds and the carrying amount of the asset is recognised in the statement of profit and loss in the period of de-recognition.

l) Impairment of non-financial assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used.

Impairment losses of continuing operations, including impairment on inventories, are recognised in the statement of profit and loss.

An assessment is made at each reporting date to determine whether there is an indication that previously recognised impairment losses no longer exist or have decreased. If such indication exists, the Company estimates the asset's or CGU's recoverable amount. A previously recognised impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognised. The reversal is limited so that the carrying amount of the asset does not exceed its recoverable amount, nor exceed the carrying amount that would have

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. Such reversal is recognised in the statement of profit or loss.

m) Non- current Asset held for sale.

Non-current assets and disposal groups are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. This condition is regarded as met only when the asset (or disposal group) is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such asset (or disposal group) and its sale is highly probable. Management must be committed to the sale, which should be expected to qualify for recognition as a completed sale within one year from the date of classification. Non-current assets (and disposal groups) classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Non-current assets are not depreciated or amortised.

n) Borrowing costs:

a. Borrowing costs that are attributable to the acquisition, construction, or production of a qualifying asset are capitalised as a part of the cost of such asset till such time the asset is ready for its intended use or sale. A qualifying asset is an asset that necessarily requires a substantial period of time (generally over twelve months) to get ready for its intended use or sale.

b. All other borrowing costs are recognised as expense in the period in which they are incurred.

o) Leases

The Company evaluates each contract or arrangement, whether it qualifies as lease as defined under Ind AS 116.

The Company as a lessee:

The Company enters into an arrangement for lease of land, buildings, plant and machinery including computer equipment and vehicles. Such arrangements are generally for a fixed period but may have extension or termination options. The Company assesses, whether the contract is, or contains, a lease, at its inception. A contract is, or contains, a lease if the contract conveys the right to

a) control the use of an identified asset,

b) obtain substantially all the economic benefits from use of the identified asset, and

c) direct the use of the identified asset.

The Company determines the lease term as the non-cancellable period of a lease, together with periods covered by an option to extend the lease, where the Company is reasonably certain to exercise that option.

The Company at the commencement of the lease contract recognizes a Right-of-Use (RoU) asset at cost and corresponding lease liability, except for leases with term of less than twelve months (short term leases) and low-value assets. For these short term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the lease term.

The cost of the right-of-use asset comprises the amount of the initial measurement of the lease liability, any lease payments made at or before the inception date of the lease, plus any initial direct costs, less any lease incentives received. Subsequently, the right-of-use assets are measured at cost less any accumulated depreciation and accumulated impairment losses, if any. The right-of-use assets are depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment.

The Company applies Ind AS 36 to determine whether an RoU asset is impaired and accounts for any identified impairment loss as described in the impairment of non-financial assets below.

For lease liabilities at the commencement of the lease, the Company measures the lease liability at the present value of the lease payments that are not paid at that date. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined, if that rate is not readily determined, the lease payments are discounted using the incremental borrowing rate that the Company would have to pay to borrow funds, including the consideration of factors such as the nature of the asset and

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

location, collateral, market terms and conditions, as applicable in a similar economic environment.

After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. The Company recognizes the amount of the re-measurement of lease liability as an adjustment to the right-of-use assets. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognizes any remaining amount of the re-measurement in statement of profit and loss. Lease liability payments are classified as cash used in financing activities in the statement of cash flows.

The Company as a lessor

Leases under which the Company is a lessor are classified as finance or operating leases. Lease contracts where all the risks and rewards are substantially transferred to the lessee, the lease contracts are classified as finance leases. All other leases are classified as operating leases. For leases under which the Company is an intermediate lessor, the Company accounts for the head-lease and the sub-lease as two separate contracts. The sub-lease is further classified either as a finance lease or an operating lease by reference to the RoU asset arising from the head-lease.

p) Corporate Social Responsibility (CSR) Expenditure

The Companies Act, 2013, read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 (the "CSR Rules"), requires that companies meet certain thresholds of net worth, turnover or net profits to constitute a CSR Committee and to spend 2% of the company's average profits, before taxes for the previous three fiscal years, on certain identified areas of CSR. This requirement became effective April 1, 2014. We have complied with this requirement, and a detailed report on CSR will form part of the Annual Report of the Company for fiscal year 2026.

CSR spend are charged to the statement of profit and loss as an expense in the period they are incurred.

q) Provisions, Contingent liabilities, Contingent assets and Commitments:

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of profit and loss.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Contingent liability is disclosed in the case of:

- A present obligation arising from past events, when it is not probable that an outflow of resources will be required to settle the obligation;
- A present obligation arising from past events, when no reliable estimate is possible;
- A present obligation arising from past events, unless the probability of outflow of resources is remote.

Commitments include the amount of purchase order (net of advances) issued to parties for completion of assets.

Provisions, contingent liabilities, contingent assets and commitments are reviewed at each balance sheet date.

r) Employee Benefits

Retirement benefit in the form of provident fund, pension fund and superannuation fund are defined contribution schemes. The Company has no obligation, other than the contribution payable to such schemes. The Company recognises contribution payable to such schemes as an expense, when an employee renders the related service. If the contribution payable to the schemes for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the schemes is recognised as a liability after deducting the contribution already paid. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognised as an asset to the extent that the pre-payment will lead to, for example, a reduction in future payment or a cash refund.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

The Company operates a defined benefit gratuity plan, which requires contributions to be made to a separately administered fund. The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method. Liability for gratuity as at the year-end is provided on the basis of actuarial valuation.

Remeasurements, comprising of actuarial gains and losses and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Remeasurements are not reclassified to profit or loss in subsequent periods.

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognises the following changes in the net defined benefit obligation as an expense in the statement of profit and loss:

- Service costs comprising current service costs; and
- Net interest expense or income

Accumulated leave, which is expected to be utilised within the next 12 months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

s) Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

i. Financial assets

Initial recognition and measurement

All financial assets are recognised initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.

Subsequent measurement

For purposes of subsequent measurement, financial assets are classified in four categories:

- Financial assets at amortised cost.
- Financial assets at fair value.

When assets are measured at fair value, gains and losses are either recognised entirely in the statement of profit and loss (i.e. fair value through profit or loss), or recognised in other comprehensive income (i.e. fair value through other comprehensive income).

A financial asset that meets the following two conditions is measured at amortised cost (net of any write down for impairment) unless the asset is designated at fair value through profit and loss under fair value option.

- Business model test: The objective of the Company's business model is to hold the financial asset to collect the contractual cash flows (rather than to sell the instrument prior to its contractual maturity to realize its fair value changes).
- Cash flow characteristics test: The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

A financial asset that meets the following two conditions is measured at fair value through other comprehensive income unless the asset is designated at fair value through profit and loss under fair value option.

- Business model test: The financial asset is held within a business model whose objective is achieved by both collected contractual cash flows and selling financial instruments.
- Cash flow characteristics test: The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Derecognition

When the Company has transferred its rights to receive cash flows from the asset or has assumed

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; it evaluates if and to what extent it has retained the risks and rewards of ownership.

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised when:

- The rights to receive cash flows from the asset have expired, or
- Based on above evaluation, either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss on the following financial assets and credit risk exposure:

a) Trade receivables that result from transactions those are within the scope of Ind AS 18

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e., all cash shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- All contractual terms of the financial instrument (including prepayment, extension, call and similar options) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument
- Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms

ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/ expense in the statement of profit and loss. This amount is reflected in the statement of profit and loss in other expenses. The balance sheet presentation for various financial instruments is described below:

- Financial assets measured as at amortized cost, trade receivables and lease receivables: ECL is presented as an allowance, i.e., as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write-off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

- **Financial Liabilities**

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss or at amortised cost, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings, net of directly attributable transaction costs.

The Company's financial liabilities include trade payables, lease obligations, and other payables.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.

Gains or losses on liabilities held for trading are recognised in the profit or loss.

The Company has not designated any financial liability as at fair value through profit and loss.

Financial liabilities at amortised cost

After initial recognition, interest-bearing loans and borrowings and other payables are subsequently measured at amortised cost using the EIR method. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires.

- **Offsetting of financial instruments**

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

- **Ordinary shares**

Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of new ordinary shares and share options are recognised as a deduction from equity, net of any tax effects.

t) Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, net of outstanding bank overdrafts as they are considered an integral part of the Company's cash management.

u) Earnings per equity share

The Company presents basic and diluted earnings per share ("EPS") data for its equity shares. Basic EPS is calculated by dividing the profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period. The diluted EPS is calculated on the same basis as basic EPS, after adjusting for the effects of potential dilutive equity shares unless the effect of the potential dilutive equity shares is anti-dilutive.

Notes to financial statements for the year ended 31st March 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 3 PROPERTY, PLANT AND EQUIPMENT

Particulars	Factory Land	Factory Building	Office Premises	Plant &Machinery	Electrical Fittings	Furniture &Fixtures	Laboratory Equipments	Office Equipment	Air Conditioners	Books	Product Registration	Computer	Motor Car*	Total	Right To Use Asset
Gross block															
At March 31,2024	104.16	856.20	1.49	2,045.16	163.67	85.86	227.09	18.40	8.76	0.87	16.75	32.25	40.30	3,600.96	71.11
Additions	5.07	433.24	-	998.33	80.50	2.21	30.78	4.29	43.03	-		14.93	14.66	1,627.04	3.35
Disposals	-	-	-	-	-	-	-	-	-	-	-	0.12	-	0.12	-
At March 31,2025	109.23	1,289.44	1.49	3,043.49	244.17	88.07	257.87	22.69	51.79	0.87	16.75	47.06	54.96	5,227.88	74.46
Additions	594.01	732.87	-	1,079.74	117.83	9.11	72.61	4.44	17.01	-	-	17.44	8.34	2,653.40	3.79
Disposals	-	-	-	13.05	-	-	-	-	-	-	-	-	-	13.05	-
At March 31,2026	703.24	2,022.31	1.49	4,110.18	362.00	97.18	330.48	27.13	68.80	0.87	16.75	64.50	63.30	7,868.23	78.25
Accumulated Depreciation															
At March 31,2024	-	87.72	1.49	292.03	54.25	22.33	43.20	10.50	4.11	0.28	5.34	19.62	23.12	563.99	23.32
Charge for the year	-	29.94	-	105.74	16.55	7.65	19.97	2.41	3.13	0.05	0.68	5.15	4.25	195.53	4.69
Disposals												0.05		0.05	
At March 31,2025	-	117.66	1.49	397.77	70.80	29.98	63.17	12.91	7.24	0.33	6.02	24.82	27.37	759.56	28.01
Charge for the year	-	44.49	-	156.94	22.10	7.27	18.69	3.00	6.93	0.05	0.63	10.39	5.01	275.50	5.01
Disposals	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
At March 31,2026	-	162.15	1.49	554.71	92.90	37.25	81.86	15.91	14.17	0.38	6.65	35.21	32.38	1,035.06	33.02
Net carrying value															
As at March 31,2024	104.16	768.48	-	1,753.13	109.42	63.53	183.89	7.90	4.65	0.59	11.41	12.63	17.18	3,036.97	47.79
As at March 31,2025	109.23	1,171.78	-	2,645.72	173.36	58.09	194.70	9.78	44.54	0.54	10.73	22.24	27.59	4,468.32	46.45
As at March 31,2026	703.24	1,860.16	-	3,555.47	269.10	59.93	248.62	11.22	54.63	0.49	10.10	29.29	30.92	6,833.17	45.23

*For property, plant and equipment existing as on the date of transition to Ind AS, i.e., April 01, 2018, the Company has used IGAAP carrying value as deemed costs.

Motor Car*

Out of the total value of Motor Car, block of Rs 60,24,645.77/- is not in the name of Company

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 4 INTANGIBLE ASSETS

Particulars	Computer Software	Patent	Total
Cost			
At March 31,2024	30.13	6.00	36.13
Additions	1.51	-	1.51
Disposals	-	-	-
At March 31,2025	31.64	6.00	37.64
Additions	2.82	-	2.82
Disposals	-	-	-
At March 31,2026	34.46	6.00	40.46
Amortisation			
At March 31,2024	19.38	0.20	19.58
Charge for the year	3.60	0.57	4.17
Disposals	-	-	-
At March 31,2025	22.98	0.77	23.75
Charge for the year	3.02	0.57	3.59
Disposals	-	-	-
At March 31,2026	26.00	1.34	27.34
Net book value			
As At March 31,2024	10.75	5.80	16.55
As At March 31,2025	8.66	5.23	13.89
As At March 31,2026	8.46	4.66	13.12

NOTE : 5 CAPITAL WORK IN PROGRESS

Particulars	Building	Plant & Machinery	Electrical Fitting	Capital WIP	Total
Gross Block					
At March 31,2024	241.44	202.36	32.07	1,012.38	1,488.25
Additions	261.85	1,072.88	78.57	207.40	1,620.70
Disposals	361.40	175.33	73.35	1,018.72	1,628.80
At March 31,2025	141.89	1,099.91	37.29	201.06	1,480.15
Additions	-	-	-	1.88	1.88
Disposals	77.94	844.37	15.28	188.96	1,126.55
At March 31,2026	63.95	255.54	22.01	13.98	355.48
As at March 31,2024	241.44	202.36	32.07	1,012.38	1,488.25
As at March 31,2025	141.89	1,099.91	37.29	201.06	1,480.15
As at March 31,2026	63.95	255.54	22.01	13.98	355.48

CWIP Aging Schedule

As at March 31, 2026

CWIP	Amount in CWIP for a period of				Total
	Less than 1 Year	1-2 years	2-3 years	More than 3 years	
Capital WIP Lote	311.06	44.42	-	-	355.48
	311.06	44.42	-	-	355.48

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

As at March 31, 2025

CWIP	Amount in CWIP for a period of				Total
	Less than 1 Year	1-2 years	2-3 years	More than 3 years	
Capital WIP, Ambernath	772.51	274.33	27.00	287.31	1,361.15
Capital WIP, Lote	119.00	-	-	-	119.00
	891.51	274.33	27.00	287.31	1,480.15

As at March 31, 2026

As on the date of the balance sheet, there are no capital work-in-progress projects whose completion is overdue or has exceeded the cost, based on approved plan.

NOTE : 6 NON-CURRENT INVESTMENTS

Particulars	March 31, 2026	March 31, 2025
A. Investments in Unquoted Instruments (Equity Shares)	0.03	0.03
B. Investments in Unquoted Instruments (Debentures & Mutual Funds)	900.43	569.52
C. Profit or Loss receivable on MTM basis on Debenture & Mutual Funds	84.77	62.86
D. Investments in Unquoted Instruments (Corporate FD)	-	-
E. Accrued Interest on investments Corporate FD	-	-
TOTAL (A)	985.23	632.41

NOTE : 7 LOANS AND ADVANCES (UNSECURED, CONSIDERED GOOD)

Particulars	Non - Current		Current	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
Loans and Advances to Staff	-	-	5.69	7.16
IT refund receivable	-	-	-	2.12
TOTAL	-	-	5.69	9.27

NOTE : 8 OTHER NON - CURRENT ASSETS

Particulars	March 31, 2026	March 31, 2025
Sundry Deposits (Assets)	15.81	13.10
Other non current asset (Advance against Property)	-	98.44
TOTAL	15.81	111.54

NOTE : 9 INVENTORIES

Particulars	Current	
	March 31, 2026	March 31, 2025
Raw Materials	956.30	703.12
Work-in-progress	301.95	279.55
Finished Goods	275.99	187.50
Stores/Spares & Packing material & Others	61.73	13.32
TOTAL	1,595.97	1,183.49

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 10 TRADE RECEIVABLES

Particulars	Current	
	March 31, 2026	March 31, 2025
Unsecured and considered good		
Over Six months		
Export Debtors	8.01	14.76
Local Debtors	44.12	37.94
Others		
Export Debtors	1,514.59	949.52
Local Debtors	636.22	346.27
	2,202.94	1,348.49
Less: Provision for Doubtful Debtors	8.46	4.87
TOTAL	2,194.48	1,343.62

Trade Receivables Aging

As at March 31, 2026

Particulars	Outstanding for following periods from due date of payments				
	Less than 6 months	6 months – 1 year	1-2 yrs	2-3 yrs	More than 3 years
Undisputed, considered good	2,174.40	2.97	13.98	10.06	1.52
Undisputed trade receivables- considered doubtful	-	-	-	-	-
Disputed trade receivables- considered good	-	-	-	-	-
Disputed trade receivables- considered doubtful	-	-	-	-	-

As at March 31, 2025

Particulars	Outstanding for following periods from due date of payments				
	Less than 6 months	6 months – 1 year	1-2 yrs	2-3 yrs	More than 3 years
Undisputed, considered good	1,295.79	23.15	27.57	0.63	1.36
Undisputed trade receivables- considered doubtful	-	-	-	-	-
Disputed trade receivables- considered good	-	-	-	-	-
Disputed trade receivables- considered doubtful	-	-	-	-	-

NOTE : 11 (A) CASH AND CASH EQUIVALENTS

Particulars	Current	
	March 31, 2026	March 31, 2025
Cash on hand	0.47	0.24
Balances with banks:		
Current accounts*	264.89	74.47
Fixed Deposits (with less than 3 month of original maturity)	9.45	112.17
Fixed Deposits (with more than 3 month but less than 12 month of original maturity)	100.65	573.69
	375.46	760.57
Bank balances other than above		
Fixed Deposits (with more than 12 month of original maturity)	413.21	30.97
	413.21	30.97
TOTAL	788.67	791.54

*In FY 2024-25 Includes an amount of Rs 0.6 Million kept in a separate bank account for a project to be undertaken under CSR.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 11(B) OTHER FINANCIAL ASSETS

Particulars	Current	
	March 31, 2026	March 31, 2025
Balances with banks:		
Accrued Interest on Fixed Deposits	-	7.11
TOTAL	**-**	**7.11**

NOTE : 12 OTHER CURRENT ASSETS

Particulars	Current	
	March 31, 2026	March 31, 2025
Prepaid Expenses	92.49	102.43
Advance to Suppliers	169.86	93.41
Advance against property	113.41	561.90
Balance with government authorities	250.93	277.62
Income Tax Provision	111.53	50.33
TOTAL	**738.22**	**1,085.68**

NOTE : 13 EQUITY SHARE CAPITAL

Particulars	March 31, 2026	March 31, 2025
Authorised share capital (No.)		
March 31, 2026: 17,50,00,000*, equity shares of Rs. 2 each	350.00	350.00
March 31, 2025: 17,50,00,000*, equity shares of Rs. 2 each		
Issued, subscribed and fully paid-up shares (No.)		
March 31, 2026: 8,04,82,800 Equity Shares of Rs.2 Each	160.97	160.97
March 31, 2025: 8,04,82,800 Equity Shares of Rs.2 Each		
Total issued, subscribed and fully paid-up shares		
March 31, 2026: 8,04,82,800 Equity Shares of Rs.2 Each	160.97	160.97
March 31, 2025: 8,04,82,800 Equity Shares of Rs.2 Each		

(a) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particular	March 31, 2026		March 31, 2025	
	No. of shares	Amount	No. of shares	Amount
At the beginning of the year	80482800	160.97	80482800	160.97
Issued during the year	-	-	-	-
Balance at the end of the year	**80482800**	**160.97**	**80482800**	**160.97**

(b) Terms/ rights attached to equity shares

The Company has only one class of equity shares having a par value of Rs. 2 per share. Each holder of equity share is entitled to one vote per share.

In event of liquidation of the Company, the holders of equity shares would be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

(c) Shares held by each shareholder holding more than five percent

Particulars	March 31, 2026		March 31, 2025	
Name of Shareholders	No of Shares held	% holding	No of Shares held	% holding
Satish.W.Wagh	54,441,205	67.64%	54,441,205	67.64%

Shareholding of Promoters:

Promoters Name	No.of Shares	% of total shares	% change during the year
Satish Wagh	54,441,205	67.64%	-

NOTE : 14 OTHER EQUITY

Particulars	Reserves and Surplus			
	Securities Premium Reserve	Retained Earnings	Items of Other Comprehensive Income	Total
Balance as at 31.03.24	**1,985.40**	**6,004.47**	**2.82**	**7,992.69**
Profit for the year	-	1,879.58	-	1,879.58
Addition during the year	-	-	-	-
				-
Other Appropriations				-
Items of OCI, net of Tax	-	-	(1.25)	(1.25)
Remeasurement of Defined Benefit	-	-	-	-
Dividends	-	(64.39)	-	(64.39)
Dividend Distribution Tax	-	-	-	-
Balance as at 31.03.25	**1,985.40**	**7,819.66**	**1.57**	**9,806.63**
Profit for the year	-	2,091.20	-	2,091.20
Addition during the year				-
				-
Other Appropriations				-
Items of OCI, net of Tax				-
Remeasurement of Defined Benefit	-	-	(0.99)	(0.99)
Dividends	-	(80.48)	-	(80.48)
Dividend Distribution Tax	-	-	-	-
Balance as at 31.03.26	**1,985.40**	**9,830.37**	**0.58**	**11,816.36**

NOTE : 15 LEASE LIABILITY

Particulars	Non - Current		Current	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
Lease Liabilities	51.89	50.57	2.46	3.23
TOTAL	**51.89**	**50.57**	**2.46**	**3.23**

NOTE : 16 OTHER FINANCIAL LIABILITIES

Particulars	Non - Current		Current	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
Security Deposit	-	-	5.74	5.74
Employee related payables	-	-	14.66	11.86
TOTAL	**-**	**-**	**20.40**	**17.59**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 17 PROVISIONS

Particulars	Non - Current		Current	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
Long term Provisions				
- Gratutiy Provision	1.91	-		
- Compensated absences	17.06	13.18		
Short term Provisions				
- Gratutiy Provision			10.63	7.52
- Compensated absences			6.08	4.41
TOTAL	**18.97**	**13.18**	**16.71**	**11.93**

NOTE : 18 TRADE PAYABLES

Particulars	Current	
	March 31, 2026	March 31, 2025
Micro Enterprises and Small Enterprises	170.01	0.00
Other than micro and small enterprises	938.46	745.46
TOTAL	**1,108.47**	**745.46**

Particulars	Current	
	March 31, 2026	March 31, 2025
a) the principal amount remaining unpaid to any supplier at the end of each accounting year;	-	-
b) the amount of interest paid by the buyer in terms of section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 (27 of 2006), along with the amount of the payment made to the supplier beyond the appointed day during each accounting year;	-	-
c) the amount of interest due and payable for the period of delay in making payment (which has been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006;	-	-
d) the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-	-
The above Disclosure in respect of amount payable to such Enterprises as at March 31, 2026, has been made in the Financial statement based on information received and avaliable with the Company. Further in view of the management the impact of Interest, if any, that may be payable in accordance with the provision of Act is not expected to be material. The Company has not received any claim for Interest from any MSME Supplier registered under the said MSME Act.	-	-

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Trade Payables Aging March 31, 2026

Particulars	Outstanding for following periods from due date of payments				Total
	Less than 1 year	1-2 yrs.	2-3 yrs.	More than 3 years	
Undisputed					
MSME	170.01	-	-	-	170.01
Others	932.27	5.52	0.67		938.46
Disputed					
MSME	-	-	-	-	
Others	-	-	-	-	

Trade Payables Aging March 31, 2025

Particulars	Outstanding for following periods from due date of payments				Total
	Less than 1 year	1-2 yrs.	2-3 yrs.	More than 3 years	
Undisputed					
MSME	-	-	-	-	-
Others	721.01	11.87	8.20	4.38	745.46
Disputed	-	-	-	-	-
MSME	-	-	-	-	-
Others	-	-	-	-	-

NOTE : 19 DEFFERED TAX LIABILITIES

Particulars	Current	
	March 31, 2026	March 31, 2025
On account of Depreciation		
Others	312.44	270.18
TOTAL	**312.44**	**270.18**

NOTE : 20 OTHER CURRENT LIABILITIES

Particulars	Current	
	March 31, 2026	March 31, 2025
Advance from Customers	31.44	43.55
Statutory Liabilities	18.34	18.42
Other Liabilities	12.62	31.76
Income Tax Provision	-	-
Unclaimed Dividend	-	
TOTAL	**62.40**	**93.73**

NOTE : 21 REVENUE FROM OPERATIONS

Particulars	March 31, 2026	March 31, 2025
Sale of Products		
Export Sales	7,261.83	6,464.99
Domestic Sales	1,630.28	1,185.02
Gross Sales	8,892.11	7,650.01
Less: GST	868.46	854.37
Net Sales	**8,023.65**	**6,795.64**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2026	March 31, 2025
Other Operating Revenue		
Duty Drawback	66.48	59.46
RODTEP Incentives	40.43	38.05
MEIS Incentive Income	2.54	-
Foreign Currency Fluctuation Gain	145.65	71.70
Revenue from Operation	**8,278.75**	**6,964.85**

NOTE : 22 OTHER INCOME

Particulars	March 31, 2026	March 31, 2025
Interest Income	0.03	-
Miscellaneous income	0.08	-
Interest on Fixed Deposit	60.08	40.07
Interest Income on Security Deposit- Asset (Udyog Bhavan 215/216 & 207/208/208A)	0.07	(0.07)
Dividend Received	0.00	0.05
Insurance Claim Received	1.11	2.38
Fair Value Adjustment of investment	49.13	55.65
Profit on Mutual Funds	4.23	-
Adjusted lease liability	-	-
Interest Income on Staff Advance	0.14	0.07
TOTAL	**114.87**	**98.15**

NOTE : 23 COST OF RAW MATERIALS, COMPONENTS AND STORES CONSUMED

Particulars	March 31, 2026	March 31, 2025
Opening Stock	703.12	584.12
Purchases	2,904.36	2,443.36
	3,607.48	**3,027.48**
Closing Stock	956.30	703.12
TOTAL	**2,651.18**	**2,324.36**

NOTE : 24 (INCREASE)/ DECREASE IN INVENTORIES

Particulars	March 31, 2026	March 31, 2025
Opening Stock		
Finished Goods	187.50	215.36
Work-in-Progress	279.55	39.10
	467.05	**254.46**
Closing Stock		
Finished Goods	275.99	187.50
Work-in-Progress	301.95	279.55
	577.94	**467.05**
TOTAL	**(110.89)**	**(212.59)**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 25 EMPLOYEE BENEFIT EXPENSE

Particulars	March 31, 2026	March 31, 2025
Salaries, Wages, Allowances and Bonus	903.73	746.28
Contribution to Employee Benefit Funds	47.01	38.80
Staff Welfare Expenses	20.64	20.11
TOTAL	**971.38**	**805.19**

NOTE : 26 OTHER EXPENSES

Particulars	March 31, 2026	March 31, 2025
Manufacturing Expenses		
Hel Majuri Exp.	1.78	1.92
Stores and Spares Consumed	143.68	94.42
Packing Materials	7.24	30.56
Power & Fuel	297.70	247.98
Laboratory Expense	128.32	76.08
Pollution Control Expenses	5.24	0.83
R&D Expenses	87.80	40.46
Repairs and Maintenance (Plant)	348.37	215.55
Environment Health & Safety (EHS)	12.36	8.27
Other Expenses	66.31	34.55
Selling and Distribution Expenses		
Commission	28.28	53.47
Sales Promotion Expenses	56.18	53.82
Distibution expense	239.56	233.45
Administrative and Other Expenses		
Travelling Expenses	60.58	36.31
Rates and Taxes	11.64	8.86
Insurance Premium	40.81	38.67
Repair & Maintenance (Head Office)	4.95	15.46
Motor Car Expenses	0.69	6.13
Postage & Courier Expenses	4.62	5.00
Printing & Stationery Expenses	17.73	11.65
Telephone & Communication Expenses	3.34	2.99
Legal and Professional Fees	82.37	63.32
Payment to Auditors	1.85	1.63
CSR Expense	35.84	32.20
Donation Expenses	20.60	21.43
Security Charges	21.15	17.47
General expenses	37.96	36.64
Subscription Expenses	9.43	2.89
Directors Sitting Fees	1.13	1.34
Branding Expenses	0.27	0.49
Share Registry Maintenance RTA fees	2.37	3.60
Listing Annual Fees	0.63	0.59
Issuer Fees (CDSL & NSDL)	0.73	0.78
IPO Expenses	25.81	25.81
Investor Expenses	0.37	0.51
Expected Credit Loss for debtors (IndAS)	5.67	8.92

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	March 31, 2026	March 31, 2025
Monitoring Agency Charges for IPO	-	0.07
IT Expenses	3.72	4.42
Interest on Statutory Liabilities	8.83	1.24
Penalty on Statutory Liabilities	-	0.09
Loss on Sales of Assets	0.09	0.06
Statutory Dues expenditure	5.18	-
TOTAL	**1,831.18**	**1,439.93**

NOTE- 26 (I) AUDITORS REMUNERATION

Particulars	March 31, 2026	March 31, 2025
Payment to the auditor's comprises of:		
For Statutory Audit	1.85	1.28
Others	-	0.35
TOTAL	**1.85**	**1.63**

NOTE- 26 (II) CORPORATE SOCIAL RESPONSIBILITIES

As per section 135 of the companies Act 2013 and rules there in, the companies is required to spend at least 2% of the average net profit of the past three years towards corporate social responsibility.

Details of Corporate social expenses is as follows :

Particulars	March 31, 2026	March 31, 2025
Gross amount required to be spend during the year	35.84	24.33
Amount of Expenditure incurred		
- Construction/ acquisition of an asset	-	-
- On purpose other than above	50.92	32.20
Total Amount spend during the period/ year	50.92	32.20
(Excess)/ shortfall at the end of the Year**	**(15.08)**	**(7.87)**

** Total Amount excess Spend for the year ended March 31, 2026 Rs. 15.07 Millions has been shown as 'CSR Prepaid Asset Account FY 25-26'

NOTE : 27 DEPRECIATION AND AMORTIZATION EXPENSE

Particulars	March 31, 2026	March 31, 2025
Depreciation of property, plant and equipment (note 3)	279.08	199.75
Depreciation on ROU	5.01	4.69
TOTAL	**284.09**	**204.44**

NOTE : 28 FINANCE COSTS

Particulars	March 31, 2026	March 31, 2025
Interest		
Working Capital Finance	-	-
Other Financial Costs	13.77	13.29
Interest Expense on Lease Liability (As per IndAS 116)	5.01	3.53
Intrest on Staff Loan (IndAs)	0.11	0.04
TOTAL	**18.89**	**16.86**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE: 29 RELATED PARTY TRANSACTIONS

(i) Details of Related Party

Particulars	Name of the Party
Enterprise over which the key managerial personnel has Control	Prime Chemicals
	Ravi Industries
	Swastik Industries
	Supriya Pharmaceuticals
	Samaira Pharmaceuticals
Key Managerial Personnel (Director)	Satish W Wagh
	Smita S Wagh
	Saloni S Wagh
	Shivani S Wagh
	Balasaheb Sawant (Whole Time Director)
Relatives of Key Managerial Personnel	Arun W Wagh
Enterprise over which the relatives of key managerial personnel have control	Vaibhav Chemicals
Key Managerial Personnel (Others)	
CEO (Resigned w.e.f 14th June 2024)	Rajeev Kumar Jain
CFO	Krishna Raghunathan
Company Secretary(Resigned w.e.f 29th January 2025)	Shweta Singh
Company Secretary (Appointed w.e.f 10th March 2025)	Prachi Sathe
President – Business Development, Strategy and R&D	Shekhar Bhirud

(ii) Table providing total amount of transactions that have been entered into with related parties for the relevant financial year:

Particulars	For the year Ended 31 March 2026	For the year Ended 31 March 2025
CSR Spending		
Satish Wagh Foundation	50.92	21.50
Lease rentals paid to		
Vaibhav Chemicals	1.04	1.04
Satish Wagh	10.73	5.70
Jobwork		
Samira Pharmaceuticals	1.93	-
Remuneration to Key Managerial Personnel		
Salaries and other benefits	275.28	267.46
Dividend paid	54.97	43.97
Salaries to relatives of Key Managerial Personnel	2.33	2.16

NOTE: 30 EARNINGS PER SHARE

Particulars	March 31, 2026	March 31, 2025
Profit after tax attributable to equity shareholders	2,091.20	1,879.57
Weighted average number of equity shares for basic EPS	80482800	80482800
Earnings per Share (Basic/Diluted)	**25.98**	**23.35**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 31 LEASES

31.1 Amounts recognised in Balance Sheet

Particulars	March 31, 2026	March 31, 2025
(i) Right to use Assets		
Opening	46.45	47.79
Add: Addition/(Deletion)	3.79	3.35
Less: Depreciation	5.01	4.69
Closing	45.23	46.45
Total	**45.23**	**46.45**
(ii) Lease Liabilities		
Opening	53.80	54.89
Add: Addition	3.72	3.12
Add: Interest Cost	5.01	3.53
Less: Lease Rent	8.18	7.74
Closing	54.35	53.80
Total	**54.35**	**53.80**

31.2 Amounts recognised in the statement of profit and loss

Particulars	Note No.	For the period ended March 31, 2026	For the period ended March 31, 2025
(i) Depreciation and amortisation expense	27	5.01	4.69
(ii) Interest Expenses (included in finance cost)	28	5.01	3.53
(iii) Expenses relating to lease payments*	-	8.18	7.74

* Expenses relating to lease payments has been accounted for applying paragraph 6 of Ind AS 116- Leases and accordingly recognised as expense in the statement of profit and loss.

31.3 The impact on the statement of profit and loss for the year ended March 31, 2026 is as below:

Particulars	For the period ended March 31, 2026	For the period ended March 31, 2025
Rent	8.18	7.74
Depreciation	5.01	4.69
Finance cost	5.01	3.53

The company has discounted lease payments @ 9.00% p.a

31.4 Additional information on extension / termination options

Extension and termination options are included in a number of property lease arrangements of the Company. These are used to maximise operational flexibility in terms of managing the assets used in the Company's operations. The majority of extension and termination options held are exercisable based on mutual consent of the Company and respective lessors.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE: 32 CONTINGENT LIABILITIES AND COMMITMENTS

Particulars	March 31, 2026	March 31, 2025
Bank Guarantees	79.83	33.43
Commitments	-	-
Disputed Income Tax, Sales Tax, Service Tax and GST Demand:		
i) Pending before Tribunal	6.55	6.55
ii) Pending before Commisioner of Customs	1.67	1.67
TOTAL	**88.05**	**41.65**

NOTE 33: RECLASSIFICATION

Previous year's figures have been regrouped/reclassified wherever necessary to correspond with the current year's classification/disclosures

NOTE: 34 (A) CATEGORY WISE CLASSIFICATION OF FINANCIAL INSTRUMENTS

Particulars	Non Current		Current	
	As at 31.03.2026	As at 31.03.2025	As at 31.03.2026	As at 31.03.2025
Financial Assets measured at Fair value through Other Comprehensive Income				
Investment in quoted instruments	850.35	-	-	-
TOTAL	**850.35**	-	-	-

Financial assets measured at Amortized cost

Particulars	Non Current		Current	
	As at 31.03.2026	As at 31.03.2025	As at 31.03.2026	As at 31.03.2025
Loans to employees	-	-	5.69	7.16
Sundry Deposits (Assets)	15.81	13.10	-	-
Trade Receivables	-	-	2,194.48	1,343.62
Cash and Cash Equivalents	-	-	788.67	791.54
TOTAL	**15.81**	**13.10**	**2,988.84**	**2,142.32**

Financial assets measured at fair value through profit and loss

Particulars	Non Current		Current	
	As at 31.03.2026	As at 31.03.2025	As at 31.03.2026	As at 31.03.2025
Investment in equity based Mutual funds	-	-	-	-
Investments in Debt based Mutual Funds	-	-	-	-
TOTAL	-	-	-	-

Financial Liabilities measured at Amortized cost

Particulars	Non Current		Current	
	As at 31.03.2026	As at 31.03.2025	As at 31.03.2026	As at 31.03.2025
Borrowings	-	-	-	-
Trade payables (including retained creditors)	-	-	938.46	745.46
TOTAL	-	-	**938.46**	**745.46**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE : 34 (B) FAIR VALUE HIERARCHY

The following table provides the fair value measurement hierarchy of the Company's financial assets and liabilities

As at 31.03.2026

Financial Assets / Financial Liabilities	Fair Value as at 31.03.2026	Fair value hierarchy		
		Quoted Prices in active markets (Level 1)	Significant observable Inputs (Level 2)	Significant unobservable Inputs (Level 3)
Financial Assets measured at Fair value through other comprehensive income				
Investments in quoted equity shares	850.35	850.35	-	-
Financial Assets measured at Fair value through Profit and Loss				
Investments in Debt based Mutual Funds	-	-	-	-
Investment in equity based Mutual funds	-	-	-	-
Financial Liability measured at Fair value through Profit and Loss				

As at 31.03.2025

Financial Assets / Financial Liabilities	Fair Value as at 31.03.2025	Fair value hierarchy		
		Quoted Prices in active markets (Level 1)	Significant observable Inputs (Level 2)	Significant unobservable Inputs (Level 3)
Financial Assets measured at Fair value through other comprehensive income				
Investments in quoted equity shares	-	-	-	-
Financial Assets measured at Fair value through Profit and Loss				
Investments in Debt based Mutual Funds	-	-	-	-
Investment in equity based Mutual funds	-	-	-	-
Financial Liability measured at Fair value through Profit and Loss				

The fair value of financial asset and liabilities measured at amortised cost approximate there fair values

NOTE: 35 FINANCIAL RISK MANAGEMENT

Company's financial risk management is an integral part of how to plan and execute its business strategies. The Company's financial risk management policy is set by the Managing Board.

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from a change in the price of a financial instrument.

The value of a financial instrument may change as a result of changes in the interest rates, foreign currency exchange rates, equity prices and other market changes that affect market risk sensitive instruments.

Market risk is attributable to all market risk sensitive financial instruments including investments and deposits, foreign currency receivables, payables and loans and borrowings.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

(i) Foreign Currency Risk

The Company operates internationally and portion of the business is transacted in several currencies and consequently the Company is exposed to foreign exchange risk through its sales and services in overseas and purchases from overseas suppliers in various foreign currencies.

Foreign currency exposure as at March 31, 2026

(In million)

Particulars	USD	EURO
Trade receivables	16.01	0.04
Bank Balances	-	-
Adavnce received from Customers	0.29	-
Loan Liabilities	-	-
Trade payables	2.31	0.06

Foreign currency exposure as at March 31, 2025

(In million)

Particulars	USD	EURO
Trade receivables	11.11	0.04
Bank Balances	-	-
Adavnce received from Customers	0.45	0.01
Loan Liabilities	-	-
Trade payables	1.31	0.02

Foreign currency sensitivity

Particulars	2025-26		2024-25	
	1 % Increase	1 % decrease	1 % Increase	1 % decrease
USD	0.14	(0.14)	0.10	(0.10)
EURO	-0.00	0.00	-0.00	0.00
Increase \ (Decrease) in profit or loss	0.14	(0.14)	0.10	(0.10)

(ii) Equity Price Risk

The company's investment portfolio consists of investments in quoted instruments like mutual funds carried at fair value in the balance sheet.

(iii) Credit risk

Credit risk arises from the possibility that counter party may not be able to settle their obligations as agreed. To manage this, the Company periodically assesses the financial reliability of customers, taking into account the financial condition, current economic trends, and analysis of historical bad debts and ageing of accounts receivable. Individual risk limits are set accordingly.

The company considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk the company compares the risk of a default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition.

It considers available reasonable and supportive forwarding-looking information such as :

(i) Actual or expected significant adverse changes in business

Exposure to credit risk

Particulars	March 31, 2026	March 31, 2025
Loans to employees	5.69	7.16
Deposits	15.81	13.10
Trade Receivables	2194.48	1,343.62
Cash and Cash Equivalents	788.67	791.54

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Expected Credit Loss Assessment

Exposures to customers outstanding at the end of each reporting period are reviewed by the company to determine incurred and expected credit losses. Management believes that the unimpaired amount that are past due are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk.

Particulars	Current	
	March 31, 2026	March 31, 2025
Export Debtors	1,522.60	964.28
Local Debtors	680.35	384.21
	2,202.95	1,348.49
Less: Expected Credit Loss	8.46	4.87
TOTAL	**2,194.49**	**1,343.62**

(iv) Liquidity risk

Liquidity risk is defined as the risk that the Company will not be able to settle or meet its obligations on time or at a reasonable price.

The Company's corporate treasury department is responsible for liquidity, funding as well as settlement management.

In addition, processes and policies related to such risks are overseen by senior management. Management monitors the Company's net liquidity position through rolling forecasts on the basis of expected cash flows.

The table below provides details regarding the remaining contractual maturities of significant financial liabilities at the reporting date based on contractual undiscounted payments.

Maturity profile of financial liabilities

The table below provides details regarding the remaining contractual maturities of significant financial liabilities at the reporting date based on contractual undiscounted payments.

As at March 31, 2026	Less than one year	1 to 5 years	Total
Borrowings	-	-	-
Retention Creditors	-	-	-
Trade payables	1,108.46	-	1,108.46
Other financial liabilities	20.40	-	20.40
	1,128.86	-	**1,128.86**

As at March 31, 2025	Less than one year	1 to 5 years	Total
Borrowings	-	-	-
Retention Creditors	-	-	-
Trade payables	745.46	-	745.46
Other financial liabilities	17.59	-	17.59
	763.05	-	**763.05**

(v) Capital management

For the purposes of the Company's Capital Management, capital includes issued capital and all other equity reserves.

The primary objective of the Company's Capital Management is to maximise shareholder value. The company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants. The company does not have gearing as its cash and reserves are substantial to cover up borrowings.

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

NOTE: 36 DISCLOSURE IN PURSUANT TO IND AS 19 DEFINED BENEFIT EMPLOYEE

Assets and Liability (Balance Sheet Position)

Particulars	March 31, 2026	March 31, 2025
Present Value of Benefit Obligation at the end of the period	59.08	45.87
Fair Value of Plan Assets at the end of the Period	46.53	38.35
Surplus / (Deficit)	(12.54)	(7.52)
Effects of Asset Ceiling, if any	-	-
Net Asset / (Liability) Recognised in the Balance Sheet	**(12.54)**	**(7.52)**

Particulars	For the period ending March 31, 2026	For the period ending March 31, 2025
In Income Statement	9.54	6.61
In Other Comprehensive Income	1.33	1.67
Total Expenses Recognized during the period	**10.87**	**8.28**

Graphical Representation of Liability and Expenses

Particulars	For the period ending March 31, 2026	For the period ending March 31, 2025
Present Value of Obligation as at the beginning	45.86	36.46
Current Service Cost	9.27	6.54
Interest Expense or Cost	3.13	2.68
Re-measurement (or Actuarial) (gain) / loss arising from:		
- change in demographic assumptions	-	-
- change in financial assumptions	(2.20)	1.70
- experience variance (i.e. Actual experience vs assumptions)	1.34	0.52
- others		-
Benefits Paid	(2.91)	(2.03)
Present Value of Obligation as at the end	**54.50**	**45.86**

Graphical Representation of Asset and Income

Particulars	For the period ending March 31, 2026	For the period ending March 31, 2025
Opening value of plan asset	38.35	35.18
Interest Income	2.86	2.61
Return on plan assets excluding amounts included in interest income	(2.19)	0.56
Contributions by Employer	7.51	-
Closing value of plan assets	**46.53**	**38.35**

Expenses Recognised in the Income Statement

Particulars	For the period ending March 31, 2026	For the period ending March 31, 2025
Current Service Cost	9.27	6.54
Past Service Cost (Refer Note 40)	4.58	-
Loss / (Gain) on settlement	-	-
Net Interest Cost / (Income) on the Net Defined Benefit Liability / (Asset)	0.28	0.07
Expenses Recognised in the Income Statement	**14.12**	**6.61**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

Particulars	For the period ending March 31, 2026	For the period ending March 31, 2025
Actuarial (gains) / losses		
- change in demographic assumptions	-	-
- change in financial assumptions	(2.20)	1.70
- experience variance (i.e. Actual experience vs assumptions)	1.34	0.52
- others		
Return on plan assets, excluding amount recognised in net interest expense	2.19	(0.56)
Re-measurement (or Actuarial) (gain)/loss arising because of change in effect of asset ceiling	-	-
Components of defined benefit costs recognised in other comprehensive income	**1.33**	**1.66**

Actuarial Assumptions

We have used actuarial assumptions selected by the Company. The Company has been advised that the assumptions selected should be unbiased and mutually compatible and should reflect the Company's best estimate of the variables of the future. The Company has also been advised to consider the requirement of Para 44 of IndAS 19 in this regard.

(i) Financial Assumptions

The principal financial assumptions used in the valuation are shown in the table below:

Particulars	As at March 31, 2026	As at March 31, 2025
Discount rate (per annum)	6.69%	6.86%
Salary growth rate (per annum)	10%	10%

The salary growth rate indicated above is the Company's best estimate of an increase in salary of the employees in future years, determined considering the general trend in inflation, senority, promotions, past experience and other relevant factors such as demand and supply in employment market, etc.

(ii) Demographic Assumptions

The principal demographic assumptions used in the valuation are shown in the table below:

Particulars	As at March 31, 2026	As at March 31, 2025
Mortality rate (% of IALM 06-08)	100%	100%
Normal retirement age	58 years	58 years
Attrition / Withdrawal rates, based on age: (per annum)		
Upto 30 years	10%	10%
31-44 years	10%	10%
Above 44 years	10%	10%

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

(iii) Sensitivity Analysis

Significant actuarial assumptions for the detemination of the defined benefit obligation are discount rate, expected salary increase and mortality. The sensitivity analysis below have been determined based on reasonably possible changes of the assumptions occurring at the end of the reporting period, while holding all other assumptions constant. The results of sensitivity analysis is given below:

Particulars	As at March 31, 2026	As at March 31, 2025
Defined Benefit Obligation (Base)	54.50	45.86

Particulars	Decrease	Increase	Decrease	Increase
Discount Rate (- / + 1%) (% change compared to base due to sensitivity)	6.86	(6.10)	7.11	(6.30)
Salary Growth Rate (- / + 1%) (% change compared to base due to sensitivity)	(4.35)	4.25	(4.55)	4.64
Attrition Rate (- / + 10% of attrition rates) (% change compared to base due to sensitivity)	0.54	(0.54)	0.87	(0.85)

NOTE: 37 INCOME TAX RECONCILIATION

(a) Tax Expense recognised in Statement of profit and Loss comprises

Particulars	March 31, 2026	March 31, 2025
Current income tax:		
Current income tax charge	614.33	566.57
Deferred tax:		
Relating to origination and reversal of temporary differences	42.26	38.66
Income tax expense reported in the statement of profit or loss	**656.59**	**605.23**

(b) Deferred tax related to items recognised in OCI during in the year:

Particulars	March 31, 2026	March 31, 2025
Net loss/(gain) on remeasurements of defined benefit plans	0.34	0.42
Income tax charged to OCI	**0.34**	**0.42**

(c) Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for March 31, 2026 and March 31, 2025:

Particulars	March 31, 2026	March 31, 2025
Accounting profit before income tax	2,747.78	2,484.79
Tax on accounting profit at statutory income tax rate 25.168% (March 31, 2025 25.168%)	691.56	625.38
Expenses that are not deductible in determining taxable profit	101.40	77.55
Change/ Credit in respect of earlier years	-	-
Others	(136.04)	(97.28)
Tax expense reported in the statement of profit or loss	656.92	605.65
Effective Tax Rate	**23.91%**	**24.37%**

Notes to financial statements for the year ended March 31, 2026

(All amounts in Indian ₹ million, except as otherwise stated)

(d) Components of Deferred tax assets/ (Liabilities) recognised in Balance sheet and Statement of profit and loss

Particulars	Balance sheet		Statement of Profit and Loss	
	March 31, 2026	March 31, 2025	March 31, 2026	March 31, 2025
Difference between Book depreciation and tax depreciation	368.40	262.02	106.38	25.54
Deferred Tax Asset on Gratuity	3.16	1.89	1.27	2.21
Deferred Tax Asset on Leave Encashments	5.82	4.43	1.39	7.05
Deferred Tax Asset on Staff Advance	0.30	0.20	0.10	0.29
Deferred Tax Asset (Rental Security Deposit -Asset)	0.20	0.20	0.00	0.36
Deferred Tax Liability on ROU IndAS 116	(11.37)	(11.69)	0.32	(23.72)
Deferred Tax Asset (Lease Liability as per IndAS 116)	13.68	13.54	0.14	27.35
Deferred Tax Asset (SD Liab-Tasly)	-	-	-	-
Other Difference	(67.75)	(0.41)	(67.34)	(0.42)
Deferred Tax Income / (Expense)	-	-	42.26	38.66
Net Deferred Tax Asset / (Liabilities)	**312.44**	**270.18**	-	-

(e) Reconciliation of deferred tax liabilities (net):

Particulars	March 31, 2026	March 31, 2025
Opening balance April 1	270.18	231.52
Tax (Income)/ Expense during the period recognised in		
(i) Statement of Profit and loss in profit and loss	41.92	38.24
(ii) Statement of Other Comprehensive Income	0.34	0.42
Closing balance	**312.44**	**270.18**

NOTE: 38 EXCEPTIONAL ITEM

Effective November 21, 2025, The Government of India has consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the ‘New Labour Codes’. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by Rs. 4.58 Millions primarily arising due to change in definition of “wages” for employees and contract labours.Considering the materiality and non-recurring nature of this impact, the Company has presented such incremental impact under “Exceptional Item” in the financials for the year ended March 31, 2026. Refer note 36.

SUPRIYA LIFESCIENCE LTD.

www.supriyalifescience.com

Concept, Content & Design
(info@wyatt.co.in)